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ABSTRACT
The high Mr (~55 kDa) thioredoxin reductases (TR) characteristic of higher
eukaryotes are members of the glutathione reductase (GR) family of pyridine nucleotide
disulfide oxidoreductases. These homodimeric enzymes catalyze the reduction of a
cognate disulfide substrate. During the enzymatic cycle, reducing equivalents pass from
NADPH to the conserved active site disulfide via an enzyme-bound FAD and then to the
cognate substrate. TRs are unique in the family as electrons are then transferred to the Cterminal active site of the adjacent molecule as part of a 16 amino acid extension (in
place of the cognate GR substrate GSSG), prior to transfer to the substrate thioredoxin.
Each electron transfer step occurs via thiol-disulfide exchange in a multi-step process
mediated by a conserved catalytic acid/base. Mammalian TRs require selenocysteine
(Sec) incorporated into the Gly-Cys-Sec-Gly-OH (GCUG) C-terminal tetrapeptide motif,
while the TR from Drosophila melanogaster (DmTR) does not, and instead contains a
Ser-Cys-Cys-Ser-OH (SCCS) tetrapeptide motif indicating that Sec is not universally
necessary to catalyze the reduction of thioredoxin.
This project has achieved three major objectives; 1) development of a
semisynthetic method for production of mouse mitochondrial TR (mTR3) for structurefunction studies, 2) establishment of a new method to study the mechanism of TR by
using tetrapeptides in the oxidized form equivalent to the C-terminal active sites as
substrates for the truncated forms of both enzymes, 3) determination of the crystal
structure of DmTR. The results show that the structure of DmTR explains the
biochemical data and has developed a new testable hypothesis in the field for the
requirement of Sec in mammalian TR.
We demonstrate that the tetrapeptides tested in Aim 2 were all better substrates
for DmTR. The data also shows a far greater dependence on Sec for mTR3 than DmTR,
which is in agreement with that observed for the collection full-length mutants produced
for each enzyme in Aim 1. As this method of investigation is more analogous to the other
enzymes of the GR family, the structures of the tetrapeptides determined by NMR
spectroscopy were oriented in the active site of the both enzymes using the diglutathione
bound in the structure of GR as template. DmTR appears to have a more open active site
than observed in the known structure of mTR3. Residues from the helical face of the
FAD-domain proximal to the FAD-associated active site are less bulky in DmTR to
accommodate the hydroxyls of the serines. This is likely to make the enzyme more
amenable for the conformational switching of the SCCS peptide necessary to protonate
the leaving group cysteine by the proposed catalytic acid/base. In contrast, mTR3 shows
a more restricted interface by incorporating bulkier residues at the interface in
conjunction with the smaller Gly residues of the C-terminal sequence GCUG. The
tetrapeptides display a conformational preference not suitable for protonation of the first
leaving group in mTR3.
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CHAPTER 1.
INTRODUCTION TO THE THIOREDOXIN
SYSTEM

Figure 1. The physiological reducing systems.
The Thioredoxin system (A) and the Glutathione system (B) are each dependent on the
system reductase, TR and GR respectively. These enzymes use a common modular
architecture to perform the function of thiol-disulfide exchange. The unique properties of
mammalian TR compared to the other related enzymes make understanding minor
mechanistic differences essential to the development of therapeutics targeting TR.
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THIOREDOXIN REDUCTASE AND PHYSIOLOGY

Oxygen…the key to life as we know it. Oxidation…an enemy of life as we know
it. Oxidation is not just damage in the form of the rust on your car it is also damage
incurred by all forms of biological macromolecules. This can lead to the inactivation of
enzymes (1), oxidation of lipids contributing to atherosclerosis (2, 3), and DNA damage
resulting in cancer (4, 5). While the extracellular environment is relatively oxygen rich,
the intracellular environment is maintained in the reduced state. However, oxidation in
both environments is also an essential process that occurs in many physiological
reactions. The key for most oxidative processes to be beneficial rather than detrimental is
that that the process be reversible. Because of this paradox, organisms have evolved
systems to control and utilize oxidative processes.
The cellular environment is maintained in the reduced state by two primary
systems, the glutathione system (sometimes referred to as the glutaredoxin system) and
the thioredoxin system. The key enzymes are referred to as the system reductases,
glutathione reductase (GR) and thioredoxin reductase (TR). A comprehensive list of
abbreviations used in this dissertation is available in Appendix A. The reductase for each
system utilizes reducing equivalents in the form of NADPH to reduce the system’s
respective cognate substrate, oxidized diglutathione (GSSG) or thioredoxin (Trx) (Figure
1). While Trx goes on directly to reduce a target substrate, there are two fates of reduced
glutathione (GSH), the tripeptide γ-glutamylcysteinylglycine. Two molecules of GSH can
be used to directly reduce a target or, more commonly, GSH will be used to reduce
glutaredoxin or glutathione peroxidase (proteins similar to Trx). Many excellent reviews
2

are available on the physiological functions of both systems (6-9). The most common
shared function between the two systems is the reduction of protein disulfides. Central to
the function of these systems is the process of thiol-disulfide exchange mediating the
directed transfer of electrons between reduced and oxidized species.
Both systems are nearly ubiquitous in all forms of life, however, there are certain
organisms of which there are substitutions for these systems. For example, the parasite
Trypanosoma utilizes the analogous trypanothione system rather than the glutathione
system (10). The system reductase is trypanothione reductase (TryR) and cognate
substrate is trypanothione. While GRs are functionally, structurally, and mechanistically
homologous, TRs are divided into two classes: higher eukaryotes have the class I high Mr
TR, which is the focus of this dissertation, while prokaryotes and lower eukaryotes have
class II low Mr TRs. These two classes have partial homology on the basis of function
and structure, but contain structural deviations and have distinct mechanisms. No GR has
yet been identified in Drosophila melanogaster even though glutathione is utilized (11).
In this system, the GSH pool is maintained by the thioredoxin system via Trx.
The essential nature of both systems makes the reductases a significant
therapeutic target for a broad range of disease processes. For example, the protozoa of
which TryR substitutes for GR are the cause of several tropical diseases. Therefore, TryR
is a target under investigation as a therapeutic target (12-14). Similarly, active site
distinctions between the high Mr TR of mammals and that of Plasmodium falciparium,
the causative parasite of malaria, make the Plasmodium falciparium TR (PfTR) an
attractive therapeutic target for treatment of malaria (15).
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Both the glutathione and thioredoxin systems are reducing equivalent donors to
ribonucelotide reductase (RNR) (8), the enzyme responsible for conversion of
ribonucleotides to deoxyribonucleotides (dNTPs) for DNA synthesis (16). This enzyme is
a target under investigation for cancer therapy, see Arnér and Holmgren for a TR-based
review (17). Initial studies performed in E. coli. showed Trx to have slightly lower
activity than glutaredoxin (Grx) as electron donors to RNR. Though Trx was less active
and showed ~10 fold higher Km (18, 19), the cellular Trx concentration is considerably
higher than Grx (20, 21). Trx knockout in yeast results in a 40% reduction of the dNTP
pool in vivo (22). However, the impact for inhibition of these systems for higher
eukaryotes in relation to ribonucleotide reductase has yet to be determined. Elevated
levels of TR in human tumors have been reported (23, 24) but the degree of up-regulation
and purpose of the elevated levels is uncertain (25).
The mammalian thioredoxin system is unique in its broad range of substrates
compared to other systems. Transcription factors such as NF-ΚB (26, 27) involved in
oxidative stress and inflammatory responses have been demonstrated to be redox
regulated by Trx. This redox control of transcription factors, and its involvement in the
response to reactive oxygen species, implicate TR as a player in afflictions such as
rheumatoid arthritis (28), cancer (17), aging, and HIV (29). Several other substrates
unique to mammalian TR have been identified. The antioxidant ascorbate (vitamin C) can
be reduced by TR (30) as can lipid peroxides (31). The unique roles that mammalian TR
plays in so many physiological processes makes understanding the mechanistic
differences of TR homologues and the related systems imperative.
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THE GLUTATHIONE REDUCTASE FAMILY

Thioredoxin reductases from higher eukaryotes are members of the glutathione
reductase (GR) family of pyridine nucleotide-disulfide oxidoreductases (32). The
Structural Classification of Proteins (SCOP) identifies the protein family as FAD/NADlinked reductases belonging to the FAD/NAD(P) binding domain Superfamily and Fold
(33). Proteins in this family of which structures are available are GR (34), TR (35, 36),
TryR (37), and LipDH (38). There are many structures for most of these proteins,
especially GR. The references given above are representative structures of each enzyme
used in direct structural comparisons in this dissertation. Glutathione, trypanothione, and
lipoamide are all small-molecule substrates whereas thioredoxin is a 12 kDa protein
(Figure 2). More distantly related family members include: alkyl hydroperoxide
reductase, NADH peroxidase, NADH-dependent ferredoxin reductase, flavocytochrome
C sulfide dehydrogenase, and apoptosis inducing factor (AIF). Although these proteins
are generally related via the binding of FAD and/or NAD, their structural topologies are
quite different from the GR family as reviewed by Dym and Eisenberg (39).
Structural Overview.
The proteins of the GR family are homodimeric (25) and have a three domain
modular structure, which is diagramed in Figure 3. Each contains a N-terminal FAD
binding domain followed by a NAD(P) binding domain. Each of these domains is
structurally similar and composed of a three-layered sandwich, which will be described
below. These two domains bind FAD and NAD(P) in a similar manner and are oriented
5

in a head to head fashion (Figure 4), essentially a mirror image, to place the flavin and
nicotinamide in proper orientation for electron transfer. The domains are tethered by a
two antiparallel β-strands with each strand representing the transition from one domain to
the other. The C-terminal domain is the dimerization/interface domain for this class of
proteins and is generally a five-stranded anti-parallel β-sheet with two alpha helices on
either side. The high Mr TR (class I) characteristic of higher eukaryotes are ~55 kDa per
monomer and have an additional C-terminal extension of 16 residues (compared to GR),
which contains an additional active site disulfide (Figure 5). Prokaryotes and lower
eukaryotes utilize class II TRs which are ~35 kDa per monomer. Class II TRs do not
have the C-terminal domain characteristic of most members the GR family and dimerize
via the FAD domain (40).
FAD Binding Domain.
The FAD binding domain is the most highly conserved domain among family
members (alignment Figure 6). This is not unexpected as the FAD is permanently bound
to the protein although non-covalently, with a few exceptions within the family such as
fumarate reductase and sarcosine oxidase. The domain contains a variant of the
Rossmann $"$"$ fold as the central motif in a three-layered sandwich; a five or sixstranded parallel central sheet, alpha helices on one face, and a three-stranded antiparallel sheet on the other (Figure 7) (41). The anti-parallel sheet is the crossover
connection to the directional change in the Rossmann fold. This retains the typical +3
topology of the Rossmann fold where strand number four in the sheet is strand seven
within the sequence. Rossmann strand four is also the transition to the NAD(P) binding
6

domain such that stand five, six for some structures, follow the NAD(P) binding domain
in the sequence.
The FAD molecule is divided into two modules connected via a pyrophosphate.
The first module is the adenosine monophosphate (AMP) and lies within a well-defined
groove created by the topological switch in the parallel $-sheet and a hydrophobic pocket
between the two $-sheets. The adenine lies in the pocket with the N6 coordinated by a
backbone carbonyl in a conserved position at the N-terminus of strand one of the antiparallel sheet. This residue is generally a small hydrophobic residue such as a glycine,
alanine or valine.

The ribose and phosphate extends through the groove with the

phosphates coordinated by the highly conserved FAD binding motif. This motif is the
most conserved sequence found within the domain. The motif is GxGxxGx(17)D/E and is
located in the loop and N-terminal end of the helix between strands one and two of the
Rossmann fold. The x represents any residue with some preference for hydrophobic
residues in the 17-residue stretch. This motif provides both a structural platform and
binding determinants for the adenosine monophosphate and pyrophosphate moieties. The
backbone amides of the GxGxxG motif provide hydrogen bonds to the pyrophosphate
and the D/E coordinates the 2’-OH of the ribose. In many structures, there is a conserved
water molecule mediating the interaction with the pyrophosphate (42).
Charge stabilization of the pyrophosphate is believed to come from the positive
helix dipole as the GxGxxG is the N-terminal end of helix 1 of the FAD domain (43). In
the GR and TryR structures, the glutamate side chain hydrogen bonds to both the 2’ and
3’-OH whereas in the E. coli TR structure it appears to be the backbone carbonyl of the
Glu and the adjacent residue that provides these bonds. There is also a conserved Thr that
7

provides a hydrogen bond to the phosphate of the AMP. The second module of the FAD
is the flavin mononucleotide, which contains the linear ribitol and the isoalloxazine ring
of the flavin. The ribitol places the FAD in a linear conformation above the $-sheet
platform, placing the flavin in contact with the alpha-helical face containing the active
site.
The FAD domain contains the active site disulfide representative of the GR
family, with exception of the small TR. It is located in the extended alpha-helical
segment that connects strand two to strand three in the parallel β-sheet. The conserved
redox active site sequence Cys-Val-Asn-Val-Gly-Cys (CVNVGC) sequence generates a
short alpha helix followed by a longer helix, which is separated by a short loop created by
the VNVG. This places the cysteines on the same face such that, when oxidized, the
disulfide bond bridges across the loop. The N-terminal Cys is referred to as the
interchange thiol and is responsible for electron exchange with the GSSG substrate (44).
The C-terminal Cys is the charge-transfer Cys responsible for interacting with the Flavin.
Reaction of reduced GR with iodoacetamide results in labeling of the interchange thiol
while the C-terminal Cys is maintained in the charge-transfer state (44).
Immediately C-terminal to the active site is a conserved lysine that coordinates
the N5 of the flavin. Interestingly, the small TR has a similar short helix followed by a
longer loop yet does not contain the active site motif. The local structure is maintained
however, the small TR loop transitions to a helix that connects directly to the crossover

$-sheet whereas the other members of the family extend towards the NAD(P) binding
domain and reconnect to the FAD domain through an additional helix resulting in a
sequence insertion of ~32 residues. This results in slightly different positioning of this
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connecting helix in E. coli TR such that it occupies the substrate binding pocket
representative of the other members of the family.
NAD(P) Binding Domain.
The NAD(P) binding domain demonstrates a similar architecture to that of the
FAD domain although it is smaller and not as well conserved. While the FAD is
permanently bound, the NAD(P) must bind and dissociate during the catalytic cycle.
Therefore binding is less stringent and involves an induced fit (45). The domain
architecture also contains a three-layered sandwich with the alpha helices being shorter
and the parallel $-sheet containing only four strands. The GxGxxG motif is also
conserved, although not as well as in the FAD binding domain. An important difference
is the coordination of the ribose of the similar AMP module. Members of the family that
bind NADP rather then NAD contain a pair of arginines in the loop where the D/E
normally resides. These residues hydrogen bond to the phosphate on the 3’-OH and it
appears that 2’-OH points toward the solvent. A series of mutations, including the Arg
residues, allows for switching of substrate specifity from NADPH to NADH (46).
A conserved tyrosine from the NADP domain, Tyr197 in GR, shows a significant
conformational change between the oxidized and reduced states of the enzyme (34, 47).
Upon binding of NADPH, the Tyr rotates to allow the orientation of the flavin and
nicotinamide for electron transfer. This same conformational change has also been
reported for mouse mitochondrial TR (mTR3) (35). This residue was initially suggested
to provide a cap to protect the flavin from access to solvent. However, mutagenesis to
Phe, Ser, or Gly indicated the flavin is still protected. The latter two mutants, however,
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resulted in a shift from the normal Ping-Pong Bi Bi mechanism to an Ordered-Sequential
mechanism (48).
While the overall architecture is maintained within the family, there is a simple
non-conserved sequence in a short alpha helix prior to the sequence returning to the FAD
domain. This short helix contains the active disulfide for small TR. The end of this helix
faces the FAD domain and contains the active-site sequence, CATC. The combined
structures for E. coli TR demonstrate a significant conformational change that is unique
to the Class II TR (49). The NAD(P) domain twists ~60o to expose the active disulfide to
the open face of the structure, opposite the dimer interface, for interaction with
thioredoxin. This sequence is GITS for GR and CISS or CITS for large TR, TryR and
LipDH while the flanking regions are relatively well conserved. However, since this
active site faces the dimer interface, it is inaccessible to a large substrate such as
thioredoxin.
The Dimerization Domain.
The C-terminal dimerization domain represents ~30% of the sequence for the
proteins of this family. As the name implies, it is this domain that is responsible for dimer
formation thereby assembling the functional active site. It is this domain that provides the
catalytic acid/base histidine for the active site of the enzyme. The conserved active site is
composed of the FAD and the conserved disulfide (CVNVGC) from the FAD domain of
Chain A, and the His-Glu dyad (His464 and Glu469 in Figure 5) from Chain B, as
proposed from the crystal structures of GR (34, 50). Residues from chain B are given a
prime designation. Implications for the His-Glu dyad will be discussed in more detail in
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terms of the catalytic cycles covered in the next section. The His-Glu dyad is shown for
the structures of GR and mouse TR3 in Figure 4. The communication between the FAD
active site disulfide on Chain A and the catalytic acid/base on Chain B was verified by
the preparation of heterodimeric GR from E. coli where one subunit contained the
Cys47Ser mutant and the other subunit contained the His439Gln mutant (51, 52). Each
mutant showed poor activity when prepared as a homodimer while the heterodimeric
form showed ~50% of wild-type activity.
Proper dimer assembly is also a significant contributor to the catalytic
mechanism. Several mutagenesis studies have been performed with GR targeting residues
at the dimer interface. Though dimeric enzymes require elements from both monomers,
cooperativity has not been reported for wild type enzymes under normal conditions. The
E. Coli GR mutant Gly418Trp results in an enzyme having high cooperativity for GSSG
binding with Hill coefficient of 1.76 (53). Mutations in this region can also disrupt the
standard Ping Pong mechanism (54).
The additional thiol-disulfide exchange step characteristic of TR utilizes a 16
amino acid C-terminal extension (absent in GR) and typically contains a Cys-Cys dyad,
which forms an intramolecular disulfide. Upon reduction of this dyad by the N-terminal
redox center (on the opposite chain), the substrate (Trx) can then be reduced. The
relationship between the N-terminal active site and the C-terminal active site was
demonstrated using the heterodimer method developed for GR by Deonarain et al.
mentioned above. In these experiments the interchange thiol Cys88 of Plasmodium
falciparum (PfTR), was mutated to Ala in one construct while Cys535 was mutated to
Ala in another (55). Each of the mutants, when produced as homodimers, showed very
11

poor activity towards Trx while the heterodimers showed ~50% of wild-type activity.
This provided evidence that the N-terminal active site was in redox communication with
the C-terminal active site.
With the exception of PfTR, which contains four intervening residues, the
disulfide forms between adjacent Cys residues of the C-terminal dyad. This vicinal
disulfide bond has a very low frequency in the Brookhaven Protein Data Bank (PDB) as
is discussed by Perczel and coworkers (56, 57) and results in a type VII β-turn (58). Only
TR has been identified as having a catalytically competent vicinal disulfide. Examples of
proteins containing a vicinal disulfide include bacterial toxins (59), the nicotinic
acetylcholine receptor (58), hepcidin (60), and methanol dehydrogenase (61). For these
proteins it is suspected that the vicinal disulfide has a structural function. Mercuric ion
reductase also contains a C-terminal vicinal disulfide but it does not appear essential for
enzyme function (62).
Mammalian TRs (mTR) are distinguished in this group since they contain the rare
amino acid selenocysteine (Sec, U) as part of the C-terminal dyad forming the redoxactive motif Gly-Cys-Sec-Gly (GCUG) (63, 64). Drosophilia melanogaster TR (DmTR)
lacks Sec as part of this motif and has the C-terminal sequence Ser-Cys-Cys-Ser (SCCS)
(11, 65) (Figure 5). Thus, high Mr TRs can be divided into enzymes that contain Sec and
those that have a conventional Cys residue (66). TryR is interesting in that it also has a Cterminal extension, but the sequence is not conserved in comparison to TR and does not
contain the active disulfide.
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Substrate Binding.
Glutathione reductase is the structural model for the family and has been
extensively studied. Both the alpha helical face of the FAD domain and the C-terminal
end of the dimerization domain provide substrate-binding determinants for GSSG (34).
Most of the binding contacts for GSSG in the structural complex appear water mediated
with the most significant direct contacts formed between Chain A and GSHI. Many of the
substrate-binding residues are conserved in TR yet the enzyme cannot reduce glutathione
or trypanothione. The arginine in position 37 for GR serves to anchor the carboxyl group
of GSHI. Trypanothione does not have carboxyl groups at both ends of the molecule and
therefore has hydrophobic substitutions at position 37 and 106 and an acidic substitution
at position 117. The extensive structural investigations of substrate binding residues for
GR and TryR have allowed for engineering of trypanothione specificity in human GR
(67) as 14 of 19 amino acids suggested to bind GSSG in GR are identical in TryR.
In the case of TR, the C-terminal tail is essentially the substrate for the FAD
domain-conserved active site substituting for GSSG (68). Since glutaredoxin and
glutathione peroxidase are the primary targets for GSH and are similar to Trx, it is as if
TR has evolved by incorporating the GSSG-like moiety into the protein. The size of
thioredoxin makes it inaccessible to the active site of GR, TryR and LipDH.
Alternatively, the C-terminal extension of rat TR occupies the binding site making it
inaccessible to glutathione, trypanothione, and lipoamide. The conservative substitution
to Lys in TR for Arg37 of GR was suggested to serve a similar purpose with respect to
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coordination of the C-terminal carboxylate of rat TR1 (36). There is no current data
pertaining to the residues involved in Trx binding for large Mr TRs.

SPECTRAL CHARACTERISTICS OF FLAVIN AND FLAVOPROTEINS

To better understand the methods currently used for investigating mechanistic
details within the GR family, an introduction to the spectral characteristics of flavin must
be presented. Much of the work describing the electronic states of flavin derivatives was
pioneered by Vincent Massey as reviewed in (69) and has been used to distinguish
between free flavin and flavoproteins and their mechanisms (70, 71). Many classes of
enzymes utilize a flavin moiety, which can participate in either one-electron or twoelectron processes as investigated potentiometrically by Michaelis et al. (72). It is this
characteristic that allows the flavin to be so versatile and results in several electronic
states (73). Each of these states has specific spectral properties as shown in Figure 8 (74)
using Old Yellow Enzyme as the example showing all four electronic states. The
simplified equation most commonly shown for the reduction of FAD is described in
equation 1.
FAD + 2e- + 2H+ → FADH2

(1)

The yellow color associated with a flavin derivative is indicative of the moiety in
the oxidized state. The color comes from an absorbance peak at ~448 nm that is shifted to
longer wavelengths for flavoproteins, ~460 nm for GR and TR (71). This peak for
flavoproteins also has a pronounced shoulder at ~430 nm and another at ~480 nm. These
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shoulders were determined to be a function of the hydrogen-bonding environment
between the protein and the isoalloxazine ring (71). As with most species with an
aromatic nature, there is also an absorbance maxima in the near ultraviolet. This peak is
~375 nm for flavin and a slightly shorter wavelength for a flavoproteins, ~370 nm for GR
and TR. Complete reduction of flavin to FADH2 results in a decrease in extinction for the
UV peak and a loss of visible color. This loss of color upon reduction, however, is not
observed in all flavoproteins (70).
As free flavin and flavoproteins have unique properties, the same can be said for
the GR and TR compared to enzymes such as glucose oxidase (71, 73). For example,
photoreduction and reoxidation experiments with glucose oxidase results in all flavin
species being observable (75). The reduction of GR, however, under physiological
conditions displays different properties (Figure 8 inset) (76). While the spectra of the
oxidized enzyme (spectra 1) resembles that of the free flavin, it is clear that the reduced
form of the enzyme using NADPH (spectra 2) or sodium borohydride (spectra 3) does not
resemble that of the reduced free flavin in the form of FADH2. The characteristic reduced
spectrum is not typically seen in GR family proteins under normal conditions. To achieve
this state, long incubations in excess NADPH or chemical reducing agents such as
dithionite are most commonly required (70, 77-79). The reduced spectrum of GR instead
appears to be a hybrid between the oxidized and anionic semiquinone states (73).
The most notable characteristic of NADPH-reduced GR or TR is a red color that
is demonstrated by the absorbance change at 540 nm in the inset of Figure 8. This color
indicates the essential species and primary intermediate of the mechanism of these
proteins, the thiolate – flavin charge-transfer complex. There is a transient covalent
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adduct with the C4a position of the isoalloxazine ring of the flavin and active site
cysteine. An adduct intermediate with substrate at this position is also proposed for many
other classes of enzymes (69). This transient species becomes the primary charge-transfer
intermediate upon reduction of the disulfide. Preliminary investigations for spectral
characteristics of the GR protein family were performed using LipDH (80-83). The twoelectron reduced enzyme showed the same red color mentioned above with proton
inventories suggesting a proton from dihydrolipoamide being taken by the catalytic
acid/base. The adduct formed between the cysteine and FAD with the subsequent
formation of the charge-transfer complex as the reduced intermediate for the GR results
in equation 2, which is typically how the FAD in the reaction cycle is represented for GR
and TR.
FAD + NADPH → FADH-

(2)

THE GLUTATHIONE REDUCTASE CATALYTIC CYCLE

Catalytic Overview.
GR is a two-substrate, two-product (or three, with a GSSG producing 2 GSH)
enzyme, shown in equation 3, following Ping-Pong Bi-Bi kinetics similar to that of
LipDH (84, 85), as reviewed in (86). Massey and Williams (87) originally proposed the
catalytic cycle of GR which has since been divided into two phases: a reductive halfreaction and an oxidative half-reaction. In the reductive half-reaction, the enzyme is
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reduced by the consumption of NADPH resulting in the formation of the thiolate-flavin
charge-transfer complex. The enzyme is re-oxidized upon consumption of GSSG in the
oxidative half-reaction, which is the prototypical enzymatic thiol-disulfide exchange. The
steps in each half-reaction have been studied extensively by stopped-flow kinetics, as
best described in (88, 89) using the spectral characteristics of the flavin. The reaction was
predicted to be acid/base catalyzed with the residue identified in the C-terminal region of
GR (90). A representation of the GR catalytic cycle is shown in Figure 9.
GSSG + NADPH + H+ → 2GSH + NADP+

(3)

His467′ for human GR (His439′ for E. coli.) from chain B has since been
identified as the acid/base catalyst in GR and is conserved throughout the protein family.
It has been shown to be essential in both the reductive half-reaction and oxidative halfreaction for GR (48, 88, 91), LipDH (80, 92), and PfTR (93). His467′ is activated by
Glu472′ (human GR) forming a catalytic dyad that acts as a potential charge-relay system
between the dyad and the N-terminal thiol of the active site disulfide, as first proposed
from the crystal structure of GR (50). For the discussion of the catalytic cycle, I have
chosen to use the GR comparison as it functions to reduce a disulfide like TR rather than
to oxidize a dithiol as is the case for LipDH.
Flavin Spectra and Enzyme Kinetics.
In the previous section we introduced the spectral characteristics of flavin and
flavoproteins in terms of the redox state of the flavin in three states - oxidized, reduced,
and charge-transfer. In terms of the catalytic cycle shown in Figure 9, there are three
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primary flavin states but more than three steps. As can be seen in the flavin spectra in
Figure 8, differences in the redox state results in changes throughout the spectrum.
Therefore, a subset of relevant wavelengths has been established for kinetic analysis (88,
89). The easiest to understand is the thiolate-flavin charge-transfer complex observed at
540 nm. The second is a charge-transfer complex between FADH- and NADP+ at 670
nm. The complete oxidation of flavin results in an absorbance maxima at ~460 nm but
partial oxidation is a characteristic of these proteins during each half-reaction. Therefore
this state is followed at 440 nm.
The method developed at The University of Michigan by Ballou and Arscott
utilizes a stopped-flow spectrophotometer adapted for anaerobic conditions. These
conditions are necessary to prevent auto-oxidation of the flavin. While the rapid reaction
kinetics using flavin spectra provides more details than steady state kinetics, it is not
without limitations. There are several species that are spectrally equivalent and cannot be
distinguished for GR (88) or TR (78, 79, 93). Of special interest are the catalytic
intermediates involving the thiol-flavin charge-transfer.
The Reductive Half-Reaction of GR.
During the reductive half-reaction (Eox to EH2(B)), the FAD-associated disulfide
from chain A is reduced upon consumption of electrons from NADPH. Three primary
phases have been spectrally observed for this reaction (88, 89). The first phase, binding
of NADPH and formation of the NADPH - FAD charge-transfer complex is complete
within the dead time of the stopped-flow instrument. The second phase includes the
reduction of FAD to form the FADH- - NADP+ charge-transfer complex. The third phase
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transfers electrons to the N-terminal disulfide and occurs via the thiolate-FAD chargetransfer complex. The mutant His439′Ala (E. coli GR), was reported to result in a modest
16 fold decrease in the overall rate for the reductive half-reaction. A closer inspection
reveals different spectra upon NADPH reduction of the wild type and mutant enzymes
(88). The mutant enzyme at the end of the reaction has much more reduced flavin
characteristic and less charge-transfer absorbance indicating the two proteins are in
significantly different states. While the rate differences are addressed in the discussion,
the magnitude of the difference in the spectra (especially at 440 nm) is not.
The Oxidative Half-Reaction of GR.
The oxidative half-reaction (EH2(B) to Eox) is the reduction of GSSG that results
in the re-oxidation of GR. For each NADPH consumed in the reductive half-reaction,
two GSH molecules are produced from a single GSSG in the oxidative half-reaction. The
intermediate of the oxidative half-reaction (EH2(C)) is a mixed disulfide formed between
the cysteine of GSH I and the active site interchange thiol (Cys58) from chain A (94).
This step is referred to as interchange. This intermediate is seen crystallographically in
PDB 1GRE compared with the bound oxidized GSSG in PDB 1GRA (34) now at <2 Å
refined from the initial 3 Å structures (47). The high temperature factors of GSGII and
the fewer direct contacts to GSHII from GR in combination with GSHI as the interchange
moiety indicates that GSHII is likely the first leaving group. The significance of this
intermediate is biochemically supported by GSH/GSSG equilibrium experiments and is
hypothesized to be the major form of GR physiologically (94). Unlike the reductive halfreaction where multiple spectral states are observed, the oxidative half-reaction is
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followed by a single state as EH2(B) and EH2(C) are spectrally equivalent. This means: 1)
formation of the mixed disulfide, 2) protonation of the first leaving group, 3) resolution
of the mixed disulfide, and 4) protonation of the second leaving group are incorporated
into a single rate constant (88).
This challenge was partially addressed by earlier experiments using mixeddisulfide substrates (95). The substrates GS-SNB (mixed disulfide of glutathione and 5thio-2-nitrobenzoic acid) and GS-SNP (mixed disulfide and 2-thio-4-nitropyridine) were
evaluated as substrates for GR using kinetic isotope effects on kcat with varying deuterium
concentrations. The mixed disulfide substrates have an aromatic thiol group with a low
pKa and would not require protonation, unlike GSH. Each substrate indicated a proton
transfer step as partially rate-limiting and results from either substrate indicated that the
same rate-limiting step was being observed. While the aromatic thiol should be the first
leaving group (94) with GSH as the interchange mixed disulfide, it was hypothesized
from this data that the GSH was the first leaving group. The rationale provided is that for
the system to be in equilibrium, the GSH would have to be the first leaving group. At
equilibrium, the free GSH would be able to re-attack the interchange mixed disulfide. If,
however, the aromatic disulfide were the first leaving group, the reaction should be
irreversible. Why the aromatic disulfide would be the second leaving group in this
experiment is not quite clear. One possibility could be a function of binding or orientation
of this modified substrate in the active site (96), which is not accounted for.
His439′ has been shown to be essential to the oxidative half-reaction for
protonation of the first leaving group, the thiol of GSHII (88). This half-reaction was
shown to be 600 fold slower in the His439′ mutant. This indicates that protonation of the
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leaving group is essential in the oxidative half-reaction. Protonation and subsequent
dissociation is essential to prevent the re-attack of the interchange mixed-disulfide by
GSHII and thereby driving the reverse reaction (88). The final step of the oxidative halfreaction is the resolution step. The resolving thiol, Cys63, attacks the interchange mixed
disulfide and reforms the enzyme Cys58-Cys63 disulfide with release of the second
molecule of glutathione (GSHI). Thus, the enzymatic thiol-disulfide exchange process
characteristic of this family of proteins involves an interchange step (requiring an
interchange cysteine) and a resolution step (requiring a resolving cysteine).

THE HIGH Mr THIOREDOXIN REDUCTASE CATALYTIC CYCLE

The addition of a second thiol-disulfide exchange in TR results in a significantly
more complicated reaction cycle (Figure 10) as best described for PfTR (93) and DmTR
(78) with partial insight from mammalian TR (79). The reductive half-reaction of TR
includes transfer of electrons from the N-terminal dithiol to the C-terminal disulfide (this
is equivalent to the combination of the reductive and oxidative half-reactions in GR) as
well as the consumption of an additional equivalent of NADPH. The oxidative halfreaction of TR is the thiol-disulfide exchange between the C-terminal dithiol and the
disulfide of Trx. The steady state cycle therefore alternates between two-electron and
four-electron reduced states of TR, EH2 to EH4, as shown for DmTR (78) and PfTR (93).
It is assumed from this work that EH4(B) is the predominant product of the reductive
half-reaction and demonstrates an enhanced flavin-thiolate charge-transfer complex.
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As much mechanistic detail as is inferred from this work, only three discernable
rate constants have been determined for the entire reductive half-reaction (93) from a
model with at least eight steps. The first constant is the consumption of the first
equivalent of NADPH foming the FADH- - NADP+ charge-transfer complex and the
second rate constant being the formation of the thiolate-FAD charge-transfer complex.
This is similar to the analysis for GR. This means the third rate constant represents the
thiol-disulfide exchange between the N-terminus and C-terminus with the spectra
complicated by the consumption of the second equivalent of NADPH. Referring to
Figure 10, these are the steps from EH2(B) to EH4(B).
Mutation of either residue of the His-Glu catalytic dyad for PfTR results in
significant decreases in rate for both the reductive half-reaction and the oxidative halfreaction (93) with the His mutation almost completely destabilizing the thiolate-flavin
charge-transfer complex. Similar results are seen by the authors for the equivalent
mutations in DmTR, but have yet to be published. This is in agreement with that observed
for the equivalent mutants in GR (88, 89) and LipDH (97, 98). Similarly, mutation of the
equivalent Glu477 in human TR results in a 6 fold reduction in kcat (99). The perturbation
of the reductive half-reaction appears greater in magnitude for the His mutation in PfTR
than mentioned above for GR. These results indicate 1) the importance of the catalytic
acid/base in both half-reactions for GR and TR; 2) could imply the catalytic acid/base is
also involved in thiol-disulfide exchange between the C-terminus of TR and the disulfide
of Trx. The latter has been proposed in a mathematical model for mammalian TR (100)
where the His would be directly involved in the exchange by deprotonation of the
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attacking thiolate of TR and/or protonation of the leaving group thiol of Trx. However
there is currently no experimental evidence for this.
It is quite possible that the decrease in rate for the His and Glu mutants of PfTR
(93, 101) represents the unfavorable formation of EH2(B) rather than catalytic association
with Trx. The authors note that the thiolate charge-transfer complex in the His mutant is
nearly absent. If the model of the catalytic cycle is correct and EH2(B) is formed prior to
Eox during reoxidation in these experiments, the His mutation could be a function of
reoxidation of the N-terminal disulfide instead. Like the reductive half-reaction, three rate
constants were determined for the oxidative half-reaction of PfTR. The first rate constant
for the His or Glu mutants is 50% of the wild type enzyme and is attributed to the thiol
disulfide exchange with Trx indicating these residues are not directly involved with Trx.
The second rate constant is attributed to the reaction of EH2(D) with the excess Trx in the
experiment. This rate would reflect conversion from EH2(B) to EH2(D) and is
significantly slower in the His and Glu mutants. The third rate constant is the slowest of
the three and reflects the complete reoxidation of the flavin.
It can be interpreted from this data that the decrease in rate for the His and Glu
mutants for PfTR in the oxidative half-reaction are actually steps in the reductive halfreaction. Each of the three rate constants for the oxidative half-reaction is significantly
lower than the rates determined for the reductive half-reaction (93). This is consistent
with results for DmTR where the single determined rate constant of 11 s-1 was suggested
to be the conversion of EH2(B) to EH2(D) during the oxidative half-reaction (78). The
overall rate constant of 5 s-1 for reduction of Trx was determined, indicating this step is
the major contributor to the overall rate of DmTR. An interpretation that is completely
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consistent for what is observed for GR where the protonation of the first leaving group in
the oxidative half-reaction is the overall rate-limiting step (88, 95). The only caveat being
that GSSG is now replaced by the C-terminal disulfide in TR. This may sound confusing
at first, but it can be better understood by comparing Figure 9 to Figure 10 and
establishing the important relationship in equation 4.
EH2(B) → Eox (GR) = EH2(B) → EH2(D) (TR)

(4)

SELENOCYSTEINE IS ESSENTIAL TO MAMMALIAN TR

Earlier in the Introduction, it was implied that mammalian TR has unique
functional properties in comparison to the other proteins in the family. Yet we have not
discussed what makes mammalian TR unique. For simplification purposes, TRs have
been discussed in general terms of the catalytic cycle, since all high Mr TRs share the
active site containing C-terminal extension. There are two major subclasses of this Cterminal active site. Looking more closely at the sequence alignment in Figure 5, the one
letter code U (selenocysteine) is in the penultimate position for mammalian forms while
others contain C (the one letter code for cysteine). Therefore the two classes are those
whose active site contains a Cys-Cys dyad and that which contains a Cys-Sec dyad,
where Sec is the three letter code for selenocysteine.
Sec containing proteins are found in prokaryotes, eukaryotes and archea but are
relatively rare. In humans for example, only 25 proteins have currently been identified
that contain Sec (102). Sec is inserted co-translationally at the ribosome during protein
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synthesis but requires a unique cis element and several unique trans factors as the codon
for Sec is the normal termination codon UGA (Figure 11). The cis element is the
selenocysteine insertion sequence (SECIS), a specific stem loop structure in the mRNA.
This sequence is adjacent to the UGA codon in prokaryotes but is found in the 3΄
untranslated region for eukaryotes (see (102) and references therein). It also requires
specialized enzymes for the assimilation and incorporation of selenium into Sec (103,
104). The process is metabolically expensive for the organism and challenging to
manipulate for the scientist interested in recombinant protein production.
Bacterial formate dehydrogenase was the first enzyme where selenium was
demonstrated as required for function (105). Several other enzymes, such as glutathione
peroxidase and 5΄ deiodinases, were also identified as requiring selenium though the
nature of the selenium moiety was not clarified, as reviewed by (106). Enoch et al.
demonstrated that selenium was likely a covalent component of formate dehydrogenase
and suggested the presence of a selenol (107). In the following year, selenium was
identified as incorporated into the selenoprotein A, an essential component of clostridial
glycine reductase, as Sec by the Stadtman group at the NIH (108). The same group did
not identify Sec as the penultimate residue in human TR (63) until 20 years later. Sec
since has been shown to be essential to the function of mammalian TR. Replacement of
the catalytic Sec residue in the mammalian enzyme with a Cys residue results in a large
decrease (>100 fold) in catalytic activity towards the cognate substrate Trx (109). Sec is
incorporated into the mammalian TR C-terminal sequence, Gly-Cys-Sec-Gly (GCUG)
(63).
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Selenium is an essential trace element and the key component of many
biologically important selenocompounds (110, 111) but is also toxic at increased
concentrations (112, 113). The incorporation of Sec into mammalian TR is responsible
for expanding the substrate range to include peroxides and lipid peroxides (31, 114),
ascorbate (30, 115) and seleno-compounds such as selenite (116), methylseleninate (117),
selenodiglutathione (118). This indicates TR may also be a component of the systems
regulating the seleno-metabolite pool (17). Sec incorporation into TR has also been
proposed to be one of the links between selenium supplementation and cancer prevention
(119) as reviewed by (120).
While the incorporation of Sec may provide a selective advantage by expanding
the substrate range, it is not required to catalyze the reduction of Trx by TR. One such
example is DmTR, which has high activity towards its cognate Trx and good activity
towards Trx from E. coli (11, 65). Gromer et al. (65) proposed that it is the flanking
serine residues in the Ser-Cys-Cys-Ser (SCCS) motif that aid in deprotonating the
catalytic Cys residue, thus obviating the need for Sec in this enzyme. Yet, when the Ser
were mutated to Gly residues, only a 7 fold reduction in activity is observed. This is not
the >100 fold loss in activity for the mutation of Sec to Cys in the mammalian enzyme or
for mutating the catalytic His in GR (88) or PfTR (93, 101). The same authors proposed
the conserved His (His106) as a second catalytic acid/base in DmTR (65). However,
mutation to Phe or Gln results in a similar 3-7 fold loss in activity as observed in the
mutation of the C-terminal Ser residues (121) with the author’s interpretation being that
His106 was not essential to catalysis. Clearly there is a discrepancy in the interpretation
of these very similar results. It was also recently reported that the mitochondrial TR from
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Caenorhabditis elegans (CeTR2), which has a Gly-Cys-Cys-Gly (GCCG) motif, also has
a high activity towards E. coli Trx (122). In CeTR2 there are no flanking Ser residues.
This is also the case for PfTR which has the sequence Gly-Cys-Gly-Gly-Gly-Lys-CysGly (GCGGGKCG) (55, 123, 124).

SPECIFIC AIMS

The question this project addresses can be phrased based on the direction of the
approach. For those who focus on mammalian TR, the question is “why selenocysteine?”
Taking into consideration that other higher eukaryotes catalyze the same reaction without
Sec, the question may also be phrased “why not cysteine?” It has been long inferred that
Sec is essential for mammalian TR due to the low pKa of Sec (~5.2) making it a better
nucleophile than Cys which has a pKa ~8.3 (125). This is the motivation behind the
proposal of Gromer et al. on the function of the flanking Ser for DmTR (65). However
CeTR and PfTR function without flanking Ser residues. It is also hypothesized that the
low pKa of Sec makes it a better leaving group. However the catalytic acid/base essential
to both half-reactions is conserved throughout the protein family, so why would the low
pKa of Sec be essential to mammalian TR but not DmTR, CeTR2, or PfTR? The purpose
of this project is to develop a testable hypothesis for the requirement of Sec in
mammalian TR.
Aim 1 is to develop a method for semisythetic production of mammalian TR. The
method produces the full-length enzyme from a ligation of two separately produced
modules using expressed protein (126-128). A truncated form of TR missing the three C27

terminal amino acids is produced for the first module as a TR-intein-chitin binding
domain fusion protein in E. coli. The second module is a C-terminal peptide with a Nterminal Cys. Using this method we will generate C-terminal mutants for structure
function studies to investigate the positional and sequence dependence of Sec in the Cterminal active site for mammalian TR. This method will allow 1) avoidance of the
complications of Sec incorporation by recombinant methods, 2) the incorporation of
synthetic functional groups or site-specific radiolabels that would not be possible using
standard recombinant techniques.
Aim 2 is to develop a new technique, termed peptide complementation, to study
the mechanism of TR. This technique will allow us to look at a specific reaction in the
catalytic cycle in a manner similar to that of GR. The formation of an intramolecular
disulfide bond between vicinal residues like that of the C-terminus of TR results in an
eight-membered ring. This ring must be opened (reduced) by the FAD-associated active
site during the catalytic cycle. Oxidized tetrapeptides, equivalent to the C-terminus of TR
are used as substrate for the truncated form of TR missing the final three residues. These
tetrapeptides are reduced by the FAD-associated active site just as GSSG is reduced by
the same active site in GR. This approach will allow us to determine the activity of CysCys and Cys-Sec peptides in this step of the catalytic cycle for correlation to activities of
the semisynthetic mutants.
Aim 3 is to determine the crystal structure of DmTR for comparison to
mammalian TR. The NMR structures of the tetrapeptides established as substrates for the
truncated TR are modeled into the active site by orientation of the Cys residues to the
binding orientation of GSSG in the structure of GR. The structure and peptide modeling
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is expected to correlate to the biochemical data collected from Aims 1 and 2 and develop
a new hypothesis for the requirement of Sec for mammalian TR.
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Figure 2. Glutathione reductase family cognate substrates.
Substrates of the Glutathione Reductase family of pyridine nucleotide disulfide
oxidoreductases. The substrates are labeled with the shown redox state in parentheses.
Diglutathione (GSSG) (34), trypanothione (37), and dihydrolipoyl (129) are small
molecule substrates while thioredoxin (Trx) (130) is a ~12 kDa protein. The reversible
disulfide of Trx with the conserved sequence Cys-Gly-Pro-Cys is shown.
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Figure 3. Diagrammatic representation of GR structure.
Glutathione reductase on the left is compared with thioredoxin reductase on the right.
Each homodimer is assembled in a head to tail fashion. Each monomer has a N-terminal
FAD domain, a central NADP domain, and a C-terminal dimerization domain. The
conserved FAD-associated active site disulfide is indicated in gray. The GR substrate
GSSG is shown in blue while the C-terminal disulfide active site for TR is in red.
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Figure 4. Ribbon diagram of GR and TR.
(Top) Ribbon diagram of glutathione reductase (34) showing the FAD (ruby), the bound
GSSG (blue), catalytic residues (red). (Bottom) Ribbon diagram of mouse thioredoxin
reductase 3 (35) showing the FAD (ruby), the bound NADP (black), catalytic residues
(red), the arrows indicate the 16 amino acid C-terminal extension. The N indicates the Nterminus of each monomer.
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Figure 5. Multiple sequence alignment (C-terminal).
Multiple sequence alignment generated by Clustal W (131) of the C-terminal
dimerization domain with either the PDB ID or accession number in parentheses. The
sequences are glutathione reductase (GR) from H. sapiens (PDB 1GRA), GR from E. coli
(PDB 1GER), Thioredoxin reductase (TR) 2 from H. sapiens (Q9NNW7), TR1 from R.
norvegicus (PDB 1H6V), TR3 from M. musculus (PDB 1ZKQ), TR1 from C. elegans
(AF148217_1), TR3 from C. elegans (NP_498971.1), TR from P. falciparum
(NP_704777.1), TR1 from D. melanogaster (AF301144_1), TR from A. mellifera
linguistica (AAP93583.1), TR from A. gambie (CAD30858.1), mercuric reductase
(MerA) from B. licheniforms (CAC14663.1), dihydrolipoamide dehydrogense (LipDH)
from H. sapiens (EAL24389.1), trypanothione reductase (TryR) from T. congolense
(AAA30258.1). The catalytic acid base dyad is His464 and Glu469 (Drosophila TR
numbering).
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Figure 6. Multiple sequence alignment (FAD Domain).
Multiple sequence alignment generated by Clustal W (131) of the FAD domain with
either the PDB ID or accession number in parentheses. The sequences are glutathione
reductase (GR) from H. sapiens (PDB 1GRA), GR from E. coli (PDB 1GER),
Thioredoxin reductase (TR) 2 from H. sapiens (Q9NNW7), TR1 from R. norvegicus
(PDB 1H6V), TR3 from M. musculus (PDB 1ZKQ), TR1 from C. elegans
(AF148217_1), TR3 from C. elegans (NP_498971.1), TR from P. falciparum
(NP_704777.1), TR1 from D. melanogaster (AF301144_1), TR from A. mellifera
linguistica (AAP93583.1), TR from A. gambie (CAD30858.1), mercuric reductase
(MerA) from B. licheniforms (CAC14663.1), dihydrolipoamide dehydrogense (LipDH)
from H. sapiens (EAL24389.1), trypanothione reductase (TryR) from T. congolense
(AAA30258.1). The alignment shows the FAD binding motif (Top) and conserved FADassociated active site sequence C57VNVGC62 (Bottom) (Drosophila TR numbering).
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Figure 7. The FAD domain topology.
(Left) The Rossman Fold of the FAD-Binding Domain from rat thioredoxin reductase 1
(36). The conserved GxGxxGx(17)D/E is Gly19 to Gly23 as the phosphate binding motif
and D-42 to coordinate the ribose of the adenosine. This is the Top panel of the alignment
in Figure 6. (Right) The topology diagram of the domain shows arrows indicating strands
and columns indicating helicies. The N indicates the NADP domain and the red arrow
indicates the active site CVNVGC.

.
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Figure 8. Spectral properties of flavin.
Spectral characteristics of the flavin moiety of Old Yellow Enzyme in various redox
states taken from (74). The inset is of the human glutathione reductase taken from (76) in
the oxidized form (1), NADPH reduced (2), and sodium borohydride reduced (3). The
spectral characteristics of the reduced GR under normal conditions do not resemble that
of the reduced flavin. It best represents a mixture between the oxidized and the anionic
semiquinone. The shoulder at 540 nm (inset) is the charge-transfer complex between the
flavin and the C-terminal Cys of the FAD-associated active site.

.
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Figure 9. The catalytic cycle of GR.
The Catalytic cycle of Glutathione Reductase. The steady state cycles between Eox and
EH2. From Eox to EH2(B) is the reductive half-reaction. From EH2(B) back to Eox is the
oxidative half-reaction. The colors for each enzyme species represent the characteristic
wavelength: the oxidized enzyme is yellow (440 nm – 460 nm), the FADH- - NADP+
charge-transfer complex is shown in blue (670 nm), and the thiolate-FAD charge-transfer
complex is shown in red (525 nm – 540 nm). The GSSG substrate is shown in green, the
catalytic acid/base from Chain B is shown in gray. Diagram adapted from (93).
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Figure 10. The catalytic cycle of TR.
The Catalytic cycle of Thioredoxin Reductase. The steady state is though to cycle
between EH2 and EH4. From Eox to EH4(B) is the reductive half-reaction. From EH4(B)
back to EH2(B) is the oxidative half-reaction. The enzyme species color code is as shown
in figure 9. The C-terminal disulfide and the catalytic acid/base from Chain B are shown
in gray. The substrate thioredoxin is shown in green. Diagram adapted from (93).
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Figure 11. Docoding of the UGA codon.
Eukaryotic decoding of the UGA codon for the cotranslational incorporation of
selenocysteine into proteins (132, 133).
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CHAPTER 2:
SEMISYNTHESIS OF MAMMALIAN
THIOREDOXIN REDUCTASE

Figure 12. Representation of semisynthetic TR.
Semisynthesis of mammalian thioredoxin reductase. Selenoproteins are difficult to
produce recombinantly due to the complicated cellular machinery, which must be
manipulated for decoding of the UGA Sec codon. Semisythesis produces the wild type
enzyme by the ligation of two modules via a thioester intermediate: 1) the truncated form
of the enzyme missing the three C-terminal amino acids and 2) the synthetically produced
C-terminal tripeptide Cys-Sec-Gly.

40

Biochemistry 2006, Apr 25; 45(16): 5158-5170
Semisynthesis and Characterization of Mammalian
Thioredoxin Reductase†
Brian Eckenroth‡, Katharine Harris‡, Anton A. Turanov§, Vadim N. Gladyshev§,
Ronald T. Raines||, and Robert J. Hondal*‡
‡

Department of Biochemistry, 89 Beaumont Ave, Given Laboratory, Room B413,
Burlington, VT 05405
||

Departments of Biochemistry and Chemistry, University of Wisconsin-Madison,
Madison, WI 53706
§

Department of Biochemistry, University of Nebraska, Lincoln, NE 68588

†

These studies were supported by National Institutes of Health Grants GM070742 to
RJH, GM044783 to RTR, and GM065204 to VNG.
*

To whom correspondence should be addressed. Department of Biochemistry, University
of Vermont, College of Medicine. 89 Beaumont Ave, Given Laboratory, Room B413,
Burlington, VT 05405. Tel: 802-656-8282. FAX: 802-862-8339. E-mail:
Robert.Hondal@uvm.edu.

41

Here, we report the development of an alternative method for producing an active
mammalian TR containing selenocysteine. This method uses expressed protein ligation to
create a semisynthetic TR. TR contains selenocysteine in a C-terminal tripeptide with a
Cys-Sec-Gly sequence, where the Sec residue is the penultimate amino acid (63). The
location of the Sec residue in the C-terminus (Figure 12) makes TR an ideal candidate
for semisynthesis. Our strategy for producing a semisynthetic TR is shown in Figure 13.
Introduction to Semisynthesis.
The term semisynthesis refers to the production of a functional entity, a single
polypeptide chain enzyme for example, from two or more separately produced
components. There are three categories of semisynthesis: 1) native chemical ligation
(NCL), 2) expressed protein ligation (EPL) which is intein mediated, and 3)
complementation. Unlike the first two techniques (127), complementation is a noncovalent association of the components. The best example of complementation is the
production of functional ribonuclease from two separate polypeptide chains achieved by
Richards (134). This technique will be addressed in Chapter 4.
The ligation methods both require the formation of a thioester intermediate at the
C-terminal end of the N-terminal fragment, which is attacked by the N-terminal Cys of
the C-terminal fragment. In native chemical ligation, the thioester is generated by
synthetic means whereas in expressed protein ligation (Figure 14) the thioester is
generated at the junction of a fusion protein. The fusion protein contains the N-terminal
piece of the protein of interest followed by an intein. The thioester is formed at the fusion
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protein junction by the N-terminal Cys of the intein. Like complementation, this
technique has also been used successfully with ribonuclease (135), as well as for
producing modified potassium channels (136, 137), and to investigate cell-signaling
mechanisms (138) using modified phosphoproteins.
The intein is a naturally occurring self-splicing protein element found in several
simple organisms such as certain bacteria as well as single-cellular eukaryotes (139).
Analogous to RNA self-splicing introns, which join two flanking exons, the intein
catalyzes the ligation of two flanking protein segments (140). This reaction is catalyzed
via formation of a thioester intermediate formed by the N-terminal Cys of the intein.
Upon ligation of the segments, the intein is released, as reviewed in (141).
Most often the two ligation techniques are used independently to assemble two
fragments, as we have used with EPL to produce semisynthetic TR. However, the two
methods can be used is combination to perform a two-step ligation product from three
fragments (Figure 15). This has been utilized for the insertion of a fluorescent probe in
between the Src homology domains 2 and 3 of a protein tyrosine kinase (142). In this
method, the C-terminal domain

(containing an N-terminal Cys) is produced

recombinantly and purified. The label to be inserted is incorporated into a short,
synthetically produced peptide. This peptide includes three features: a C-terminal
thioester, the incorporated label, and a N-terminal factor Xa protease sequence. This
peptide is mixed with the C-terminal domain to form the first ligated product by NCL.
The product is treated with the factor Xa protease generating a new N-terminal Cys. The
N-terminal domain is produced as the intein fusion protein of which the new N-terminal
Cys will attack the thioester resulting in the final product by EPL.
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METHODS

Peptide Synthesis.
Fmoc-selenocysteine(pMob)-OH was synthesized as reported previously(127,
128). This derivative of Sec was then used to make the Cys-Sec-Gly tripeptide (CUG) or
the Ac-GCUG tetrapeptide using solid-phase peptide synthesis as described (143).
Peptide were purified by preparative HPLC from the Shimadzu Corporation (Kyoto,
Japan) and verified by Matrix Assisted Laser Desorption Time of Flight Mass
Spectrometry on a Voyager DE PRO Workstation from Applied Biosystems
(Framingham, MA). A comprehensive list of materials used in this dissertation is
available in Appendix B.
Mutagenesis and Transformation.
DNA primers were purchased from Integrated DNA Technologies Inc.
(Coralville, IA) for the mutation of the Sec residue (encoded by TGA) at position 489 to
cysteine (encoded by TGT) (mutant Sec489Cys). A comprehensive list of PCR primers
used in this dissertation is available in Appendix C. The template used was plasmid
pTR3, which contained the full-length sequence of the mouse thioredoxin reductase-3
gene (mTR3 GenBank accession number AF171053) was a generous gift from Vadim N.
Gladyshev. Mutagenesis was performed by PCR on the GeneAmp PCR System 2400
from Perkin-Elmer Life Sciences Inc. (Boston, MA) using Vent DNA polymerase. The
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PCR product was purified using the QIAquick purification kit from Qiagen (Valencia,
CA) according to product instructions. The PCR product containing the mutated sequence
was inserted into the pTYB3 plasmid (New England Biolabs) by restriction digestion
with Nco I and Sap I for 2 h at 37

C followed by purification with a Qiagen spin

column, and ligation with T4 DNA ligase at 16
inactivated at 70

C for 16 h. The ligase was heat

C for 30 min, followed by incubation at 37

C with Eco RI. Eco RI

cuts only the plasmid that has not been ligated with the PCR insert, thus enriching the
pool of positive clones. The resulting plasmid (pTYB3TR), also containing the gene for
ampicillin resistance and a T7 promoter, was used to produce the thioredoxin reductaseintein-chitin binding domain fusion protein in E. coli ER2566 cells.
E. coli DH5 cells, purchased from Stratagene (La Jolla, CA) were transformed
with pTYB3TR by addition of 100 ng of plasmid to 200 µL of cells and incubation on ice
for 30 min. The cells were heat shocked at 37

C for 2.5 min and placed back on ice for

5 min. A 1 mL aliquot of LB broth was added to the cells and the mixture incubated at 37
C for 60 min. The cells were then plated onto LB-ampicillin agar and incubated
overnight. Colonies were then picked and used to inoculate 3 mL of 2×YT medium
containing 0.2 mg/mL ampicillin and grown in a shaking incubator for 24 h at 37

C.

The plasmid was purified from culture using the Perfectprep Plasmid Mini Kit from
Eppendorf (Hamburg, Germany). Transformants were screened by restriction analysis
and then analyzed by agarose gel electrophoresis. Positive clones were then sequenced to
verify the complete coding sequence of mTR3.
An additional construct was also generated for the truncated form of TR missing
the C-terminal tripeptide Cys-Sec-Gly (mTR3-G487) using the method above. This
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construct is used to produce either the truncated form of the enzyme or for ligation of the
synthetic peptides to produce the wild type enzyme by semisynthesis.
Thioredoxin Reductase Expression and Cleavage from Chitin Resin.
The full-length U489C mutant and a truncated version of mTR3 that was missing
the C-terminal CUG tripeptide were expressed in E. coli ER2566 cells (New England
Biolabs). The cell culture (6 L) contained 0.2 mg/mL ampicillin, and cells were grown at
25

C until an OD of 0.6 at 600 nm was achieved. Expression was then induced for 6 h

by the addition of IPTG to a final concentration of 0.5 mM. Cells were harvested by
centrifugation and frozen at -20

C overnight. The cell pellet was homogenized with 300

mL of buffer containing 150 mM sodium chloride (NaCl) in 50 mM 3-(Nmorpholino)propanesulfonic acid (MOPS) at pH 7.0 and probe-sonicated on ice for 20
min. The suspension was then centrifuged at 9000 rpm in a Beckman J21B preparative
centrifuge (JA-14 rotor) from Beckman Coulter (Fullerton, CA).
The supernatant was gravity-loaded onto a column containing chitin resin (New
England Biolabs) with a bed volume of 50 mL, and the column was washed with
MOPS/NaCl until the absorbance at 280 nm of the eluant dropped to <0.1. For the
truncated product and the full-length U489C mutant, the column was then equilibrated
with cleavage buffer [50 mM MOPS, 150 mM NaCl, and 70 mM Nmethylmercaptoacetamide (NMA) or β-ME (pH 7.2)]. The resin-bound TR-intein fusion
protein was then incubated with this buffer at 4 C overnight.
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Ligation of the CUG Peptide to Truncated Construct.
The ligation of the synthetic CUG peptide to the truncated enzyme was performed
with concomitant cleavage from the chitin resin. The resin-bound truncated construct was
cleaved from the chitin resin with cleavage buffer containing 12 mM peptide (305 µmol100 mg) added directly to the chitin column. On the basis of typical protein yields, this
represents a 3000:1 peptide:protein ratio. For a more optimized procedure with respect to
ligation efficiency, the same amount of peptide (in cleavage buffer) was added to the
chitin column in which only half the total amount of protein (supernatant from 3 L of cell
culture instead of 6 L) was loaded onto the column. For a direct comparison of our
methods of TR production, the peptide Cys-Cys-Gly (CCG) was also ligated to produce
the Sec489Cys mutant by semisynthesis.
Final Purification of Enzymes.
The protein was batch eluted from the chitin resin with 1-3 column volumes of the
cleavage buffer, depending on preparation scale. The ligated product was dialyzed
extensively with the MOPS/NaCl buffer at pH 7.0 with a molecular mass cutoff of 6000
Da for removal of any unligated peptide. A separate control experiment was performed in
which the truncated form of mTR3 was isolated in the same manner as the semisynthetic
TR. Each step in the purification of the truncated mTR3 was the same except that
tripeptide CUG was not added to the chitin column.
The pooled protein fractions were prepared for the next step in the purification by
the addition of Tris to 50 mM and ammonium sulfate to 1.0 M, and the pH was adjusted
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to 7.5. Samples were then gravity-loaded onto a column containing Fast Flow 6 Low
Substitution Phenyl Sepharose from Pharmacia-Amersham Biosciences (Uppsala,
Sweden) with a bed volume of 60 mL. Protein was eluted from the column with a 400
mL gradient of ammonium sulfate (from 1.0 to 0 M) with collection of 4 mL fractions.
Collected fractions were evaluated by the absorbance at 280 nm and 460 nm, as well as
12% SDS-PAGE. Fractions containing mTR3 were pooled, dialyzed against 10 mM
potassium phosphate and 10 mM NaCl (pH 7.8), and gravity-loaded onto DEAESephacel from Sigma Diagnostics (St. Louis, MO) with a bed volume of 60 mL. The
protein was eluted with a 400 mL linear gradient of NaCl (from 10 to 300 mM),
collecting 4 mL fractions. Fractions containing mTR3 were verified by SDS-PAGE,
pooled, dialyzed against 100 mM potassium phosphate (pH 7.4), 1 mM EDTA, and 150
mM NaCl, and concentrated using Centriprep 10 concentrators from Millipore (Bedford,
MA). The purification process was monitored via 12% Tris-glycine SDS-PAGE with
Novex precast gels from Invitrogen (Carlsbad, CA) and stained as previously described
(144).
Determination of the Selenium Content of the Semisynthetic TR.
Semisynthetic TR was analyzed by inductively coupled plasma mass
spectrometry (ICP-MS) to determine the selenium content of the enzyme. The TR
samples were in phosphate-buffered saline, and the corresponding buffer was also
analyzed in parallel as a control. The selenium content (in parts per million) was then
recalculated to the molar amount of the analyzed protein.
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"Off-Resin" Ligation Efficiency.
The cell extract from 6 L of E. coli cells was loaded onto a chitin-agarose column
as described above. After being extensively washed with column buffer, the resin was
treated with cleavage buffer to elute the protein. The eluate was concentrated as before
and then dialyzed against 50 mM MOPS buffer (pH 7.0) with 150 mM NaCl to remove
excess NMA. The concentrated protein sample was then divided into four aliquots. The
CUG tripeptide was added to each of three aliquots at a concentration of 5 mM: one
aliquot received 50 mM NMA, the second aliquot received 50 mM NADPH, and the third
aliquot received buffer. The fourth aliquot received only buffer, contained no peptide,
and served as the negative control. The samples were allowed to incubate at room
temperature for 4 h, after which they were dialyzed against 50 mM potassium phosphate
buffer (pH 7.4) containing 150 mM NaCl and 1 mM EDTA to remove excess peptide and
reagent. After dialysis, the samples were assayed using 90 µM thioredoxin (Trx) to
determine a specific activity.
Enzymatic Characterization of Thioredoxin Reductase.
The TR mutants were assayed for activity towards DTNB, Trx, and hydrogen
peroxide as described by Arner (145). All assays were performed on a Cary 50 UV/VIS
spectrophotometer from Varian (Walnut Creek, CA) at 25 oC, pH 7.0, and were initiated
by addition of enzyme. Concentration of homodimeric TR was determined using the
flavin extinction coefficient of 22.6 mM-1cm-1. Activity was monitored over two minutes
and Vo determined from the linear fit. Plots of Vo/ET vs. substrate concentration were fit
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by the Michaelis-Menten equation using KaleidaGraph 4.02 from Synergy Software
(Reading, PA) and activities reported as moles of NADPH consumed per minute per
mole of homodimeric TR.
DTNB Reductase Activity.
The DTNB assay contained 0.2 mM NADPH and 10 mM EDTA in 100 mM
potassium phosphate. For each concentration of DTNB, activity was corrected for
background by addition of buffer only. Activity was measured by the increase in
absorbance at 412 nm, calculated using the extinction coefficient for TNB-, 13.6 mM1

cm-1, and divided by two to account for the production of 2TNB- per NADPH consumed.

The concentration of TR in the assay was 2 nM.
Thioredoxin Reductase Activity.
The Trx assay contained 0.15 mM NADPH, 1 mM EDTA, and 10 mg/mL insulin
in 50 mM potassium phosphate. Activity was background corrected for each
concentration of Trx by addition of buffer only as well as in the absence of substrate.
Activity was measured by the decrease in absorbance at 340 nm for the consumption of
NADPH and calculated using the extinction coefficient of 6200 M-1cm-1. The
concentration of the semisynthetic mTR3 in the assay was 2 nM. The concentration of
each mutant TR was adjusted to achieve a similar change in absorbance at 340 nm as that
of semisynthetic TR.
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Peroxidase Activity.
The hydrogen peroxide assay for semisynthetic mTR3 is formulated similar to
that of the DTNB assay with activity measured at 340 nm and background corrected as
with the previous assays. The concentration of semisynthetic TR in the assay was 50 nM
and the concentration of each mutant TR was adjusted to achieve a similar change in
absorbance 340 nm.
Production of Thioredoxin.
The clone containing the gene for Trx A from Escherichia coli was a gift from
Ronald T. Raines (146) and was produced similar to methods previously described (32).
Calcium chloride competent E. coli BL21DE3 cells were transformed with 50 ng of DNA
and plated onto LB agar supplemented with 200 µg/mL ampicillin. Single colonies were
used to inoculate 100 mL ampicillin-containing LB media and allowed to shake overnight
at 37 oC.
One liter of LB media supplemented with 200 µg/mL ampicillin was inoculated
with 10 mL of starter culture and grown to an OD of 0.6 at 600 nm while shaking at 37
o

C in a C25KC Shaker Incubator from New Brunswick Scientific. The cells were induced

for 3 hours at 37 oC with 0.5 mM IPTG then harvested by 10 minute centrifugation at
10,000 rpm in a JA-14 rotor using a Model J-21B centrifuge from Beckman and pellets
frozen at –20 oC.
Cells were thawed on ice, homogenized in 20 mM Tris pH 8.4 containing 1 mM
EDTA, and lysed by probe sonication using a Branson Sonifier. The lysis was
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centrifuged as above for 90 minutes and the supernatant loaded onto DEAE sephacel, 70
mL bed volume, from Sigma-Aldrich equilibrated in the lysis buffer. After loading, the
column was washed with buffer until the OD at 280 nm of the effluent was 0.05. The
sample was eluted using two 400 mL gradients containing NaCl (0 mM to 0.1 mM and
0.1 mM to 0.25 mM). Fractions were collected and evaluated by absorbance at 280 nm
and SDS-PAGE. Fractions containing Trx were pooled adjusted to 60% ammonium
sulfate and centrifuged as above for 60 minutes. The pellet was solubilized in a minimal
volume of 20 mM Tris pH 8.4, 250 mM NaCl, and 1 mM EDTA.
A 2mL sample was loaded onto a Sephacryl S-100 HR (98 cm X 3.3 cm) gel
filtration

column

from

Pharmacia-Amersham

Biosciences

(Uppsala,

Sweden)

equilibrated with sample buffer. Collected fractions were evaluated by absorbance at 280
nm and SDS-PAGE. The fractions containing Trx were pooled, concentrated using an
Amicon Ultra with 5000 molecular weight cutoff from Millipore. Purity was >95% as
judged by 15% SDS-PAGE and Trx concentration was calculated using the extinction
coefficient at 280 nm of 13,700 M-1.
Determination of the Mass of Truncated and Semisynthetic TRs.
The enzymes were concentrated to 1 mg/mL in 10 mM ammonium bicarbonate
buffer (pH 8.0). The protein samples were then spotted on a 100-well plate at various
dilutions. A solution of sinnapinic acid at 10 mg/mL was overlaid onto the protein spots,
and the samples were left to air-dry. A Voyager-DE MALDI-TOF mass spectrometer in
the linear mode was then used to analyze the samples. The instrument was externally
calibrated using BSA.
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Peptide Mass Mapping of Tryptic Fragments.
Purified thioredoxin reductase (truncated or semisynthetic) at a concentration of
0.3 mg/mL was digested using 10 µg/mL sequencing grade trypsin (Promega) in 150 mM
ammonium bicarbonate at 37

C for 16 h. The digested sample was stored frozen until

mass spectrometric analysis. Samples for MALDI-TOF were prepared by serial dilution
in 10 mg/mL matrix, 2,5-dihydroxybenzoic acid (DHB), or -cyano-4-hydroxycinnamic
acid (CHCA), with a 50% acetonitrile/0.05% TFA mixture as a diluent. Samples were
applied to the MALDI plate as 1 µL spots and dried under vacuum.
A Voyager-DE PRO Workstation (Applied Biosystems) was used to analyze
MALDI-TOF samples. Positive ion spectra (mass + H+) were collected in reflector mode
with an accelerating voltage of 20 000 mV and a delayed extraction time of 175 ns. Data
were collected as the accumulated spectra containing a minimum of 10 spectra at 50 laser
shots per spectrum. Monoisotopic masses were corrected by external calibration using
Applied Biosystems Calibration Mixture 2: angiotensin I (1296.6853), ACTH clip 1-17
(2093.0867), clip 18-39 (2465.1989), and clip 7-38 (3657.9294) prepared in the
equivalent matrix. The resulting (mass + H+) data were compared to a theoretical digest
generated using the ExPASy Peptide Mass Proteomics tool.
Digested samples were also analyzed by LC-MS using a Thermo-Finnigan LCQ
Deca XP Plus liquid chromatograph via ion trap mass spectrometry with peaks subjected
to MS/MS fragmentation sequencing by collision-induced dissociation. Full MS of parent
ions and MS/MS fragmentation data were processed using the Turbo-SEQUEST database
for peptide identification. The mass + H+ of the semisynthetic C-terminal tryptic
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fragment (SGLEPTVTGCUG), molecular formula of Se1C44H73N12O18S1 representing the
oxidized form, was compared to the theoretical isotope pattern generated using MSIsotope from USCF ProteinProspector version 4.0.5.

RESULTS AND DISCUSSION

Expression and Purification.
We have constructed a fusion protein that consists of mouse thioredoxin
reductase-3, intein, and chitin binding domain. The chitin binding domain is a small
peptide that has a high affinity for the chitin-agarose fusion, and this resin provides a high
level of purification of the fusion protein. The fusion construct is made so that glycine
487 of mTR3 is the amino acid at the junction between mTR3 and the intein. Addition of
a cleavage buffer containing thiol (NMA, β-ME or DTT) causes elution of the thioestertagged mTR3 from the affinity column. The fusion protein appears as a band near 110
kDa in the 12% SDS-PAGE gel. Figure 16 shows a 12% SDS-PAGE gel of pooled
protein fractions from each step in the purification process. As the chitin resin is an
affinity resin, the purity of the eluted mTR3 (either truncated or semisynthetic) is very
good with only minor contaminants showing. These contaminants are removed after the
phenyl-sepharose and DEAE chromatographic steps as shown in Figure 16. The elution
profile for semisynthetic mTR3 for each column is shown in Figure 17.
The purity of the truncated mTR3 is such that large crystals can be grown from
the purified enzyme (Chapter 5). The purity of the semisynthetic enzyme is similar to
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that of the truncated enzyme as shown in Figure 16. The purity is also verified by the
characteristic absorbance spectra of TR. Three main peaks are observed for the oxidized
enzyme (86). The 275 nm peak is the protein peak and the 370 nm and 460 nm peaks are
the characteristic flavin peaks. The flavin spectra are shown in Figure 18 and a summary
of corresponding wavelengths in Table 1. For the oxidized form of the enzyme, the 460
nm peak is expected to be larger than the 370 nm peak at a ratio of ~1.1 which is what is
typically observed for our proteins. A purity ratio of ~8.5 for the 275 nm to 460 nm peak
has been established for rat TR1 (109). The rat TR1 and mTR3 have similar predicted
extinction coefficients for the protein sequence (147), 59,205 and 60,110 M-1cm-1
respectively. Therefore, the 275 nm to 460 nm ratio should be similar for mTR3. Purified
mTR3 also shows a 275 nm to 460 nm ratio of ~8.5.
The purified proteins have excellent stability when stored in the final dialysis
buffer of 50 mM potassium phosphate pH 7.4, 150 mM NaCl, 1 mM EDTA. Storage at 4
o

C shows no loss of activity for >12 months. Preparation of a 50% glycerol stock for

storage at –20 oC showed no loss in DTNB reductase activity after 18 months. Protein
solution is concentrated most effectively using the Millipore Amicon Ultra. The storage
pH of 7.4 and the DEAE purification at pH 7.8 is to aid in the solubility. Concentrated
protein stored at pH 7.0 tended to form precipitate which can partially be recovered by
incubation with DTT. Precipitate was also observed for higher yield preps during the
dialysis step prior to the DEAE purifcation, which was addressed by using pH 7.8 during
this step. However, the protein must still remain dilute until bound to the column and 10
mM NaCl is added to help prevent the precipitation. These observations lead to the
conclusion that the solubility is significantly dependent on salt concentration. At 150 mM
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NaCl the limit of solubility is 10 – 15 mg/ml. Increasing to 300 mM NaCl allows for
concentration to 30 mg/ml, which was critical to the crystallographic progress in Chapter
5.
Selenium Content of the Semisynthetic Enzyme.
The selenium content of the semisynthetic enzyme determined by ICP-MS was
found to be 0.63 mol of selenium/mol of enzyme. Our yield of TR from this method was
24 mg from 6 L (4 mg/L) of cell culture. The selenium content of the semisynthetic
enzyme using half the bound resin of the initial trial was found to be 0.91 mol of
selenium/mol of enzyme, with a yield of 9 mg of enzyme from 3 L (3 mg/L) of cell
culture. By comparison, the selenium content of the recombinant mTR3 prepared by
fusing a bacterial SECIS element to the 3' end of the gene had a selenium content in the
range of 0.4-0.5 mol of selenium/mol of enzyme depending on the preparation (148). In
both cases, the final preparations of enzymes are a mixture of the truncated form and the
full-length form. The ligation efficiency can be estimated from ICP-MS analysis since the
ligated tripeptide is the only source of selenium for the enzyme.
DTNB Reductase Activity.
A summary of activities for DTNB is shown in Table 2. DTNB is a small
molecule disulfide that is a non-physiological substrate as can be seen by the high
micromolar to low millimolar values for Km. These high values for Km are consistent with
reports in the literature, however unlike with the substrate Trx, kcat is rarely reported for
DTNB (Table 3). The wild type TR from rat and human shows significantly higher
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activity towards DTNB than a Sec to Cys mutant (109) or a C-terminal truncation (149).
Therefore, it is rather surprising to see that all of our mutant forms have very high DTNB
reductase activity (>60% of wild type). However, for each of the mutants, the Km is 3 to 7
fold higher, resulting in a significant decrease in catalytic efficiency, kcat/Km. The
semisynthetic wild type at 63% and 91% selenium incorporation have similar activities.
The 63% incorporation has ~5% greater activity than the 91% but the higher
incorporation has the higher kcat/Km.
A similar phenomena has been reported for the non-selenium containing DmTR
and PfTR. The C-terminal mutant Cys535Ala of PfTR shows 64% of wild type activity
with ~2 fold increase in Km, while mutation of the FAD associated Cys88 has essentially
no activity (55). The same is the case for DmTR where the C-terminal mutants display
DTNB reductase activity with a 7 fold increase in Km (78). Unfortunately, no kcat is
reported for DmTR of PfTR. These results are similar to what we observe for mTR3. It is
not clear why there is such a broad range of activities for DTNB by these proteins while
the range of activities for Trx are rather narrow. Regardless of whether there is a relevant
value for kcat, it does provide an alternative means to semi-quantitatively assess the
production of a functional protein for those mutants that are inactive to Trx. The
questions regarding DTNB as a substrate for the truncated and mutant forms of TR will
be further addressed in the following chapters.
Activity toward Thioredoxin.
The peptide complementation system described above led to the development of a
semisynthetic enzyme that covalently links the tripeptide containing Sec to the main body
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of the enzyme through a peptide linkage. The semisynthetic enzyme could be constructed
by addition of peptide CUG to the cleavage buffer, as described above. Since this peptide
has an N-terminal cysteine residue (and is not N-acylated), the sulfhydryl group of the
cysteine residue can attack the C-terminal thioester group of the enzyme. Rearrangement
then occurs to the amide form (141). To test whether the peptide becomes truly
incorporated into the enzyme, we tested the ability of the semisynthetic enzyme to reduce
Trx. The presence of a Sec residue has been shown to be necessary to reduce E. coli Trx
with high efficiency (109). The semisynthetic enzyme at a concentration of 2 nM
exhibited excellent activity toward E. coli Trx in comparison to both the truncated form
and a mutant form of the enzyme in which a cysteine residue replaces Sec489 as part of a
full-length construct. A Michaelis-Menten plot for our semisynthetic construct in
comparison to the Sec489Cys mutant is shown in Figure 19, and a summary of our
kinetic data is given in Table 4. As shown in Figure 7, the Sec489Cys mutant has much
lower activity, as would be expected and as was reported previously (109). In contrast to
the cysteine mutant enzyme, our semisynthetic enzyme shows very high activity, with
values of kcat ranging from 1500 to 2220 min-1, depending on the preparation. This high
activity strongly indicates that the C-terminal tripeptide was successfully ligated to the
thioester-tagged enzyme. The enzyme preparation with a higher kcat value resulted from
using a higher peptide:protein ratio during the ligation and resulted with an enzyme with
a higher selenium content (91% Se). The truncated enzyme (ending with amino acid 487
and missing the tripeptide) has no detectable activity toward oxidized Trx.
The thioredoxin reductase activity of our enzyme compares very favorably to the
value of 3000 min-1 reported for rat TR1 (145, 150). The Km for thioredoxin of our
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semisynthetic enzyme is in the range of 35-70 µM. This is 10-20-fold higher than the Km
reported for rat TR1 with human Trx, but the sequences of the two enzymes are only 56%
identical so some difference in Km is to be expected (the difference is between the
cytosolic form of the rat enzyme and the mitochondrial form of the mouse enzyme). This
is nearly identical for that observed for the originally identified human TR (24) which
showed a 3.7 µM Km for rat Trx but 34.0 µM Km for E. coli Trx as was the case for rat
TR1 with E. coli Trx (145, 150). As was observed for the DTNB assays, the Sec489Cys
produced recombinantly or by semisynthesis display similar kinetic parameters.
Comparison of the Activity of Semisynthetic TR to That of Recombinant TR.
The activity of the semisynthetic enzyme was compared to that of the
recombinant mTR3. The latter protein was expressed in E. coli and contained 0.5 equiv
of selenium (148). The recombinant TR enzyme is made by fusing a bacterial SECIS
element to the 3' end of the TR3 gene. This allows for heterologous expression of the
recombinant enzyme in E. coli. The results in Figure 20 show that the recombinant
mTR3 and the semisynthetic mTR3 have similar activities with both E. coli Trx and
recombinant rat Trx2. The recombinant mTR3 has an estimated kcat of 1770 min-1. These
data further verify that the semisynthetic method resulted in a functional TR.
Peroxidase Activity.
Mammalian thioredoxin reductases also exhibit hydrogen peroxidase activity.
This activity is a characteristic feature of the mammalian enzymes because non-seleniumcontaining TRs have been shown to have little, if any, hydrogen peroxidase activity
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(109). Figure 21 shows the results of our hydrogen peroxidase activity assays with our
semisynthetic enzyme and the Sec489Cys mutant. The mutant enzyme has barely
detectable hydrogen peroxidase activity, while the semisynthetic enzyme shows high
peroxidase activity with a kcat of 71 ± 7 min-1 and a Km of 6.6 ± 0.50 mM. This rate was
achieved with 200 nM semisynthetic enzyme present in the assay though the plot shows
very poor saturation. The kinetic data derived from Figure 21 compare favorably to the
data reported by Zhong and Holmgren (109) for reduction of H2O2 by human placental
TR1. The high peroxidase activity of our enzyme provides additional strong support for
the incorporation of the selenocysteine-containing tripeptide by our semisynthetic
approach.
Ligation Efficiency for Off-Resin Ligations.
As shown in Figure 13, our method of making a semisynthetic TR makes use of
the addition of the oxidized tripeptide to a thiol-containing cleavage buffer, which is then
added directly to the resin-bound protein. The thiol in the cleavage buffer can either
liberate the protein from the resin to produce a thioester-tagged protein or reduce the
oxidized tripeptide, which in turn could directly attack the resin-bound protein and
become incorporated as part of the polypeptide chain. Alternatively, the liberated
thioester-tagged protein can undergo a thioester exchange reaction with the reduced
tripeptide and then be incorporated into the polypeptide via a stable amide bond. All three
pathways lead to the eventual incorporation of the tripeptide into the larger polypeptide
of mTR3. The key to ligating this tripeptide to the larger polypeptide of mTR3 is keeping
this tripeptide reduced by using a large excess of thiol in the cleavage buffer. The thiol in
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the cleavage buffer functions to effect cleavage of the resin-bound protein and also to
keep the tripeptide reduced so that it can ligate to the liberated thioester-tagged protein.
We compared the efficiency of the ligation when the peptide is added directly to a
slurry of resin-bound TR and cleavage buffer to that of addition of the peptide to a
semipurified, concentrated form of the thioester-tagged TR off-resin. Concentrated
thioester-tagged protein was treated with either oxidized peptide or oxidized peptide with
70 mM NMA. After dialysis to remove excess peptide and reagents, the resulting
enzymes were assayed for thioredoxin reductase activity. The results are summarized in
Table 5 and clearly show that the efficiency of ligation is much higher when the peptide
is added directly to the slurry of resin-bound TR and cleavage buffer. One reason for this
decline in efficiency when the ligation is done off-resin is that the lifetime of the
thioester-tagged TR may be short in this protein context. Hydrolysis of the thioester
would yield the C-terminal carboxylate form of the protein, which is unproductive with
respect to ligation. Second, the reduced tripeptide can directly attack the resin-bound TRintein fusion protein with concomitant ligation. This process should be kinetically faster
than when an intermediary thiol attacks first.
In the absence of thiol, the CUG peptide is likely to oxidize to form the
intramolecular selenylsulfide or dimeric peptides. Either fate will decrease the ligation
efficiency. An interesting observation is that the NADPH ligation sample resulted in
three fold higher activity than the buffer only ligation. This suggests that the enzyme can
reduce the tripeptide to promote ligation. This would not be unexpected as the conserved
FAD-associated active site functions to reduce the C-terminal selenylsulfide during the
catalytic cycle.
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Determination of the Mass of Truncated and Semisynthetic TRs.
The mass spectrographs of the truncated and semisynthetic TRs are shown in
Figure 22. The predicted masses of the truncated and semisynthetic enzymes are 52,857
(carboxylate form) and 53,164 Da, respectively. The experimentally observed masses
were 52,787 and 53,144 Da, respectively, and are in good agreement with the expected
values. An overlay of the two spectra shows a clear mass increase due to the presence of
the ligated peptide. The experimental mass increase of the semisynthetic enzyme is 357
Da, which is very close to the expected mass increase of 329 Da.
Peptide Mass Mapping of Tryptic Fragments.
To unambiguously demonstrate that our peptide had been ligated to the Cterminus of mTR3, we undertook a peptide mass mapping experiment. In this
experiment, both the truncated and semisynthetic enzymes were digested with trypsin and
analyzed by MALDI-TOF MS and ESI-MS. Figure 23 shows a peptide with a sequence
of SGLEPTVTGCUG found in the ESI-MS experiment, which is at m/z 1169.3
(calculated value of m/z 1169.4). The mass of this peptide corresponds exactly to the
mass of the C-terminal peptide containing Sec. Further proof of the identity of this
peptide is provided by a MS/MS experiment shown in Figure 24. In this experiment, the
peptide is fragmented by collision-induced dissociation (CID), and the resulting ions
unambiguously identify the sequence of the peptide as the peptide corresponding to the
C-terminus. This data in combination with the enzymatic activity data indicate successful
semisynthetic production of mTR3. Identification of the C-terminal tryptic fragment
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SGLEPTVTGCUG is very difficult using MALDI-TOF. The sequence is very is
hydrophobic and, as trypsin cut C-terminal to Lys and Arg, is less likely to hold a
positive charge. Should this technique be used for future analysis, the protease LysC
would be a better choice. LysC will cut C-terminal to Lys only and the sequence
preceding our C-terminal Fragment is Lys-Arg. Digesting with LysC would leave the Nterminal Arg and likely improving the ionization using MALDI. Approximately 70% of
the total peptides were identified by mass mapping (Figure 25). A summary of all of the
identified peptides is available in Figure 26.
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Figure 13. Method for semisynthetic production of mTR3.
Thiol-mediated cleavage of the mTR3-intein fusion construct by addition of exogenous
thiol. The junction between mTR3 and the intein exists in equilibrium between amide and
thioester forms. Addition of exogenous thiol causes cleavage of the target protein from
the thioester form of the fusion protein. (B) Mechanism of incorporation of tripeptide
CUG into the mTR3-intein fusion protein. The ligation is achieved by adding oxidized
tripeptide to the cleavage buffer containing 70 mM thiol. The excess thiol both reduces
the tripeptide and causes cleavage of mTR3 from the intein fusion. The reduced peptide
can then attack the thioester-tagged protein and become stably ligated to the protein
because of the presence of the N-terminal amino group, which enables rapid
rearrangement to the amide form of the protein.

64

Figure 14. Mechanism of expressed protein ligation.
Example of semisynthesis using expressed protein ligation utilizes a target-intein-chitin
binding domain fusion protein. Generation of the thioester at the ligation junction is
catalyzed by the N-terminal Cys of the intein. Figure adapted from (135, 139).
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Figure 15. Native chemical ligation and expressed protein ligation.
Example of Semisythesis using native chemical ligation (Ligation 1) and expressed
protein ligation (Ligation 2) to insert a label in between two protein domains adapted
from (142). Both protein domains are produced recombiantly, with the N-terminal
domain produced as the intein fusion protein. The factor Xa protease cleaveage site
produces a new N-terminal Cys for Ligation 2
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Figure 16. SDS-PAGE of semisynthetic and recombinant mTR3.
SDS (12%)-PAGE characterization of recombinant mouse thioredoxin reductase 3: lane
1, cell culture pre-induction; lane 2, IPTG-induced cell culture; lane 3, supernatant of the
cell lysate; lanes 4 and 8, molecular mass markers; lane 5, truncated TR cleaved from the
intein on-resin by 2-mercaptoethanol and eluted from the chitin resin; lane 6, truncated
TR eluted from the phenyl-Sepharose column; lane 7, truncated TR after elution from the
DEAE column; lane 9, purified semisynthetic TR after elution from the DEAE column;
and lane 10, purified truncated TR cleaved from the intein on-resin by the amino acid
cysteine.
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Figure 17. Chromatographic elution profiles for semisynthetic mTR3.
Elution profile of semisynthetic mTR3 from phenyl sepharose (■) and DEAE Sephacel
(●). The plot also shows the fraction of the elution gradient (▬).
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Figure 18. Flavin spectra for semisynthetic and recombinant mTR3.
Absorbance spectra for semisynthetic (●), Sec489Cys mutant (□), and truncated (●)
thioredoxin reductase 2 in 50 mM potassium phosphate pH 7.4, 150 mM NaCl, 1 mM
EDTA

Table 1. Spectral properties of mTR3.
λmax Absorbance Ratioa

λmax nm
Enzyme

1

2

3

(1) / (2)

(3) / (1)

Semisynthetic

463

376

275

1.04 ± 0.11

8.55 ± 0.91

Sec489Cys

462

375

276

1.00 ± 0.15

8.10 ± 0.22

Truncated

463

377

276

1.11 ± 0.05

8.66 ± 0.65

a

Ratios are averages for 3 preparations of the semisynthetic, 3 preparations of the
Sec489Cys mutant, and 6 preparations of truncated.
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Table 2. DTNB reductase activity of mTR3 semisynthetic and mutant enzymes.
Enzyme

kcat (min-1)

Km (mM)

kcat / Km
(s-1 M-1)

a

TR-Gly487

856 ± 43

2.72 ± 0.43

5.2 x 103

b

TRSec489Cys

794 ± 78

1.75 ± 0.41

7.6 x 103

TR-semisynthetic Sec489Cys

908 ± 37

3.08 ± 0.32

4.9 x 103

1307 ± 102

0.59 ± 0.16

3.7 x 104

1251 ± 71

0.46 ± 0.09

4.5 x 104

c

TR-semisynthetic (63% Se)
d

TR-semisynthetic (91% Se)

a

The truncated enzyme ends at Gly487 and is missing the C-terminal tripeptide.

b

The full-length mutant in which cysteine replaces the catalytic selenocysteine residue
and is produce recombinantly.
c

The full-length mutant in which cysteine replaces the catalytic selenocysteine residue
and is produce by semisynthesis.

d

Data from optimized procedure using a higher ratio of peptide to protein as described
under Methods.
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Table 3. DTNB reductase activity reported for homodimeric TR in the literature.
kcat (min-1)

Enzyme

Km (mM)

Rat TR1 native (109)

2666

Rat TR1 native (150)

4000

0.66

Rat TR1 recombinant (151)

1726

0.12

Rat TR1 Sec to Cys mutant (109)

126

Human TR native (149)

4000

0.08

Human TR truncated (149)

92

4.5

Human TR Sec498Cys (149)

34

0.7

330 ± 36

0.7 ± 0.2

1176

0.21

Anopheles gambiae (152)
Plasmodium falciparum (15)
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Table 4. Activity of semisynthetic and mutant mTR3 towards thioredoxin.
kcat / Km

Enzyme

kcat (min-1)

Km (µM)

a

TR-Gly487

No activity

No activity

NA

b

TRSec489Cys

4.1 ± 0.11

49.1 ± 3.2

1.4 x 103

c

TR-semisynthetic Sec489Cys

4.2 ± 0.24

72.5 ± 8.6

1.0 x 103

TR-semisynthetic (63% Se)

1500 ± 81

35 ± 5

7.1 x 105

d

2220 ± 78

67.6 ± 6

5.4 x 105

3000

35

1.4 x 106

e

TR-semisynthetic (91% Se)

rat TR1

a

(s-1 M-1)

The truncated enzyme ends at Gly487 and is missing the C-terminal tripeptide.

b

The full-length mutant in which cysteine replaces the catalytic selenocysteine residue
and is produce recombinantly.
c

The full-length mutant in which cysteine replaces the catalytic selenocysteine residue
and is produce by semisynthesis.
d

Data from optimized procedure using a higher ratio of peptide to protein as described
under Methods.

e

Taken from (145, 150), purified from rat liver and assayed using E. coli Trx.
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Figure 19. Trx activity plot for semisynthetic mTR3.
Michaelis-Menten plot of Vo/ET vs thioredoxin concentration for semisynthetic enzyme
(□) and the Sec489Cys mutant (● with insert). Both curves could be fitted to a
hyperbolic plot. The semisynthetic data are the average of four replicates per Trx
concentration.
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Figure 20. Trx activity of semisynthetic and engineered SECIS produced mTR3.
The activity of the recombinant TR produced in E. coli by using an engineered SECIS
element (148) is represented by the circles. The activity of the semisynthetic TR is
represented by the squares. E. coli thioredoxin (closed symbol) and rat thioredoxin-2
(open symbol) were used as substrates.
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Figure 21. Peroxidase activity plot for semisynthetic mTR3.
Peroxidase activity of semisynthetic enzyme ( ) and the Sec489Cys mutant (●). Activity
is reported as moles of NADPH oxidized per minute per mole of homodimeric enzyme.
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Table 5. Comparison of methods used to construct a semisynthetic TR.
Chitin Resin

Reductant

On

a

TR concentration in
assay [nM]

mol
NADPH/min/mol
TR

NMA

2

1008

Off

NMA

100

48

Off

NADPH

100

27

Off

none

100

8

a

The enzyme was assayed using 90 µM thioredoxin as substrate. All other assay
conditions were the same as those described in Methods.
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Figure 22. MALDI-MS of semisynthetic and truncated mTR3.
The semisynthetic (theoretical average mass = 53,164) spectrum is in black with an
average mass of 53,144, and the truncated (theoretical average mass = 52,857 for
carboxylic acid, 52,944 for thioester tagged) spectrum is in light gray with an average
mass of 52,787. The difference in mass is clearly observable. The semisynthetic spectrum
has a shoulder, which lines up with the peak of the truncated spectrum. The peak width of
the semisynthetic enzyme shows that it is a mixture of the two forms.
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Figure 23. ESI-MS of semisynthetic mTR3 C-terminal tryptic fragment.
ESI-MS of the C-terminal tryptic fragment of mTR3, peptide sequence
SGLEPTVTGCUG. The peptide corresponds to the C-terminal peptide of mTR-3
containing the ligated tripeptide CUG. The inset at the right is the predicted isotope
pattern for this peptide containing selenium. The mass of the peptide corresponds to the
oxidized form as would be expected for a peptide containing selenocysteine.
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Figure 24. ESI-MS-MS of semisynthetic mTR3 C-terminal tryptic fragment.
ESI-MS-MS of the C-terminal tryptic fragment of mTR3, peptide sequence
SGLEPTVTGCUG. The peptide was fragmented by Collision-Induced Dissociation. Ions
produced by fragmentation are labeled in the figure with the corresponding peptide
sequence.
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A.

B.
MGGQQSFDLLVIGGGSGGLACAKEAAQLGKKVAVADYVEPSPRGTKWGLGGTCVNVGCI
PKKLMHQAALLGGMIRDAHHYGWEVAQPVQHNWKTMAEAVQNHVKSLNWGHRVQLQDRK
VKYFNIKASFVDEHTVRGVDKGGKATLLSAEHIVIATGGRPRYPTQVKGALEYGITSDD
IFWLKESPGKTLVVGASYVALECAGFLTGIGLDTTVMMRSIPLRGFDQQMSSLVTEHME
SHGTQFLKGCVPSHIKKLPTNQLQVTWEDHASGKEDTGTFDTVLWAIGRVPETRTLNLE
KAGISTNPKNQKIIVDAQEATSVPHIYAIGDVAEGRPELTPTAIKAGKLLAQRLFGKSS
TLMDYSNVPTTVFTPLEYGCVGLSEEEAVALHGQEHVEVYHAYYKPLEFTVADRDASQC
YIKMVCMREPPQLVLGLHFLGPNAGEVTQGFALGIKCGASYAQVMQTVGIHPTCSEEVV
KLHISK RSGLEPTVTGCUG

Figure 25. MALDI-TOF of semisynthetic mTR3 digested with trypsin.
(A) MALDI-TOF average mass spectrum for trypsin digest of semisynthetic mTR3. A
few peptides are indicated for orientation. (B) Sequence coverage for the trypsin digest of
semisynthetic mTR3 using MALDI-TOF (AA) with additional fragments identified by
ESI-MS (AA).
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Figure 26. Mass spectrometry peptide mapping for trypsin digests of mTR3.
.
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CHAPTER 3.

STRUCTURE-FUNCTION STUDIES OF THE CTERMINAL TETRAPEPTIDE MOTIF OF
THIOREDOXIN REDUCTASE USING
SEMISYNTHESIS

Figure 27. The pathway for transfer of electrons to Trx by mTR3.
The catalytic cycle for mammalian thioredoxin reductase. This Chapter investigates
structural details of the C-terminal vicinal selenylsulfide between Cys488’ and Cys489’.
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In the study presented here, we have used semisynthetic production of mouse
mitochondrial thioredoxin reductase (mTR3) to investigate the enzymatic dependence on
the C-terminal structure of the Sec-containing TR compared to the Cys-containing TR
from Drosophila melanogaster (DmTR). These enzymes can be divided chemically:
those containing Sec and those containing Cys, and they can also be divided structurally:
those whose active site contains a vicinal disulfide and that which does not, Plasmodium
falciparum (PfTR). Here we have investigated two forms of the vicinal disulfide group.
The vicinal disulfide forms an eight-membered ring that must be a) opened by the FAD
associated dithiol and b) closed after reduction of the substrate thioredoxin (Trx). Each of
the steps in the catalytic will have structural implications in two forms. Firstly is the
inherent energy strain of the ring. For each intervening residue the size of the ring
increases by three atoms and likely reducing the strain. The second is proper orientation
of the catalytic residues involved in each step. The results show that insertion of Ala
residues between the cysteines in DmTR results 100 fold or greater decrease in Trx
activity whereas the equivalent insertions between the Cys and Sec residues of mTR3
results in only a 4 fold decrease.
We have also investigated the role of the C-terminal carboxylate charge. In the
structure of rat TR1 (36) it was suggested that the conserved position, Lys29, would form
a salt bridge with the C-terminal carboxylate to correctly position the C-terminus for
thiol-disulfide exchange with the N-terminal active site. A similar role was suggested for
Arg351 from a TR-Trx complex modeling study (100). In neither case is biochemical
evidence provided. As either Lys29 or Arg351 could serve different functions, simple
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mutagenesis would be unable to distinguish a specific interaction. Therefore, we have
used semisynthesis to modify the C-terminal carboxylate to a neutral carboxamide. This
mutant shows a significant increase in catalytic activity indicating that the proposed salt
bridge is likely not involved in catalysis.
Finally, we have investigated the dependence on the relative position of Sec in the
Cys-Sec dyad for mTR3. We have produced the mutant Gly-Sec-Cys-Gly (GUCG) that
shows poor activity similar to Sec489Cys. This indicates the Sec incorporation is for a
specific function and that the residue must be the C-terminal moiety of the dyad. This
relates directly to the results for the Ala insertion mutants and suggests that the role of
Sec is not in nucleophillic attack on Trx but possibly as the leaving group during thioldisulfide exchange with the N-terminal active site.

METHODS

Peptide Synthesis.
Selenocysteine containing peptides were produced by Fmoc solid phase synthesis
as previously described (143). Peptide were purified by preparative HPLC from the
Shimadzu Corporation (Kyoto, Japan) and verified by Matrix Assisted Laser Desorption
Time of Flight Mass Spectrometry on a Voyager DE PRO Workstation from Applied
Biosystems (Framingham, MA). Synthesis of the CUG peptide with C-terminal
carboxyamide utilized a similar protocol with the exception of substitution of Fmoc-PAL
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resin from PE Biosystems (Hamburg, Germany) to yield the carboxamide upon cleavage
from the resin.
Cloning and Expression of mTR3.
The expression, purification and semisynthesis for mutants in this section are as
described in the previous chapter. An additional mutant of mTR3 with the C-terminal
sequence of Ser-Cys-Cys-Ser (SCCS) was produced by mutagenesis (via PCR
amplification). Reaction conditions and methods were as described for the GCCG mutant
in Chapter 2. To help the reader distinguish the mTR3 mutants from the DmTR mutants
in this study, the abbreviation mTR3 will precede the C-terminal sequence (mTR3GCUG for example).
Cloning and Expression of DmTR.
The Drosophila melanogaster TR clone (accession number AF301144), was a
generous gift from Stephan Gromer. For production of DmTR in E. coli, we subcloned
the coding region of DmTR (via PCR amplification) into plasmid pTYB1 of the Impact
System from New England Biolabs, to generate the TR-intein-fusion protein. Primers
were purchased from Integrated DNA Technologies Inc. (Coralville, IA). Primers were
designed for production of the full length TR containing the C-terminal tetrapeptide SerCys-Cys-Ser (SCCS488-491), a truncated TR, removing the C-terminal tripeptide CCS489491

, the full-length mutants Ser-Cys-Ala-Cys-Ser (SCACS488-492) and Ser-Cys-Ala-Ala-

Cys-Ser (SCAACS488-493).
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The PCR reaction mixtures contained 100 pg template DNA, 50 pmol of each
primer, 2 units of Vent DNA Polymerase, 2-3 mM magnesium chloride, in a volume of
100 µL. Each PCR was performed on a GeneAmp PCR System 2400 from Perkin Elmer
Life Sciences, Inc. (Boston, MA) using 25 cycles with the following parameters: 96 oC
for 45 sec, 50 oC for 30 sec, and 72 oC for 180 sec. The product was analyzed by
analytical agarose gel electrophoresis and then purified using the QIAquick Purification
Kit from Qiagen (Valencia, CA). The PCR product and plasmid pTYB1 were each
incubated with Kpn I and Nde I for 2 h at 37 oC, purified using the QIAquick kit, then
ligated at 16 oC for 16 h using T4 DNA ligase at 37 oC. To enhance the amount of
positive clones, the ligation was digested Sal I, a unique restriction site removed upon
product insertion. E. coli DH5α cells were made competent via the Inoue method (153)
and then transformed with 50 ng of purified DNA. The culture was plated onto LB agar
containing 200 µg/mL ampicillin and incubated at 37 oC. Individual colonies were used
to inoculate 100 mL of LB containing 200 µg/mL ampicillin and allowed to shake at 37
o

C overnight.

Plasmids were purified using the QIAfilter Plasmid Prep Midi from

Qiagen, screened by 1% analytical agarose gel electrophoresis, and verified by
sequencing at the University of Vermont DNA Sequencing Facility using an ABI 3100Avant Genetic Analyzer.
Production of C-terminal Mutants of DmTR.
Each of the TR mutants from Drosophila are expressed as the TR-intein-chitin
binding domain fusion protein and are affinity purified from chitin agarose as described
for the mTR3 (Chapter 2). Escherichia coli ER2566 cells were used for production of
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recombinant wild-type (WT) and mutant DmTR. The cells were transformed with 50 ng
of plasmid, plated on LB-ampicillin plates containing 200 µg/mL ampicillin, and
incubated at 37 °C overnight. A single colony was used to grow a 100 mL inoculum
culture of LB (200 µg/mL ampicillin). This culture was incubated overnight at 37 °C with
shaking. Ten milliliters of inoculum culture was added to a 1 L baffled Pyrex Fernbach
flask containing TB media at pH 7.0 containing 200 µg/mL ampicillin. The cells were
incubated at 37 °C with shaking (100 rpm) until the O.D. 600 nm reached 1.0. The cells
were then chilled on ice until the temperature decreases to 20 °C and induced by adding
IPTG to a to final concentration of 0.5 mM followed by incubation at 20 °C overnight
with shaking (100 rpm). The cells were harvested by centrifugation in a Beckman J21B
centrifuge (JA-14 rotor) at 7000 X g at 4 °C for 10 min and then stored at –20 °C. Cells
are thawed on ice and homogenized in MOPS buffer, and lysed by sonication with a
Branson 350 Sonifier (Danbury, CT). The wild type enzyme, C-terminal sequence SCCS,
as well as the C-terminal sequence mutants SCACS and SCAACS were released from the
intein by the addition of NMA.
Thioredoxin Activity pH Optima.
Activity towards Trx was tested as a function of pH for each construct. Due to the
insolubility of insulin below pH 7.0, each assay utilized 500 µM Trx, which is
approximately ten times greater than the calculated Km. To avoid differences in ionic
strength, each assay contained buffer with a final concentration of 30 mM citrate/ 30 mM
Tris/ 30 mM phosphate adjusted from pH 5.5 to 9.5 with the exception of the GUUG
mutant which required the profile to be extended to pH 10.5. The concentration of TR in
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the assay was that which was used for the Trx Michaelis-Menten profile: 2nM for wild
type mTR3 and 25 nM for wild type DmTR. The concentration for each mutant was
adjusted to get signal similar to that of the respective wild type. Each assay contained
0.15 mM NADPH and 1 mM EDTA. The activity was measured at 340nm and
background corrected. The data in duplicate were normalized to the percent of maximal
activity for each given mutant and plotted as Activity % vs. pH.

RESULTS AND DISCUSSION

Production of TR.
The expression and purification methods for DmTR are identical to mTR3 with
the exception of expression in pTYB1 rather than pTYB3. The reason for this is due to
the presence of Nco I and Sap I restriction sites within the DmTR sequence. The
background digest to increase the number of positive clones was performed with Sal I as
there is also a Hind III restriction site in the DmTR coding sequence. The expression of
DmTR was significantly increased in TB media versus LB media. Initial production of
the truncated form of DmTR yielded approximately 20 mg per 6L of cell culture in LB
media. This was also the case for mTR3 in the previous chapter. Expression in TB media
yielded 20-30 mg per 1L of media for DmTR. Improvement was also shown for mTR3,
though not to the same degree (35 mg per 6L culture). Subsequently, the mutants
produced for this study were produced in TB media as described in the methods section
of this chapter.
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A representative SDS-PAGE for expression and chitin cleavage for the wild type
DmTR can be seen in Figure 28. Excellent solubility of the fusion protein is
demonstrated by comparison of the lysate supernatant (lane 13) and the lysate pellet (lane
12). For each of the cleavage reagent cocktails, the eluant and chitin retained samples
respectively are shown. The cleavage from the intein was significantly slower than
observed for truncated mTR3 as can be seen by the fusion protein band still remaining on
the resin after a 24-hour incubation with cleavage reagent. Like mTR3, very little elution
is observed with buffer not containing a cleavage reagent (lane 9). This experiment
yielded 127 mg from 6L of cell culture (21 mg/L), with a significant amount still retained
on the resin. Estimation from the SDS-PAGE and NaOH strip of the chitin resin indicates
only about 50-70 % is cleaved from the intein. Cleavage of DmTR from the intein was
also tested from pH 7.5 to 8.5 using NMA with similar results. Yield was only slightly
improved by sequential rounds of incubation with fresh cleavage reagent. This indicates
that a significant amount of DmTR remains as the fusion protein.
The truncated form of DmTR shows incomplete cleavage from the intein though
yield in this step is not an issue due to the high level expression for DmTR. Poor cleavage
from the intein was seen with the mTR3-SCCS mutant where the majority of the fusion
protein was retained on the resin. The yield for this mutant was only 2.6 mg for 6L of cell
culture. This is less than 10 % of a typical yield for mTR3. These results indicate that a
Ser residue at the intein cleavage junction is partly inhibitory for our system.
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Activity of mTR3 Towards Thioredoxin.
Sufficient activity towards the natural substrate Trx has been shown to be
dependent on the incorporation of selenocysteine as the penultimate reside in mammalian
thioredoxin reductase. During the TR catalytic cycle the conserved cysteine position is
expected to form a disulfide intermediate with Cys52 and the Sec489΄ being the leaving
group. Upon resolution of this disulfide and release of the C-terminus in its reduced form,
the Sec residue is then the attacking nucleophile to form a mixed selenylsulfide with the
substrate Trx. The re-oxidation of the C-terminus occurs by attack on the mixed
selenylsulfide by the resolving cysteine, Cys488΄, of mTR3 with subsequent release of
reduced Trx. As shown in Table 6, sequence containing the C-terminal carboxamide was
considerably more active (3010 min-1) than the naturally occurring carboxylic acid (2220
min-1). The mTR3-GUCG shows similar activity to the Sec489Cys mutant, 8.3 and 4.1
min-1 respectively, while the mTR3-GUUG mutant was even less active. As indicated by
the % peptide incorporation, the ligation reaction is less efficient with Sec as the residue
attacking the thioester. However, even with correction for the incorporation, the GUCG
and GUUG mutants would still have poor activity compared to wild type. Mutation to the
SCCS motif of DmTR shows similar activity to that of the Sec489Cys mutant. Similar
results for the human homologue of TR have recently been reported (154). Interestingly,
the insertion mutants mTR3-GCAUG and mTR3-GCAAUG show ~25 % of the wildtype activity.
The TR activity was also evaluated as a function of pH. Both the leaving group
and nucleophillic effects of the conserved selenocysteine position would be expected to
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contribute to the observed activity dependence on pH. The optimal pH for activity
towards Trx was determined for each of the TR mutants from pH 5.5 to 9.5 with the
exception of the mTR3-GUUG mutant, which required pH 10.0 to reach maximal
activity, Figure 29. Both the wild type carboxylic acid and carboxamide achieve optimal
activity at a similar pH, approximately 7.0 to 7.2, whereas the Sec489Cys mutant has a
pH optimum between pH 8.0 and 8.5. This is as would be expected due to the pKa of 5.3
for selenocysteine and the pKa of 8.2 for cysteine where at physiological pH the cyteine is
expected to be protonated and therefore less nucleophillic than the selenol.
This is not the observation for the mTR3-GUCG mutant where the interchange
position and the resolving position have been reversed. For this mutant, there is only a
modest alkaline shift in pH optima to which is still 0.5 units lower than the Sec489Cys
mutant Figure 29. This mutant has a similar kcat for Trx as the Sec489Cys at pH 7.0. The
pH optima measured during the steady state is likely to include a contribution from the
resolving position of TR. In the wild-type enzyme with high activity, the low pKa of the
selenol is expected to dominate the reaction profile. In the mutants with lower activity,
however, we begin to see the impact of the resolving position. This may explain the
lower pH optima for the mTR3-GUCG mutant where the selenocysteine is in the
resolving position.
The insertion mutants mTR3-GCAUG and mTR3-GCAAUG have activity
towards Trx that is 25 % of wild type and is 100 fold higher than the mTR3-GUCG and
mTR3-GCCG mutants yet the pH optima is near 8.0. In these insertion mutants, the
relative position of the Sec has been retained. If the Sec position were responsible for
interchange with the N-terminal active site, one would expect poor activity for the Ala
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insertion mutants. Therefore the insertion is expected to impact: 1) the strain on the ring
formed when in the C-terminus exists in the oxidized state and; 2) the potential distance
the TR resolving cysteine would be from the mixed selenylsulfide between Sec489΄ and
Cys32 of Trx. It would be expected that both of these difference would affect the rate but
a shift in the pH optima higher than that of the mTR3-GUCG mutant is unexpected.
Low Activity TR Trx Assays and Consumption of NADPH.
The proposed general mechanism of a high Mr TR was discussed in Chapter 1
(Figure 10) in terms of individual steps. Theses steps are an extrapolation of the
mechanistic investigations of GR where each type of enzyme has two distinct cycles; the
reductive half reaction where NADPH is consumed to reduce the enzyme and the
oxidative half reaction where the enzyme is re-oxidized by consumption of the cognate
substrate GSSG or Trx. GR converts between the oxidized form (Eox) and the 2-electron
reduced form (EH2) to complete both cycles, with consumption of 1 equivalent of
NADPH. The addition of the C-terminal active site for TR requires an additional
equivalent of NADPH (EH4) to be consumed before Trx can be reduced. Fully reduced
GR (EH4) or TR (EH6) form extremely slowly. This means that TR in the steady state
will cycle between EH2 and EH4. Therefore, TR mutants that have poor activity towards
Trx could still consume 1-2 equivalents of NADPH per subunit in the pre-steady state.
And this is what we typically observe in the Trx assay.
Enzymes that have the lowest activity towards Trx require 1-2 µM enzyme in the
assay. When performing these assays, it was observed that there was a significant change
in absorbance at 340 nm after addition of mutant TR to the cuvette (~5 seconds). This is
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due to the high TR concentration resulting in a visible consumption of NADPH at the
start of the assay followed by the slow decrease in absorbance during the assay even in
the absence of Trx. While this analysis is at best semi-quantitative compared to the
establish stopped-flow method developed by Arscott, Ballou, and Williams (78, 93), it
does provide support in addition to the DTNB reductase activity that the low activity
mutants produced are functional enzymes.
Activity for DmTR Towards Thioredoxin.
The Trx activity of the mutants produced for DmTR can be seen in Table 7.
Residue insertions between the Cys residues for DmTR results in a loss of activity that is
much greater than that observed for mTR3. Both mutants show poor activity towards Trx
with a 142 fold and 328 fold decrease from wild type respectively. Nearly identical
results are observed for mitochondrial TR from Caenorhabditis elegans (CeTR2) where
Ala insertions result in >100 fold loss in activity (Brian M. Lacey, personal
communication). This is in stark contrast to the equivalent mutations for mTR3 which
still retain ~20 % of the wild type activity. The only difference is the Sec residue for
mTR3.
Modifications of the C-terminal carboxylate of DmTR show a gain in activity
similar to that of mTR3 (Adam P. Lothrop, personal communication). These
modifications are produced by cleavage from the intein using reagents other than thiol.
The neutral hydroxamic acid produced by cleavage with hydroxylamine shows a 70 %
increase in activity, which is in agreement with that observed for the mTR3 carboxamide
mutant. The thiocarboxylate produced by cleavage with ammonium sulfide also shows
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this increase in activity along with a 3 fold decrease in Km. The pH optima for the wild
type enzyme is ~8.0 with no change observed with either of the carboxyl variants. An
alkaline shift is observed for the Ala insertions mutants (Figure 30) as it is for the
equivalent mutants from CeTR2. These trends are identical to that observed for mTR3.
Comparison of DTNB Reductase Activities.
The small molecule disulfide DTNB has long since been used for quantification
of free thiols in proteins (155) as well as to evaluate thiol-disulfide exchange reactions
(156), as is the process catalyzed by TR. The DTNB can therefore be a substrate for the
C-terminal selenylsulfide (or disulfide) and the N-terminal disulfide as discussed in the
previous chapter. Each TR in this study displays significant DTNB reductase activity. We
also observe product inhibition with very high concentrations of DTNB near 5-10 times
Km. In both mTR3 and DmTR, the presence of the C-terminus imparts an increase in
DTNB reductase catalytic efficiency (kcat/Km) compared to the truncated forms of TR.
This is consistent with that observed for DmTR (78) as well as PfTR (55).
For our truncated form of the mTR3 (Table 8), we observe a kcat of 856 ± 43 min1

whereas the semisynthetic wild-type enzyme has a kcat of 1251 ± 71 min-1. The increase

in kcat for the wild type represents the activity of the selenylsulfide relative to the Nterminal disulfide towards DTNB. The truncated enzyme also exhibits a 6-fold increase
in Km compared to wild type. This increase in Km is also seen in full length Sec489cys
mutant as well as the semisynthetic mTR3-GUCG and mTR3-GUUG forms. The
semisynthetic variants mTR3-GCAUG and mTR3-GCAAUG do not display a significant
difference in kcat compared to the truncated yet have Km values similar to that of the wild
95

type. The DTNB reductase data can therefore be divided into three groups on the basis of
catalytic efficiencies (kcat/Km) that correlate to Trx activities. The mutants with poor Trx
activity have the lowest DTNB efficiency and are similar to truncated mTR3. This is
attributed to the increase in Km, as has been reported for mutants of DmTR (78) and PfTR
(55). The mTR3 low efficiency group (5000-20,000 s-1 M-1) includes the truncated,
SCCS, GCCG, GUCG, and GUUG mutants. The wild-type efficiency group (~5 X 104 s-1
M-1) includes both Ala insertion mutants where the single Ala shows an increase in
efficiency while the double Ala shows a decrease. The C-terminal carboxamide mutant is
distinguished as a high efficiency group at 105. This is >10 fold higher than the wild-type
group when the 28 % lower selenium content of this mutant is taken into consideration.
The non-selenium containing DmTR also show excellent activity towards DTNB
with results that very similar to the mTR3. The respective wild type enzyme has a kcat of
178 min-1 for truncated DmTR (Table 9), and 157 min-1 for the wild type. This is ~12 %
the activity seen in the wild-type mTR3. The DmTR also shows the decrease with the
double Ala insertion seen with the mTR3. There are much smaller differences in both kcat
and kcat/Km for DmTR. For mTR3 there is a 10 fold increase in kcat/Km while it is only 3
fold for DmTR. The kcat/Km for DmTR fall into the low efficiency group for mTR3. The
C-terminal hydroxamic acid of DmTR shows a significant increase in efficiency (2.3
fold). The thiocarboxylate does show an increase in activity but has identical efficiency
when compared to wild type. These results are in agreement with what is observed in the
mTR carboxamide mutant where neutralization of the negative charge at the C-terminus
results in an increase in catalytic efficiency.
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Peroxidase Activity of Semisynthetic mTR3.
Peroxidase activity is characteristic of the selenium incorporation in mammalian
TR. Like DTNB, it also has been reported to have a low millimolar Km and is likely not a
physiologically relevant activity for the enzyme. Peroxidase activity plots for thioredoxin
reductase previously reported show poor saturation, but have been limited to
concentrations less than 5 mM (109, 157). In performing this study, we have expanded
the profile to 70 mM peroxide. The results demonstrate poor saturation for wild type
carboxylic acid and carboxamide forms, Figure 31A, as well as the Sec489Cys mutant.
We previously reported an activity of 71 ± 7 min-1 with a Km of 6.6 ± 0.5 mM when
limiting the analysis to substrate concentrations equivalent to that reported in the
literature (5 mM). After repeated extended analysis of the wild type carboxylic acid
enzyme we observe an activity of 1753 ± 257 min-1 with a Km of 259 ± 33 mM using 50
nM enzyme while the carboxamide has an activity of 3204 ± 351 min-1 with a Km of 167
± 17 mM using 20 nM enzyme. A result of this is the extremely low kcat/Km which are
>100 fold lower than DTNB (Table 10).
As shown in Figure 31B, the profiles of the mTR3-GCAUG, mTR3-GCAAUG,
and mTR3-GUCG mutants display a different property, however. The mTR3-GUCG
required 500 nM enzyme and shows only about 10-15 % of the activity of the mTR3GCAUG and mTR3-GCAAUG yet each of these three mutants shows saturation with
estimated Km values of 14 mM, 6.8 mM, and 9.5 mM respectively. These values are in
better agreement with previous estimations. The interpretation of this data is that, while
the wild type enzyme displays significant peroxidase activity, a definitive estimation of
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kinetic parameters is not applicable, as it does not represent a reasonable binding event.
We have, however, produced three mutants with mM Km values are more indicative of a
potential binding event. A complete summary of the data is shown in Table 10.
We also tested the impact of the concentration of the co-substrate NADPH on the
saturation profile. Figure 32A shows the wild-type enzyme while Figure 32B shows the
mTR3-GCAUG mutant. With each enzyme the saturation curve remains the same from
25 µM to 500 µM NADPH. In each case, progress curves remained linear over the 2minute time frame of the assay with the exception of the 25 µM NADPH at the 70 mM
peroxide concentration where linearity was maintained to 90 seconds due to eventual
depletion of NADPH. A characteristic of the DTNB assay is the observation of product
inhibition at very high concentrations of substrate. This effect is not observed with H2O2
as substrate.
Interpretation of Structure-Function Study.
We have determined that the Cys containing enzymes are far more dependent on
vicinal residues to reduce the natural substrate Trx than the Sec containing enzyme from
mouse. The mTR3 mutant GCAUG retains 16 % kcat while the GCAAUG mutant has 22
% kcat when compared to the wild type sequence GCUG. This is in stark contrast to that
which is observed for DmTR and CeTR2. The SCACS mutant for DmTR shows a 142
fold reduction in kcat while the GCACG mutant for CeTR2 shows a 145 fold reduction in
kcat. For the double insertion, the SCAACS mutant for DmTR shows a 328 fold reduction
in kcat while the GCACG mutant for CeTR2 shows a 90 fold reduction in kcat.
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Insertion of each Ala is expected to progressively reduce the ring strain. In a
strictly chemical sense, the larger ring is expected to be more stable and therefore less
reactive in the ring opening step. In contrast there should be a corresponding decreased
energy barrier to closing the ring. Therefore, the combined impact of ring strain on the
enzymatic cycle is currently unknown and cannot be eliminated as a contributing factor
in each of these enzymes. This is demonstrated by the partial loss of activity for the
GCAUG and GCAAUG mTR3 mutants. However, simply replacing a single selenium
atom in the ring with a sulfur atom, as is the case for both DmTR and CeTR, results in a
far greater loss of activity.
The pH optima determined for wild type mTR3 is 7.0-7.2 while the Ala insertions
both shift to pH 8 (Figure 29). Similarly, the wild type DmTR has an optimal pH of 7.5 8.0 while the Ala insertions shift to pH 8.5 (Figure 30). The kinetic parameters are
determined at pH 7.0 where wild type mTR3 activity is at maximum. At this pH, the
mTR3 Ala insertions still retain 70-80 %, the wild type DmTR 80%, and the DmTR Ala
insertion 50 %, of their respective maximal activities. However, the shift in the pH
optima is only responsible for ~20 % of the loss in activity for the Ala insertions and
adjusting solution pH will not recover the 100 fold loss in activity observed in DmTR and
CeTR2. The identical shift in pH optima indicates an alteration in the same chemical step,
but one that is compensated for by the presence of selenium in mTR3.
We have also investigated the impact of the negative charge of the C-terminal
carboxylate in catalysis. It was suggested from the crystal structure of the rat enzyme that
the conserved Lys26 could serve as an anchor to position the C-terminus for electron
transfer from the FAD associated disulfide by salt bridge formation during the catalytic
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cycle (36). If this were a critical interaction, alteration of the C-terminus would be
expected to decrease activity. A second possibility is that the proximity of the negative
charge to electron and proton transfer during the enzymatic cycle would be inhibitory to
the enzyme in which case neutralization should result in an increase in activity. Our
results indicate that a specific interaction with, or charge contribution from, the Cterminal carboxylate does not appear critical to catalysis.
Neutralization of the carboxylate charge by conversion to the carboxamide for
mTR3 results in a 2-fold increase in activity towards Trx and peroxide. The carboxamide
mutant also shows a greater than 3 fold increase in activity with a 10 fold increase in
kcat/Km with the negatively charged substrate DTNB. These results are similar to what is
observed for small peptide thiol-disulfide exchange reactions investigated by Zhang and
Snyder (158) where the 5-fold decrease in thiol disulfide exchange for the peptide CysCys compared to Cys-Cys-Ala was hypothesized to be due to the proximity of the
carboxylate to the thiol. Substitution to a hydroxamic acid for DmTR also shows the
same behavior as the mTR3 carboxamide with both Trx and DTNB as substrate. The lack
of a change in pH optima indicates a chemical step has likely not been altered in these
variants but possibly involves product release.
From interpretation to hypothesis.
Under Michaelis-Menten conditions we are looking at the impact on the overall
rate of catalysis. Therefore, the effect we see reflects the combination of the ring opening
step, where the C-terminus becomes reduced, and the ring closing step, where the Cterminus is re-oxidizes after electron transfer to Trx. Each step is broken into two coupled
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reactions (Figure33); 1a) formation of a mixed disulfide with 1b) the first leaving group,
and 2a) resolution of the mixed disulfide with 2b) a second leaving group. If these
mutants perturb the structural position for formation of either mixed disulfide, one would
expect equivalent results. Since this is not what is observed for the Ala insertions, we can
eliminate 1a from each step as the critical point for mTR3. However, this assumption
must be made cautiously due to the low activity for the DmTR and CeTR Ala mutants as
there is no biochemical data that defines which Cys forms the interchange with the FAD
associated active site.
Once the mixed disulfide is formed, the structural position should be fixed and
therefore its role as the second leaving group should also be retained, eliminating 2b from
each step. Resolution of the mixed disulfide in the ring opening step is performed by the
FAD-associated resolving cysteine Cys62 and is conserved, therefore 2a for the ring
opening can also be eliminated.
Even after elimination of several reactions for mTR3 we are still left with the first
leaving group (1b) of the ring-opening step and the TR-Trx mixed disulfide resolution
(2a) of the ring closing step. The ring closing step is governed by two opposing forces.
For example, insertion of residues will favor ring formation by reducing the energy
barrier of ring strain but becomes less favorable due to the increase in conformational
entropy. Again, these forces should impart the same effect for each of the equivalent TR
mutants in the absence of an altered chemical step. Therefore it is the hypothesis here that
disruption of the vicinal disulfide results in the alteration of an enzymatic chemical step,
likely during ring opening, that is more critical in the non-selenium containing TRs. This
is supported by the alkaline shift in pH optima observed for each TR by increasing the
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size of the ring. With such the dramatic loss of activity of mTR3 with Trx for the GUCG,
GCCG, and SCCS mutants in comparison to the GCAUG and GCAAUG mutants, we
conclude that maintaining the Sec C-terminal to the Cys is essential but the vicinal nature
is not.
Each of the mTR3 mutants produced in this study that display poor Trx and H2O2
activity fall into the DTNB efficiency category (due to increased Km) characteristic of the
truncated enzyme. This is important, as it is likely that the DTNB reductase activity of
these mutants is attributed to the FAD-associated active site. We suspect that the loss of
activity for these mutants is due to the poor reduction of the C-terminal motif by the
FAD-associated active site (the ring opening step). This is best demonstrated by the
mutant mTR3-GUCG. This mutant also has significantly lower Trx and H2O2 activity
with DTNB efficiency similar to that of the truncated enzyme. The peroxidase activity
profile of the WT is characteristic of a chemical reaction and not enzymatic. Therefore,
one would expect the peroxidase reaction to be independent of the Sec position once the
C-terminal motif is reduced. Since a significant loss in activity is observed
experimentally, this further supports our interpretation that the C-terminal motif is not
efficiently reduced in the ring opening step. Combining the results from all three
substrates (Trx, DTNB, and H2O2) we hypothesize that the Sec is required for mTR3 in
the ring opening step, likely functioning as the leaving group (LG1 in Figure 33). We
will address this hypothesis experimentally in the next Chapter.
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Figure 28. SDS-PAGE of DmTR cleavage from the intein.
Evaluation of DmTR cleavage from the intein with alternative reagents by 10 % SDSPAGE. Lane 1, loaded chitin resin; lane 2, markers; lane3, NMA eluted; lane 4, resin
after NMA elution; lane5, ammonium sulfide eluted; lane 6, resin after ammonium
sulfide elution; lane 7, hydroxylamine eluted; lane 8, resin after hydroxylamine elution;
lane 9, buffer only eluted; lane 10, resin after buffer elution; lane 11, blank; lane 12, pre
induction; lane 13, cell lysate supernatant. Resin-bound samples are evaluated by
stripping with 1% SDS. Eluant lanes represent equivalent loads, as do the lanes
containing the resin strip.
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Table 6. Semisynthetic mTR3 thioredoxin reductase activity.
kcat / Km

Enzyme

kcat (min-1)

Km (µM)

% Peptide
Incorporation

a

mTR3-G- COO-

No activity

No activity

NA

NA

b

mTR3-GCCG- COO-

4.1 ± 0.11

49.1 ± 3.2

NA

1.4 x 103

mTR3-SCCS- COO-

5.0 ± 0.06

32.0 ± 8.8

NA

2.6 x 103

c

2220 ± 78

67.6 ± 6

91

5.5 x 105

3010 ± 351

41.6 ± 5.0

63

1.2 x 106

mTR3-G-UCG- COO-

8.3 ± 0.1

36.1 ± 1.3

32

3.8 x 103

mTR3-G-UUG- COO-

1.2 ± 0.1

64.8 ± 16.1

10

3.1 x 102

mTR3-G-CAUG- COO-

350 ± 14

20.8 ± 3.5

100

2.8 x 105

mTR3-G-CAAUG- COO-

501 ± 41

34.9 ± 10.0

100

2.4 x 105

3000

35

NA

1.4 x 106

mTR3-G-CUG- COO-

d

e

mTR3-G-CUG-CONH2

rat TR1

(s-1 M-1)

a

The truncated form of the enzyme missing the C-terminal tripeptide Cys-Sec-Gly.

b

The full length mutant Sec489Cys.

c

The wild type enzyme, the hyphen between Gly and Cys (or Sec) indicates production
by semisynthesis.

d

The wild type enzyme produced by semisynthesis with a C-terminal carboxamide.

e

Taken from (145, 150), purified from rat liver and assayed using E. coli Trx.
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Figure 29. Trx activity as a function of pH for mTR3.
Activity towards thioredoxin as a function of pH for semisynthetic mutants of mTR3. The
key indicates the C-terminal sequence following mTR3-G; -GCUG-COO- (●), -GCUGCONH2 (○), -GCAUG (♦) -GCAAUG (∆), -GUCG (◊), -GUUG (■), -GCCG (▲).
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Table 7. DmTR thioredoxin reductase activity.
kcat / Km

Enzyme

kcat (min-1)

Km (µM)

a

TR-S- COO-

No activity

No activity

NA

b

TR-SCCS- COO-

299.4 ± 7.4

173.3 ± 8.1

2.9 x 104

TR-SCCS-CONHOH

513.3 ± 33.3

172.5 ± 21.7

5.0 x 104

TR-SCCS-COS-

491.9 ± 19.6

67.8 ± 7.3

1.2 x 105

TR-SCACS- COO-

2.12 ± 0.3

298.3 ± 58.0

118

TR-SCAACS- COO-

0.91 ± 0.2

166 ± 58.0

91

c

d

(s-1 M-1)

a

The truncated form of the enzyme missing the C-terminal tripeptide Cys-Cys-Ser.

b

The wild type enzyme.

c

The wild type enzyme produced as the C-terminal hydroxamic acid (Adam P. Lothrop).

d

The wild type enzyme produced as the C-terminal thiocarboxylate (Adam P. Lothrop).
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Figure 30. Trx activity as a function of pH for DmTR.
Activity towards thioredoxin as a function of pH for the DmTR mutants SCCS (●),
SCACS (□), SCAACS (▲).
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Table 8. DTNB reductase activity for semisynthetic mTR3.

Enzyme

kcat (min-1)

Km (mM)

kcat / Km
(s-1 M-1)

a

mTR3-G-COO-

856 ± 43

2.72 ± 0.43

5.2 x 103

b

mTR3-GCCG- COO-

794 ± 78

1.75 ± 0.41

7.6 x 103

627 ± 18

0.53 ± 0.19

2.0 x 104

1251 ± 71

0.46 ± 0.09

4.5 x 104

3284 ± 133

0.13 ± 0.02

4.2 x 105

mTR3-G-UCG- COO-

751 ± 51

1.61 ± 0.34

7.8 x 103

mTR3-G-UUG- COO-

914 ± 18

1.84 ± 0.12

8.3 x 103

mTR3-G-CAUG- COO-

1010 ± 26

0.26 ± 0.03

6.5 x 104

mTR3-G-CAAUG- COO-

999 ± 44

0.43 ± 0.08

5.6 x 104

mTR3-SCCS- COOc

mTR3-G-CUG- COO-

d

mTR3-G-CUG-CONH2

a

The truncated form of the enzyme missing the C-terminal tripeptide Cys-Sec-Gly.

b

The full length mutant Sec489Cys.

c

The wild type enzyme, the hyphen between Gly and Cys (or Sec) indicates production
by semisynthesis.

d

The wild type enzyme produced by semisynthesis with a C-terminal carboxamide.
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Table 9. DTNB reductase activity for DmTR.
kcat / Km

Enzyme

kcat (min-1)

Km (mM)

a

TR-S-COO-

178.0 ± 7.0

0.75 ± 0.09

4.0 x 103

b

TR-SCCS-COO-

157.0 ± 12.4

0.22 ± 0.07

1.2 x 104

TR-SCACS-COO-

187.5 ± 17

0.20 ± 0.06

1.7 x 104

TR-SCAACS-COO-

94.9 ± 4.1

0.25 ± 0.03

6.3 x 103

(s-1 M-1)

a

The truncated form of the enzyme missing the C-terminal tripeptide Cys-Cys-Ser.

b

The wild type enzyme.
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Figure 31. Peroxidase activity for mTR3 mutants.
Michaelis-Menten plots in the form of Vo/ET vs. hydrogen peroxide concentration for
mammalian thioredoxin reductase C-terminal mutants. Panel A shows the wild-type
enzyme with the naturally occurring carboxylic acid (●) and wild-type peptide sequence
produced as a C-terminal carboxamide (□). Panel B shows the GCAUG (●), GCAAUG
(□), and GUCG (○) mutants.
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Table 10. Peroxidase activity of semisynthetic mTR3.
kcat / Km

Enzyme

kcat (min-1)

Km (mM)

a

mTR3-G- COO-

2.1 ± 0.04

65 ± 17

0.5

b

mTR3-GCCG- COO-

19.6 ± 1.9

233 ± 36

1.4

mTR3-G-CUG- COO-

1753 ± 257

259 ± 46
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3204 ± 351

167 ± 24

320

mTR3-G-UCG- COO-

19.7 ± 0.8

9.5 ± 1.2

35

mTR3-G-UUG- COO-

6.0 ± 0.7

47 ± 10

2.1

mTR3-G-CAUG- COO-

284 ± 3.9

14 ± 0.7

338

mTR3-G-CAAUG- COO-

125 ± 6.4

6.8 ± 1.2

306

c

d

mTR3-G-CUG-CONH2

(s-1 M-1)

a

The truncated form of the enzyme missing the C-terminal tripeptide Cys-Sec-Gly.

b

The full length mutant Sec489Cys.

c

The wild type enzyme, the hyphen between Gly and Cys (or Sec) indicates production
by semisynthesis.

d

The wild type enzyme produced by semisynthesis with a C-terminal carboxamide.
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Figure 32. Peroxidase activity as a function of NADPH concentration.
Hydrogen peroxidase activity for semisynthetic mTR3 with NADPH concentrations at 25
µM (●), 100 µM (□), 200 µM (○), and 500 µM (×). Panel A is wild type, B is the Cterminal mutant GCAUG.
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Figure 33. Steps of thiol-disulfide exchange for TR.
The steps for thiol-disulfide for thioredoxin reductase that occurs between the FADassociated active site (Cys57, Cys62) and the C-terminus, the ring opening step. 1a) Upon
reduction of the FAD-associated disulfide, Cys57 will form the interchange (IC) with a
Cys from the C-terminus with the other Cys being the first leaving group (LG1) which
would need to be protonated (1b) if Cys but would not be if Sec. The resolution step, 2a
and 2b, should proceed as in the GR cycle. The same general cycle subsequently occurs
between the C-terminus or TR in the reduced state and the oxidized disulfide of Trx and
would be the ring closing step.
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CHAPTER 4.
TRUNCATED THIOREDOXIN REDUCTASE AS A
DISULFIDE OXIDOREDUCTASE INVESTIGATED
BY PEPTIDE COMPLEMENTATION

Figure 34. Peptide complementation of TR.
Peptide Complementation of thioredoxin reductase (TR). Oxidized tetrapeptides
corresponding to the C-terminal active site motif of TR are substrates for the truncated
form of the enzyme in a manner similar to glutathione reductase and its cognate substrate
oxidized glutathione.
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In the course of developing the semisynthetic method, we also attempted to
produce a non-covalent semisynthetic TR by using a technique called peptide
complementation. In such a system, a truncated enzyme missing part of its active site can
be restored to full or partial activity by exogenous addition of a synthetic peptide that
complements the active site with the missing amino acids. The most prominent example
of peptide complementation is the S-protein/S-peptide system developed by Richards
(134). In our peptide complementation system, we demonstrate that tetrapeptides in the
oxidized form equivalent to the C-terminal active sites of both mTR3 and DmTR, only
weakly complement thioredoxin reductase activity but behave more like substrates for the
truncated enzymes. This is reasonable because as part of the enzyme, the oxidized form
of the C-terminal tetrapeptide must be reduced by the N-terminal redox-active dithiol
during the enzymatic cycle. A disulfide bond formed between vicinal Cys-Cys (or CysSec) residues results in the formation of an eight-membered ring and this assay examines
the kinetics of the ring opening step that occurs during the enzymatic cycle of TR. The
observation that oxidized tetrapeptides can serve as substrate for the truncated forms of
TR demonstrate that TR, like GR, may be considered a disulfide oxidoreductase where its
own C-terminus is the cognate substrate (Figure 35). Using this assay we can isolate the
ring-opening step for TR in a manner analogous to the GSSG reduction by GR (Figure
33 of Chapter 3). We observe that for each of the peptides assayed, DmTR showed higher
activity than mTR3. There is also a dramatic dependence for Sec in the second position
demonstrated by mTR3 but not DmTR.
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METHODS

Activity of truncated TR towards C-terminal Tetrapeptide Substrates.
Tetrapeptides Ac-GCUG(ox), Ac-GCCG(ox), Ac-SCUS(ox), and Ac-SCCS(ox)
were prepared by Fmoc solid-phase peptide synthesis and oxidized to the monomeric
form using a newly described procedure for making disulfide bonds on-resin (143). The
peptides were purified by preparative HPLC and verified as intramolecular disulfides by
MALDI-TOF mass spectrometry using a Voyager-DE PRO from Applied Biosystems
(Framingham, MA). The peptides were treated as substrates for the truncated DmTR and
mTR3 using conditions similar to the DTNB assay and enzyme concentrations were
adjusted to get a signal at 340 nm as is seen in the thioredxin (Trx) assay. Activity was
measured by the decrease in absorbance at 340 nm for the consumption of NADPH,
corrected for background in the absence of enzyme as well as in the absence of substrate,
and plotted as mole of NADPH consumed per minute per mole of homodimeric TR. Due
to the uniqueness of this system, we have reported the activity values for each peptide as
the slopes of the plot of Vo/ET vs. peptide concentration. Each peptide assayed is then
evaluated as a fold difference in slope when compared to another peptide.

RESULTS AND DISCUSSION

A peptide complementation approach was tested in comparison with the ligated
semisynthetic mTR3 as only three amino acids out of a total of 490 are missing from the
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intact enzyme. Peptide Ac-GCUG was synthesized and tested for its ability to
“complement” the truncated enzyme missing tripeptide CUG. This tetrapeptide is Nacylated and begins with a glycine residue and as such, cannot ligate to the thioestertagged enzyme produced from the intein fusion. Variations of the Trx assay were
performed in which Trx, insulin, or both were missing from the assay. The results of
these experiments are summarized in Table 11 and demonstrate that the seleniumcontaining peptide was required for NADPH consumption. The function of the insulin in
the assay is to provide a source of oxidant for Trx so that the concentration of the
oxidized Trx remains high during the course of the assay. When Trx was absent, the
oxidized form of the peptide was reduced by the truncated form of the enzyme, resulting
in the consumption of NADPH. The results in Table 1 show that more NADPH is
consumed when both Trx and insulin are present in the assay mixture. The transiently
formed enzyme/peptide complex may reduce Trx, or the resulting reduced peptide may
reduce Trx. These results indicate that the peptide is primarily acting as a substrate for
the truncated enzyme, rather than forming a reconstituted enzyme as in the S-protein/Speptide complex (134).
Truncated TR as a Disulfide Reductase.
Preliminary results demonstrated that the oxidized tripeptide Cys-Sec-GlyOH(ox) is a substrate for mTR3 when added to the assay mixture containing NADPH and
truncated TR (Figure 36) with an activity of 260 min-1. The low affinity observed for the
peptide by the enzyme, is likely the result of minimal binding contacts in this
complementation system. When the selenium atom is replaced with a sulfur atom in the
117

homologous peptide CCG(ox), the activity is reduce to 0.81 min-1, indicating that the ring
opening step is greatly affected by the replacement of a selenium atom with a sulfur
atom.
We subsequently tested oxidized tetrapeptides as substrates for both DmTR and
mTR3 so that we could fully examine the effect of flanking residues on either side of the
Cys-Cys or Cys-Sec dyad. We tested the tetrapeptides: Ac-GCUG(ox), Ac-GCCG(ox),
Ac-SCCS(ox), and Ac-SCUS(ox) (all as the oxidized, monomeric-cyclic peptides) as
substrates for the truncated enzymes. A summary of the kinetic data for ring opening is
given in Table 12 with the plots shown in Figure 37. Comparing Ac-GCUG(ox) to AcGCCG(ox) demonstrates that there is a 308 fold decline in activity in mTR3 and only a
36.2 fold decrease for DmTR. The ratio of ring-opening rates for the peptides AcSCUS(ox) and Ac-SCCS(ox) with mTR3 is 511 fold while the equivalent comparison is
only 5.65 fold with DmTR, Table 13. Since the assays do not reach saturation,
differences in Km must still be taken in consideration when comparing Ser and Gly
containing peptides. However, it is reasonable to assume that the equivalent peptide pairs
(SCCS/SCUS and GCCG/GCUG) would not have a significant difference in Km as a
result of the substitution of a selenium atom for a sulfur atom. The data demonstrates a
dramatic difference in the rate of peptide turnover in this step of the reaction mechanism
between the two enzymes. There is a 10 to 100 fold greater dependence on the Sec
residue for mTR3 compared to DmTR for these peptide pairs.
Prior to the cloning of DmTR, the peptide Ac-GCAUG(ox) was assayed in
comparison to Ac-GCUG(ox) for truncated mTR3 (Figure 38). For this peptide, the Sec
is retained C-terminal relative to Cys but separated by a single Ala residue. The fold
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difference for this pair GCUG/GCAUG was only 8.4 fold, which is minor in comparison
to the 308 fold for GCUG/GCCG with mTR3. Preliminary results were also obtained for
the peptide Ac-GUCG(ox). The peptide was not completely purified therefore a value for
direct comparison to the other peptides is not possible. However, the crude peptide was
assayed with both mTR and DmTR with no difference in activity observed between the
two enzymes. Neither mTR nor DmTR showed activity to the disulfide substrates cystine,
homocystine, or GSSG.
Finally, we also assayed peptides containing the non-protein D-isomer of cysteine
substituted individually for the two positions. There was no activity observed for AcGCDCLG(ox) or Ac-GCLCDG(ox) for mTR3. DmTR (Figure 39) showed a 3 fold
decrease in activity for Ac-GCDCLG(ox) compared to Ac-GCCG(ox) and no activity for
Ac-GCLCDG(ox). This difference in activity observed by a stereo-isomer substitution
indicates there is an additional structural component impacting the ring opening step.
Indication of a Critical Leaving Group Effect for mTR3.
The data in Chapter 3 demonstrates that the truncated forms of both enzymes can
catalyze the reduction of the disulfide DTNB. An explanation of why DTNB is a
substrate for TR but cystine is not has been partially addressed by Ascott and coworkers
(94) in applications with the mixed disulfide R-S-S-TNB (TNB-S is 5-thio-2nitrobenzoate). In this example, TNB-S- will be the leaving group because of the strong
electron withdrawing properties of the 2-nitrobenzoate group. Such mixed disulfides are
also easier to break than a typical disulfide bond because they are highly polarized. This
property has been used in investigating the mechanism of GR. The mixed disulfide
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between glutathione and TNB-S- (G-S-S-TNB) is a substrate for GR with kinetic isotope
effects indicating a single proton transfer step as rate limiting (95). The interpretation of
this data is that the departing GSH would require protonation but the TNB-S- would not.
Therefore, we posit that DTNB is a substrate for TR due to the very low pKa (4.75) of the
leaving group thiol that is formed upon reduction of this disulfide (159).
The exact same situation exists in the peptide Ac-GCUG(ox), which has a low
pKa leaving group (Se) and the S-Se bond is also much weaker than a typical disulfide
bond due to the polarization in the bond conferred by the Se atom. By comparing the rate
of reduction of peptide Ac-GCUG(ox) vs. peptide Ac-GCCG(ox) by the truncated mTR3,
this large difference in the rate of ring opening between these two peptides can be
understood in terms of leaving group pKas. This is further supported by the 8.4 fold
decrease in ring opening for the GCUG/GCAUG pair compared to the 308 fold decrease
for the GCUG/GCCG pair for mTR3. In the Ac-GCAUG(ox) peptide, the Sec position
relative to Cys (C-terminal) is retained. It can therefore be hypothesized that the necessity
for Sec in mTR3 is its function as the leaving group in the ring opening step.
Correlation to C-terminal Structure-Function Results.
A comparison of full-length TR activities determined by the steady-state Trx
activity and the data for the ring opening step assayed with the truncated TR is shown in
Table 14. Taking into consideration that the data from the two methods are derived rather
differently, there is a remarkable level of agreement between the two methods. For
DmTR, the GCUG/GCCG and SCUS/SCCS pairs correlate 20% and 30% of the loss in
Trx activity to the ring opening step while the GCUG/SCCS are within 50%. In each pair,
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there a greater fold difference in ring opening than observed in Trx activity. For mTR3,
the fold difference in activity for the GCUG/GCCG pair for Trx is 292 and ring opening
is 308. This near identical result is also observed for the GCUG/GCAUG pair with 6.3
and 8.4 fold difference in activity observed by the methods respectively. From this
analysis, we hypothesize that the loss in Trx activity upon mutation of the Sec to Cys in
mTR can be attributed to the reduction in the rate of ring opening.
While these results from the two methods are in agreement, and peptide
complementation data lead us to a leaving group effect hypothesis, the question of why
still remains. Why would Sec be required as a leaving group if the catalytic base is
conserved in TR? A simplified interpretation would be that DmTR has a functional
catalytic base but mTR3 does not. However, the well-established model based on
mechanistic studies with GR and recently with TR from Plasmodium falciparum (93),
indicate that the catalytic His is essential for multiple steps in the reaction cycle (see
Figure 10 of Chapter 1). Therefore, if mTR3 did not have a functional base it should
have little or no activity regardless of whether it contains Sec or not.
A second possibility is that the reaction cycle requires a second catalytic base
which is functional in DmTR but non-functional or absent in mTR3. For example, one
base would be required for protonation of the first leaving group and another for
protonation of the second leaving group that is generated upon resolution of the
interchange mixed-disulfide. Based on sequence alignments, this residue was proposed to
be His106 in DmTR (65). However, this residue is also conserved in mammalian TRs,
and mutation of His106 to Phe in DmTR results in only a 3 fold reduction in activity
(121). Finally there is no explanation as to why cystine is not a substrate for DmTR
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considering its activity towards the Cys-Cys cyclic peptides. The same conundrum exists
for GR where GSSG is a substrate but cystine activity is poor (160) even though both
molecules are intermolecular cysteine disulfides.
There is also an interesting observation when considering the Ser and Gly
containing sequences for the two enzymes. DmTR shows no preference for SCCS or
GCUG with either assay method yet mTR3 does. Based on the proposed function of Ser
acting as a general acid/base in the DmTR motif (65), there should be better agreement
between the two enzymes. The peptide complementation data shows minor rate
enhancement by replacing Gly with Ser in a Cys-Cys or Cys-Sec peptide indicating some
potential functionality of the Ser residues. However, there is still no explanation as to
why the SCCS motif cannot replace the GCUG motif in mTR3, as they appear
interchangeable for DmTR. It also does not explain why the effect Sec has with both
methods for mTR3 and why it is muted in DmTR. Our conclusion is that there is a
structural difference between mTR3 and DmTR, other than the C-terminal tetrapeptide
motif, responsible for the requirement for Sec in mTR3. Chapter 5 will examine this
question and correlate the enzymatic data to structural differences between these two
enzymes.
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Figure 35. Cognate substrates revisited for truncated TR.
Using oxidized tetrapeptides equivalent to the C-terminal motif of TR as substrates for
the truncated enzyme we are able to look at steps in the catalytic cycle in a manner
equivalent to GR, TryR or LipDH and their cognate substrates (34, 37, 130). The
tetrapeptides are the cognate substrate in the peptide complementation assay.
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Table 11. Summary of TR/Ac-GCUG peptide acomplementation kinetics.
c

Enzyme

100 µM peptide

160 µM insulin

3 µM Trx

Rate (nmoles
NADPH/min)

TRGly487

+

+

+

4.20 ± 0.60

TRGly487

+

-

-

2.25 ± 0.21

TRGly487

+

-

+

1.96 ± 0.086

TRGly487

+

+

-

2.60 ± 0.062

b

a

Enzyme assays were performed in a volume of 600 µL containing 100 mM potassium
phosphate buffer, pH 7.0, 1 mM EDTA, with 8.4 µM enzyme. Other assay components
are as indicated in the table.
b

Indicates that the truncated form of the enzyme ends at residue 487.

c

The rate is calculated by monitoring the loss of NADPH at 340 nm.

124

Figure 36. Peptide complementation of mTR3 with CUG(ox).
Rate of reduction (ring opening) of oxidized tripeptide CUG(ox) with truncated mTR3.
A linear increase in activity is observed as the concentration of tripeptide increases in the
assay. The truncated enzyme could not be saturated with tripeptide due to solubility
limits of the peptide under the assay conditions. The rates of peptide turnover were
calculated by measuring the slope of a plot of NADPH consumption (in min-1) vs peptide
concentration (in mM).
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Table 12. Summary of activities toward tetrapeptides for the truncated TRs.
a

Enzyme

Peptide (turnover
rate in min-1/mM)
Ac-SCCS(ox)

Ac-SCUS(ox)

Ac-GCCG(ox)

Ac-GCUG(ox)

mTR3-G

0.21

107.3

0.06

18.5

DmTR-S

57.0 (271)d

322.6 (3)

2.4 (40)

87.0 (4.7)

b

c

a

The rate of peptide turnover was determined at pH 7.0 in potassium phosphate buffer as
described in the methods. The relative activities for the individual peptides are the slopes
from the titration curve in min-1/mM.
b

Mouse mitochondrial TR missing the C-terminal tripeptide Cys-Sec-Gly.

c

Drosophila melanogaster TR missing the C-terminal tripeptide Cys-Cys-Ser.

d

The ratio of rates (fold difference) between DmTR-S and mTR3-G are given in
parentheses in bold.
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Table 13. Ratio of peptide turnover rates for the truncated TRs.
SCUS/SCCS

GCUG/GCCG

GCUG/SCCS

SCCS/GCCG

SCUS/GCUG

(Se/S)

(Se/S)

(Se/S)

(S/S)

(Se/Se)

Enzyme
a

mTR3-G

c

511

308

88.1

3.5

5.8

b

DmTR-S

5.65

36.2

1.5

23.7

3.7

a

Mouse mitochondrial TR missing the C-terminal tripeptide Cys-Sec-Gly.

b

Drosophila melanogaster TR missing the C-terminal tripeptide Cys-Cys-Ser.

c

The ratio of rates (fold difference) between the peptide pair.
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Figure 37. Rate of ring opening for tetrapeptides(ox).
Rate of reduction (ring opening) using oxidized tetrapeptides as substrates for truncated
enzymes DmTR (solid) and mTR3 (dashed). (A) Peptide Ac-GCUG(ox) as substrate; (B)
Peptide Ac-SCUS(ox) as substrate; (C) Peptide Ac-GCCG(ox) as substrate; and (D)
Peptide Ac-SCCS(ox) as substrate.
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Figure 38. Rate of ring opening Ac-GCAUG(ox) for mTR3.
Rate of reduction (ring opening) using the oxidized tetrapeptides Ac-GCUG(ox) (solid)
and Ac-GCAUG(ox) (dashed) as substrates for truncated mTR3. The Activity for the AcGCUG(ox) was 14.0 while the Ac-GCUG(ox) activity was 1.66. This results in an 8.4
fold activity ratio.
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Figure 39. Rate of ring opening for Ac-GCDCLG(ox) with DmTR.
Rate of reduction (ring opening) using oxidized tetrapeptides as substrates for truncated
DmTR. The peptide Ac-GCCG(ox) as substrate is shown in black. The peptide AcGCDCLG(ox) as substrate is shown in grey.
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Table 14. Rates of ring opening step compared to full-length TR activities.
Peptide pair

DmTR
b

Full length

e

f

DmTR-S

mTR3

mTR3-G

Ring Opening

Full Length

Ring Opening.

GCUG/GCCGa

c

7.5

36.2

292

308

SCCS/GCCG

7.5

23.7

0.7

3.5

GCUG/SCCS

1

1.5

435

88.1

N.D.d

N.D.

6.3

8.4

GCUG/GCAUG
a

The DmTR full length data is taken from (65).

b

Activities from thioredoxin assay.

c

The numbers represent the ratio of each pair.

d

Not determined.

e

Mouse mitochondrial TR missing the C-terminal tripeptide Cys-Sec-Gly.

f

Drosophila melanogaster TR missing the C-terminal tripeptide Cys-Cys-Ser.
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CHAPTER 5.
THE CRYSTAL STRUCTURE OF THIOREDOXIN
REDUCTASE FROM DROSOPHILA
MELANOGASTER WITH TETRAPEPTIDE
MODELING FOR COMPARISON WITH
MAMMALIAN THIOREDOXIN REDUCTASE

Figure 40. The crystal structure of mTR3.
The homodimeric structure of the mTR3 with a zoom of the key conserved catalytic
components NADPH (blue), FAD (yellow), and N-terminal disulfide from chain A
(green backbone). The Glu-His pair from chain B (orange backbone) is also shown. The
structure is mTR3 from this Chapter. The NADPH is from (35).
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In order to explain why mammalian thioredoxin reductase (TR) requires Sec but
TR from Drosophila melanogaster (DmTR) can utilize Cys, we have solved the X-ray
crystal structure of DmTR in the truncated form (missing the C-terminal tripeptide
sequence Cys-Cys-Ser) at 2.4 Å resolution. We have also solved the X-ray crystal
structure of mouse mitochondrial TR (mTR3) in the truncated for (missing the C-terminal
tripeptide Cys-Sec-Gly) at 2.25 Å resolution, though refinement is not complete. The
NMR structures of the oxidized tetrapeptides used in the peptide complementation
studies were oriented in the active site of both mTR3 and DmTR using oxidized
diglutathione bound to GR as a template. DmTR has a more open tetrapeptide binding
pocket than the mouse enzyme and accommodates peptide Ser-Cys-Cys-Ser(ox) in a cis
conformation that allows for protonation of the leaving group Cys by His464′. In
contrast, mTR3 shows a more narrow tetrapeptide binding pocket, which restricts the
mammalian redox-active tetrapeptide Gly-Cys-Sec-Gly to a trans conformation. This
places the Sec residue further away from the conserved catalytic histidine residue into a
position unsuitable for protonation. The analysis here explains why DmTR can function
with Cys but mTR3 requires Sec as a low pKa leaving group.
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METHODS

Crystallization of TR from Drosophila.
Purified DmTR was dialyzed against 10 mM potassium phosphate pH 7.4 with
300 mM NaCl and 1 mM EDTA then concentrated to 26 mg/mL. Crystals were grown at
20 oC using the hanging drop diffusion method with a reservoir solution containing 200
mM succinate pH 5.5 and 22 % PEG 6000. Hanging drops were 10 µL in volume
containing 6 µL protein, 3 µL reservoir, and 1 µL of 10 mM NADP. Crystals (280 x 100
x 100 µm) were fully grown in 5 to 7 days. Cryoprotection was achieved by dipping the
crystal in reservoir solution containing 4 % increments of ethylene glycol for 4 min per
step until a final concentration of 20 % was achieved.
Crystallization of TR from Mouse.
Purified mTR3 was dialyzed against 10 mM potassium phosphate pH 7.4 with
300 mM NaCl and 1 mM EDTA then concentrated to 25 mg/mL. Crystals were grown at
20 oC using the hanging drop diffusion method with a reservoir solution containing 150
mM MES pH 5.5, 2 % ethylene glycol, and 23 % PEG 6000. Hanging drops were 8 µL
in size with 5 µL of protein, 2 µL of reservoir, and 1 µL of 10 mM NADP. Crystals
(1000 x 240 x 240 µm) were fully grown in 1 to 3 days. Cryoprotection was achieved by
dipping the crystal in reservoir solution containing either a final concentration of 36 %
PEG 6000 or 25 % ethylene glycol for 5 minutes.
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Data Collection, Structure Determination and Refinement for DmTR.
Data was collected at –169 °C using a Rigaku RU-H3R generator with a copper
rotating anode on a Mar345 image plate detector. The data was indexed using DENZO
and scaled and merged using SCALEPACK (161). The structure of rat TR1 (PDB
1H6V) was used for molecular replacement routines with CNS (v 1.1)(162). The crossrotation search yielded a single peak 2.8σ above the mean and the translational search
found a peak 2.1σ above the mean. Rigid-body refinement reduced the R-factor to 0.46
for data from 15 to 2.4 Å. Data were processed using space group R32. Model building
was based upon simulated-annealing omit map interpretation with the graphics program
O (163). Successive rounds of refinement were performed by simulated annealing,
occupancy, and B-factor refinement using CNS and CCP4 (164). In the later stages of
refinement, the position of the FAD as well as the NADP (minus the nicotinamide
moiety) was determined by fitting omit maps. Final refinement was performed using
REFMAC5 (165) in CCP4, version 5.0.2, with the entire model as a single TLS group.
Electrostatic surface maps were computed using GRASP (166). All electrostatic maps are
in units of kT/e where k is the Boltzmann’s constant, T is the absolute temperature, and e
is the proton charge. The scale is –11 (red), 0 (white), and +11 (blue). Images were
generated using PyMOL (167).
C-terminal Peptide Structure and Docking.
The oxidized tetrapeptides Ac-GCUG, Ac-GCCG, and Ac-SCCS were examined
by NMR spectroscopy and found to exist as a population of four major conformers
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(Deker and Hondal, unpublished) as has been previously described for a similar peptide
with a vicinal disulfide bridge (58). Each of the four conformers was placed at the
reaction interface proximal to the conserved flavin-associated active site sequence
CVNVGC of both DmTR and mTR3 (PDB 1ZKQ) (35). Because of the high similarity
between the reaction mechanisms of GR and TR, we used the orientation of oxidized
glutathione (GSSG) in the active site of GR (PDB 1GRA, (34)) to orient the structures of
our oxidized peptides in the active site of TR. The disulfide bond of the oxidized
peptides was placed in an orientation similar to that of the disulfide bond of GSSG and
evaluated for the potential to form the interchange mixed-disulfide as well as for
positioning of the leaving group in relation to the catalytic histidine of GR and TR.
Additional restrictions on the placement of the peptide were imposed by the covalent
interchange mixed-disulfide structure of GR (PDB 1GRE (34)). Using the two GR
structures, priority was given in the peptide modeling to the first step (interchange) of the
GR GSSG-dependent oxidative half-reaction by super-positioning of the Cβ and sulfur
(or selenium) atoms to the interchange cysteine of glutathione I (GSH I).
Independent fits for each peptide were performed for both cysteines in peptide
SCCS(ox), or the Cys and Sec in peptide GCUG(ox), as the interchange residue.
Alignments were performed using the graphics program O (163). Each aligned
conformation was evaluated for steric and electrostatic interactions. (Note: In the analysis
below we have used the residue numbering for mTR3 as deposited for the structure
1ZKQ (35) to make it easier for the reader should they wish to view the PDB file. The
authors of this deposited structure retained the mitochondrial leader sequence in their
numbering system. For reference, this places Sec as residue 523 rather than residue 489.)
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RESULTS AND DISCUSSION

Crystallization of TR.
In the methods section of this Chapter are the optimized conditions for
crystallization of mTR3 and DmTR. Both enzymes went through extensive screening to
achieve these conditions and throughout the optimization process, some key trends and
observations were made. The optimized conditions for mTR3 generated amazing crystal
formation that could be observed in real time and resulted in extremely large crystals
(Figure 41). It is expected that these crystals could be used for high-resolution studies in
the future. The current space group is I4122 and the data is 95 % complete at 2.25 Å with
the current Rfree at 31.7 % (Table 15). However, the mouse structure refinement was not
completed, as it was published by another group (35). Therefore, this published structure
was used for the analysis within this Chapter. The crystallization process for mTR3 did
provide the groundwork to crystallize DmTR in a much shorter time frame.
Both enzymes have several observations in common. The primary challenge was
hypernucleation, usually in the form of long thin needles. An example of this effect is
shown in Figure 42. Both enzymes preferred PEG 6000 as the precipitant with lower
molecular weight PEGs resulting in either increased hypernucleation or no development
and higher molecular weight PEGs typically resulting in precipitation of the protein
rather than crystal formation. This effect could also be reduced by the addition of a small
molecular weight PEG such as 1000 or the addition of ethylene glycol. These additives
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were effective in the 1 % – 5 % range with the ethylene glycol being the most effective.
The concentration of PEG 6000 could range from 18 % to 25 % with protein
concentrations in the 20 – 30 mg/mL range. This high concentration could be achieved by
increasing the NaCl to 300 mM in the protein dialysis buffer prior to concentrating.
Lower protein concentrations resulted in hypernucleation.
An increase in buffer concentration was also a contributor to producing fewer and
larger crystals. Most commercial screens begin with 100 mM buffer, but 150 – 200 mM
buffer was most effective for these proteins. Both proteins preferred pH 5.5 and could
form crystals with MES (preferred by mTR3), succinate (preferred by DmTR), or citrate
as buffer. A decrease in pH inhibited crystal formation while an increase in pH increased
the hypernucleation. Screens with pH > 7.0 most commonly resulted in either
precipitation of the protein or conversion of the needles to clusters of a thin, hair-like
morphology. Phosphate buffers were to be avoided as they often formed salt crystals,
especially when screening with metal salts (often zinc or calcium) as the precipitant. As a
result of this experience, the protein storage buffer was reduced to 10 mM phosphate
buffer for crystallization samples. The final key to crystallization of these enzymes was a
modified droplet ratio. It is typical to use equal volumes of reservoir solution and protein.
The best crystal conditions for TR used reservoir solution at half the volume of the
protein.
Cryoprotection was deemed necessary for diffraction of both proteins as room
temperature capillary mounts were not suitably stable for the time to collect a data set,
and as crystals of equal size were 1 – 2 Å higher in resolution when cryoprotected. The
means of cryoprotection, however, was usually trial and error. Four different data sets
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were collected for mTR3 and three were collected for DmTR with each having different
conditions. Each DmTR condition contained ethylene glycol but the method varied from
a single concentration soak for 5 or 10 minutes to the 2 % incremental additions used for
the data set resulting in the final structure. The mTR3 conditions were a) increasing to 36
% PEG 6000, b) 30 % glycerol, c) 14 % ethylene glycol and d) 25 % ethylene glycol.
This inconsistency in conditions resulted in the consumption of large numbers of crystals.
Fortunately, crystals were not a limiting factor due to their rapid growth for both
enzymes. However, for DmTR especially, individual droplets had a limited lifespan once
we began removing crystals. Upon accessing a droplet, precipitation of non-crystallized
protein began to develop and the remaining crystals mottled. An individual drop could be
used for 1 – 2 hours before the crystals became unusable.
Crystal Structure of TR from Drosophila.
A representative crystal used to collect the data is shown in Figure 43. The
crystal belongs to the space group R32, has a single monomer in the asymmetric unit, and
the physiological dimer is generated by the two-fold symmetry axis. The final model has
an Rfree of 24.7 % at a resolution of 2.4 Å (Table 16). Truncated DmTR has 488 residues
of which 8-488 were observed in the electron density and deposited in the final model
(PDB 2NVK). Residues 487 and 488 showed weak density (Figure 44) and high B
factors, which agrees with previous results where the electron density of the C-terminal
tail containing the second redox active disulfide of the enzyme was either very weak or
absent in the crystal structures of rat TR1 (36) and mTR3 (35). The overall fold is as
expected for a GR family member with an N-terminal FAD-binding domain, a NAD(P)140

binding central domain, and C-terminal dimerization domain (Figure 45). The position
of the FAD and NADP were verified during refinement by multiple iterations of
annealing while omitting the cofactors. The enzyme has low affinity for the oxidized
form of the NADP cofactor, which is evident in the crystal structure by the absence of
clear density for the nicotinamide moiety and high B factors for the remaining atoms of
the cofactor. The physiological dimer is generated by the crystallographic two-fold
symmetry and is shown in Figure 46.
The DmTR model has a RMS residual of 0.84 Å upon least squares superposition
of the Cα atoms to those of mTR3 (PDB 1ZKQ), 1.15 Å to rat TR1 (PDB 1H6V) (36),
and 1.16 Å to human GR (PDB 1GRA) Table 17. A structural overlay of DmTR and GR
displaying the essential catalytic components of GR is shown in Figure 47. DmTR shares
55 % sequence identity with mTR3 and the majority of sequence deviations are found on
external loops, primarily in the NADP-binding domain. A distinct difference in the
structures is observed at the interface where thiol-disulfide exchange takes place between
the FAD-associated disulfide and the C-terminal disulfide motif of the adjacent monomer
of TR. Helix 1 (residues 19-29), helix 3 (residues 97-121) and helix 6 (residues 335-347)
compose the Rossman fold helical face of the FAD-domain.

Helix 1 contains the

conserved Lys26, previously suggested as a potential anchor for the carboxyl terminus
(36), while helix 2 contains the conserved active site sequence CVNVGC.
Helix 3 is of particular interest as the residues projecting toward the interface are
each smaller compared to the mammalian enzymes containing Sec (Figure 48A). For
DmTR the residues are Val110, Thr114, and Asp117 as is the case for A. gambie and A.
mellifera, which have C-terminal sequences similar to that of DmTR (TCCS and SCCS,
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respectively). While valine occupies position 110 in DmTR, bulkier amino acids Leu or
Ile are found at the equivalent position in mammalian TRs. Threonine114 of DmTR is
replaced by either His or Tyr at this position in the mammalian enzyme (Figure 48B).
The amino acid at position 117 is most variable when comparing sequences, Asp in
DmTR, but is the bulkier Gln (numbered 146) in mTR3.

Additionally in both

mammalian TR structures (rat TR1 (36) and mTR3 (35)), these residues also project
towards the interface.
In addition to residue substitutions in helix 3, the widening of the substratebinding site is contributed to by the rotation of helix 3 away from the active site and
towards the dimer interface. This is analogous to the rotation observed for the equivalent
helix, Figure 49, in trypanothione reductase (TryR) when compared to GR for
accommodation of the larger trypanothione substrate (37, 168). The movement is limited
to turns 2-5 of the 6-turn helix from Asn105 to Leu118 (this is Asn134 to Leu147 in
1ZKQ) with a maximum shift of 1.68 Å at Val110. The source of this shift does not
appear to be a function of residue substitutions at the packing between helix 2 and 3 but
rather a packing interaction between His 106 in helix 3 and Phe404’. This residue is
within the helix between stands 3 and 4 of the dimerization domain of the second
molecule and follows a conserved bulky hydrophobic residue, which packs within the
dimerization domain. While His106 is conserved in TR there is a Thr substituted for Phe
404’ for the mammalian enzymes (Thr437’ in 1ZKQ). His 106 was previously suggested
to be a base catalyst for DmTR (36) however results from recent mutagenesis studies
indicate a structural role instead (121).
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Electrostatic Surface Potential of DmTR.
The electrostatic surface potential calculated for DmTR was compared to that of
mTR3, rat TR1, and GR (Figure 50). The most electropositive was GR and the most
electronegative was rat TR1 in the general ranking (+++) GR, mTR3, (-) DmTR, (---) rat
TR1. While the three TRs show significant differences, neither shows significant
electropositive potential at the GR substrate-binding pocket. This is significant in three
areas. The first is in the lack of activity for TRs toward GSSG. The GSSG molecule
contains four acidic groups that must be stabilized in the substrate-binding pocket for GR.
The unsuccessful attempt in the literature to convert human TR1 to a GR by a 16 amino
acid C-terminal truncation and mutagenesis concluded the failure to do so was due to the
negative electrostatic potential of TR (149). This conclusion is consistent with the
equivalent observation in DmTR.
The second point is in reference to the loss in activity reported upon mutation of
the serines in the DmTR motif to aspartic acids (65). Each of the mutants, DCCG,
GCCD, and DCCD showed less activity than the GCCG mutant. Firstly, increasing the
local negative charge surrounding and electron transfer step is expected to be
unfavorable. Second, this introduction of local charge at an already electronegative active
site would be less favorable as well.
The final area of significance is the difference in DTNB reductase activity
observed for truncated forms of TR. Truncated mTR3 shows very high DTNB reductase
activity (856 min-1), which is 60 % of the wild type activity. The truncated DmTR shows
good activity (178 min-1), which is nearly identical to the wild type activity. These results
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are in stark contrast to that reported fot truncated forms of human TR1 (149) and mutant
rat TR1 (109) which show very low DTNB reductase activity (33 min-1 and 63 min-1
respectively) that are <5 % of the respective wild types. DTNB, like GSSG, is a
negatively charged substrate with a carboxylic acid group on each TNB-. Upon reduction
of the DTNB disulfide, the low pKa of the TNB thiolate means it will be unprotonated.
This results in a significant generation of local negative charge during the reaction. The
activity trends for DTNB with the truncated TRs follow the electronegativity trends
where mTR3 is the least electronegative and has the highest activity while rat TR1 is the
most electronegative and has the least activity. Similar results have been recently
reported for the reactivity of a reversible disulfide on the surface of yellow fluorescent
protein with GSSG (169). Engineering of a more positive electrostatic surface by
mutagenesis of three local surface residues to Arg resulted in a 13-fold increase in the
rate of thiol-disulfide exchange for the negatively charged GSSG but very little change in
the reactivity towards the neutral substrate HED (2-mercaptoethanol in disulfide form) or
the positively charge substrate cysteamine disulfide (169). Therefore, the increase in Km
for DTNB as well as the difference in activities between mutant forms of different TRs
could be explained by comparing differences in the active site surface electrostatic
potentials. This is further supported by the observed increase in DTNB efficiency upon
neutralization of the C-terminal carboxylate in mTR3.
Alignment of Tetrapeptides with GSSG.
One of the key questions in the TR mechanism is how the C-terminal redox dyad
is reduced by the N-terminal redox center on the opposite subunit. The C-terminal redox
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center is either a Cys-Cys or Cys-Sec dyad as we have introduced earlier. Our analysis
begins with the known conformations of a Cys-Cys(ox) dyad (which are rare in protein
structures) that have been reported previously. For example, the solution structure of AcCys-Cys-NH2(ox) has been examined by NMR spectroscopy and found to exist as a
mixture of four different conformers (58, 170). These conformers are designated as C+,
C-, T-, and T′-. The designations “C” and “T” represent the geometry of the peptide
bond as either cis or trans, whereas the designations “+” and “-” refer to the helicity of
the disulfide bond. It was found that peptide Ac-Cys-Cys-NH2(ox) also had a second Tconformer that is defined by a larger separation of Cα atoms and this peptide was
designated as T′-. Our NMR solution studies of peptides Ac-SCCS(ox), Ac-GCCG(ox),
and Ac-GCUG(ox) also show that the same four major conformers described by Reitz
and coworkers are also the major conformers of these three peptides which are
summarized in Table 18 (Deker and Hondal, unpublished).
The observation that oxidized tetrapeptides can serve as substrate for the
truncated forms of TR demonstrate that TR, like GR, may be considered a disulfide
oxidoreductase where its own C-terminus is the cognate substrate.

Using this

relationship and the available structures for GR, we started by asking the question: which
of the four known conformers of Cys-Cys(ox) aligns with GSSG in the GR structure?
We therefore aligned the four known conformations of peptide Ac-SCCS(ox) to the thioldisulfide interchange step observed in GR (34). The formation of the mixed-disulfide
between Cys57 and a Cys from the C-terminus of the second molecule of TR in the
Drosophila homodimer would represent the binding of GSSG in GR (PDB 1GRA) and
the formation of the subsequent mixed-disulfide intermediate (PDB 1GRE).
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We

hypothesize that this step, interchange, is to be structurally and biochemically conserved
between GR and TR. The comparison of these two GR structures shows the primary
difference is the movement toward each other of the interchange Cys (Cys58 of GR) side
chain and the Cys side chain from GSH I. Using GSH I of GSSG as a reference (Figure
47), each tetrapeptide was fit such that the position and angle of the cysteines involved in
the interchange step were equivalent.
Altogether, we evaluated eight possible orientations for a given tetrapeptide in the
active site of TR because each of the four conformations can be overlaid with the sulfur
atoms of GSSG in two different orientations (by rotation of 180°), which would either
place the N-terminal Cys in the interchange position or the C-terminal Cys in the
interchange position. To form the interaction between the C-terminal carboxylate and
Lys29 in rat TR1 (Lys26 in DmTR or Lys56 in 1ZKQ) proposed by Sandalova (36), the
C-terminal Cys or Sec must be in the interchange position. For each of the alignments, no
additional electrostatic interactions or hydrogen bonds are predicted without requiring
significant changes of the peptide positioning such that the chemistry is unlikely to occur.
This is not unexpected as: 1) the C-terminal tail is quite mobile, 2) is normally covalently
attached to the protein and likely does not require binding contacts (demonstrated by the
peptide assays), and 3) even in GR, most of the contacts with the GSSG substrate are
water mediated (see Chapter 1) only a few interactions are direct contacts.
Upon alignment of the sulfur atoms of peptide SCCS(ox) with the sulfur atoms of
GSSG, it is clear that peptides in the C+ conformation place the leaving group Cys (Cterminal Cys) in a favorable position for protonation from His464′ (His467′ in GR,
His497′ in mTR3, see Figure 51A). This histidine has been shown to be essential for GR
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(88) and proposed as a conserved acid/base catalyst throughout the protein family (97,
168) including TR (93, 99). Maintaining the interchange position and angle for the trans
(T- and T-′) peptides, however, results in a rotation of the leaving group Cys by
approximately 90o (Figure 51B) as is also observed for the C- conformation. This moves
it away from His464′ by increasing the distance from 3.5 Å to 5.1 Å and to an angle not
reasonable for protonation.

In order to align the C-terminal sulfhydryl of peptide

SCCS(ox) in the T- conformation with the GSH II Cys so that it would be in a favorable
position for protonation from His464′, the interchange cysteine (N-terminal Cys of
SCCS(ox)) must be rotated away from the interchange residue (Cys57). Therefore, for
protonation of the first leaving group by His464′, the ring must be in the C+
conformation.
Figure 52 models the interface between subunits where the oxidized tetrapeptide
would be reduced by the N-terminal redox center in DmTR and mTR3, respectively. As
can be seen in the Figure, the binding pocket for the oxidized tetrapeptide is significantly
larger in the case of DmTR (Figure 52A) compared to that of mTR3 (Figure 52B). This
larger binding pocket in DmTR can accommodate the larger size of the C+ conformer of
the SCCS(ox) tetrapeptide. The distance from the NH of the N-terminal Cys to the CO of
the C-terminal Cys is larger in the C+ conformer than in the T- conformer. In addition,
the larger binding pocket of DmTR can also more easily fit the bulkier side chains of Ser.
The T- conformer is much more compact and forms a tight turn structure that is better
accommodated in the binding pocket of mTR3.
Using this same analysis with the mTR3 structure published by Biterova et al.
(35) (PDB 1ZKQ) using our NMR structures of GCUG(ox) (Deker and Hondal,
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unpublished), we find that GCUG(ox) in the T- conformation with Cys in the interchange
position appears to be the most favorable conformation for interchange with Cys86 from
chain A. With Sec oriented in the interchange position, an unfavorable interaction with
the carbonyl from the adjacent Cys residue occurs with His497′, but we would like to
emphasize that we cannot rule out the T- orientation with Sec in the interchange position.
The fit of the GCUG(ox) tetrapeptide in the binding pocket of mTR3 is shown in Figure
52D. A surface representation of tetrapeptide SCCS(ox) in the C+ conformation docked
in the binding pocket of DmTR is shown in Figure 52C for comparison. A stereo
diagram of tetrapeptide GCUG(ox) in the C+ conformation positioned in the binding
pocket of mTR3 is shown in Figure 53. This stereodiagram clearly shows the steric
clashes from the residues of helix 3 that makes this a poor fit in the binding pocket.
The peptides GCDCLG and GCLCDG fall into structural classifications different
than the other peptides. Introduction of the D-form amino acid in either position results in
a rigid structure that is 100% in a single conformation. Placing D-Cys in the first position
results in a T- like conformation while placing it in the second position results in a T+
like position. As seen in Figure 54A, the D-L peptide is more compact and is fits at the
reaction interface while the L-D peptide shown in Figure 54B is very elongated and is
not well fit to the reaction interface.
Structural Explanation for the Peptide Complementation Data.
In the mammalian enzyme, replacement of Sec with Cys greatly impairs this ring
opening step as can be seen in Table 12 Chapter 4. For example, the ratio of turnover
rates for peptides Ac-SCUS(ox) and Ac-SCCS(ox) is 511 fold, which is similar to the
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308 fold difference between peptides Ac-GCUG(ox) and Ac-GCCG(ox). These data
strongly support our hypothesis that the ability of mTR3 to protonate the leaving group in
the ring opening step of the catalytic cycle is greatly impaired compared to DmTR. Our
interpretation that proton transfer to the leaving group is partially rate limiting is in
agreement with conclusions made about the GR mechanism, where proton transfer from
His467′ to the thiol of GSH II has also been shown to be partially rate limiting (94, 95).
In DmTR, the presence of a Sec residue does not radically alter the rate of ring
opening as it does for mTR3. For example, if we compare the ratio of turnover rates for
peptides Ac-SCUS(ox) and Ac-SCCS(ox) we see only a 5.65 fold difference. This ratio
is increased to 36 fold when comparing peptides Ac-GCUG(ox) and Ac-GCCG(ox). A
24 fold increase is observed for DmTR when the effect of flanking residues of the
tetrapeptide motif is examined by comparing the ratio of turnover for peptides AcSCCS(ox) and Ac-GCCG(ox). In the mammalian enzyme, the presence of flanking
serine residues on either side of the Cys-Cys or Cys-Sec dyad only slightly (3-6 fold)
improves the activity (Table 13 Chapter 4). These data indicate that the ability of
DmTR to protonate the leaving group is not impaired, as is the case for the mammalian
enzyme, since it allows for the C+ conformation. This interpretation provides a better
answer to the question as to why DTNB is a substrate for TR and cystine is not. Since
DmTR can utilize cysteine in the SCCS or GCCG motif, the final piece of the answer is
the structure. Both DTNB and cystine are linear intermolecular disulfides. A linear
molecule in not likely to be able to adopt the C+ type conformation conferred by the
intramolecular vicinal disulfide ring, which is why DTNB with its low pKa is a substrate
but cystine is not.
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When this data is put in context with the structural data, we can explain the loss of
activity when Sec is replaced with Cys in the mammalian enzyme and why Cyscontaining TRs (such as DmTR) can function with high activity. DmTR has a more open,
interfacial active site than the mammalian enzyme. The residues from helix 3 proximal
to the FAD-associated active site are less bulky to more freely accommodate the
hydroxyls of the adjacent serines (SCCS). The increase in the available space is also
likely to make the enzyme more amenable to the conformational switching of the
SCCS(ox) peptide from T- (trans) to C+ (cis) necessary to protonate the leaving group
cysteine during interchange. The GCDCLG(ox) peptide, due to its rigid nature, is likely to
require extra space for rearrangement rather than a simple ring flip to receive the proton
from His464′. This would account for the lower activity in DmTR compared to AcGCCG(ox) and lack of activity with mTR3. In contrast to DmTR, the mammalian TRs
have evolved a more restricted active site by incorporating bulkier residues on helix 3.
This smaller active site shows a steric preference for Gly compared to Ser and was unable
to accommodate either peptide in the C+ conformation without requiring significant
rearrangement of the active site. Exclusion of the C+ conformation would make Sec
essential as the first leaving group in the ring opening step for mTR3.
Other crystallization trials.
Several other crystallographic approaches to study TR were investigated but are
currently without success. The structure reported in this Chapter is of the truncated form
of DmTR used in the peptide complementation studies, as was the case for the mTR3
structure. As indicated previously, the available TR structure from rat (1H6V) (36) and
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mouse (1ZKQ) (35) do not have structural information for the C-terminus. Crystallization
of the semisynthetic mTR and the wild type DmTR was attempted but have yet to
produce diffraction quality crystals. In the case of mTR3, clusters of thin, hair-like quasicrystals developed. Attempts to furthur evaluate these were limited by material.
With DmTR, the starting material is not limiting but issues with hypernucleation
and rapid needle formation are currently hampering diffraction quality crystal
development. Variations in buffer, PEG, pH, additives, and protein concentration that
were successful with the truncated forms have not been useful with the full length
enzyme. The addition of reducing agent or NADPH has also been explored and did
partially reduce the hypernucleation, but this is counter to the aims of this project as it is
the oxidized form of the C-terminus that we are interested in.
Co-crystallization and soaking-in experiments have been explored with mTR and
the peptide CUG(ox). Data sets were collected and difference Fourier did not reveal any
bound peptide. These experiments are hampered by the low solubility of the mammalian
motif and the low affinity the enzyme shows for the small peptide, as discussed in the
previous Chapter. Not only are high concentrations of peptide required to saturate the
enzyme, but the low affinity also means it is likely to be displaced by the cryoprotectant.
The results from these experiments and absence of the C-terminus from the previously
published TR structures demonstrates the significance of using the peptide
complementation approach to establish a GR-like system for TR. Establishing this GR –
truncated TR relationship demonstrates the relevance of the peptide modeling.
As indicated in the Introduction, there is no structural or biochemical information
on the interaction between TR and Trx. Co-crystallization of mTR3 with Trx was briefly
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investigated. The crystals and a SDS-PAGE gel are shown in Figure 55. Addition of Trx
to the droplet resulted in beautiful crystals (Figure 55A) but the Trx remained in the
droplet (Figure 55B). Formation of a covalent complex was also investigated, as was
done for TR from E. coli (49, 171). Following this previous work, we cloned the Trx
active site mutant Cys32-Gly-Pro-Ser (wild type is Cys32-Gly-Pro-Cys) and the Cterminal mTR mutant Gly-Ser-Cys-Gly. The Cys32 in Trx is reacted with DTNB to form
a Trx-TNB mixed disulfide, which can be attacked by the C-terminal Cys in the mTR3
mutant to form the complex. After many variations of this experiment, only Trx dimer
and no complex was observed. It was concluded that several side reactions could be
occurring. We first demonstrated that the truncated mTR3 reduced the Trx-TNB disulfide
via the N-terminal active site. Secondly, depending on the redox state of mTR3 several
other mixed disulfides could form to prevent the desired complex.
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Figure 41. Crystal of mTR3 with x-ray diffraction pattern.
The space group currently used in refinement is I4122. The data processed to >95 %
complete at the limit of the range collected, 2.25 Å.
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Table 15. Crystallographic statistics for amTR3-G.
Cell Parameters
space group
a, b, c (Å)

I4122
110.509
110.509
208.025

Data Collection Statistics
resolution range (Å)
unique reflections
completeness (%)
redundancy
Rmergeb (%)
I/σ
Model Statistics
Rworkc
Rfreed
# Atoms, non-hydrogen
Protein
Ligand
r.m.s. deviation, bonds (Å)
r.m.s. deviation, angles (o)
Ramachandran plot (%)
most favored regions
additionally allowed
generously allowed
disallowed regions
a
b

15 – 2.25
29,494
95.6 (95.4)
5.23
8.1
21.3 (6.6)
28.3
31.7
3679
53
0.008
1.08
86.3
12.7
1.0
0.0

Mouse mitochondrial TR missing the C-terminal tripeptide Cys-Sec-Gly.
Rmerge = ΣΣI(h) j - <I(h)>/ ΣI(h), where I (h)j is the jth measurement of diffraction intensity
P

B

B

of reflection h and <I(h)> is the average intensity of reflection h for all j measurements.

c

Rwork = Σ(|F o | - |F c |)/Σ|F o |.
Rfree is calculated using a test set of 10% of the reflection excluded from refinement
B

B

B

B

B

B

d
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Figure 42. Hypernucleation of TR crystals.
Example of the hypernucleation in the needle form seen for mTR3 (shown) and DmTR.
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Figure 43. Crystal of DmTR with x-ray diffraction pattern.
The crystal and diffaction pattern for the structure of DmTR solved at 2.4 Å resolution
(Rwork = 19.8 %, Rfree = 24.7%).
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Table 16. Crystallographic statistics for aDmTR-S.
Cell parameters
space group

R32
151.487
151.487
134.259

a, b, c (Å)
Data collection statistics
wavelength (Å)
resolution range (Å)
unique reflections
completeness (%)
redundancy
Rmerge (%)b
I/σ
Molecular replacement search models
Model statistics
Resolution (Å)
Rworkc
Rfreed
Refined model
# amino acid residues
# FAD molecules
# NADP molecules
# Water molecules
# Atoms, non-hydrogen
protein
ligand
r.m.s. deviation, bonds (Å)
r.m.s. deviation, angles (°)
Ramachandran plot (%)
most favored regions
additionally allowed
generously allowed
disallowed regions
Average B-factor (Å 2 )
Range of B-factors (Å 2 )
P

P

P

a
b

P

1.5418
15 – 2.4
22,987
98.7 (90.3)
7.85
5.9
36.8 (2.8)
1H6V
15 – 2.4
19.8
24.7
480
1
1
121
3684
92
0.011
1.359
89.0
9.6
0.7
0.7
49.14
39.6 – 95.7

Drosophilia melanogaster TR missing the C-terminal tripeptide Cys-Cys-Ser.
Rmerge = ΣΣI(h) j - <I(h)>/ ΣI(h), where I (h)j is the jth measurement of diffraction intensity
P

B

B

of reflection h and <I(h)> is the average intensity of reflection h for all j measurements.

c

Rwork = Σ(|F o | - |F c |)/Σ|F o |.
Rfree is calculated using a test set of 10% of the reflection excluded from refinement
B

B

B

B

B

B

d
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Figure 44. Omit density map for DmTR C-terminus.
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Figure 45. The crystal structure of DmTR.
The figure shows a cartoon representation of TR (left), the structure of DmTR (right), and
the protein sequence (bottom). The color-coding correlates the linear sequence to
segments in the structure. The description of TR is simplified three-domain architecture.
The dimerization domain (black) is continuous with the sequence while the FAD binding
domain and NADP binding domain are not. For example, segment 1 extends beyond the
NADP binding domain and contributes to the dimerization interface and segment 5 is
within the FAD binding domain but is C-terminal to the NADP binding domain.
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Figure 46. The homodimeric model of DmTR.
The homodimeric model of DmTR with chain A in green and chain B in gray. The
SCCS(ox) tetrapeptide in the C+ is oriented with Cys489′ as the interchange and shown
in space-filling model. The NADP without the nicotinamide moiety is indicated in blue,
the FAD in dark red. The prime designation for residue numbers indicates the B chain of
the TR homodimer.
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Figure 47. Structural alignment of DmTR and GR.
Structural alignment of Glutathione Reductase (1GRA) (34) and DmTR (Green). The
residue numbers are for DmTR. Essential catalytic components are shown along with
GSSG in purple
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Table 17. Least squares structural comparison of the aGR family.
Structure 1

Structure 2

c

d

DmTR

DmTR

0.84

Rat TR1 (1H6V)

1.15

GR (1GRA)

1.16

TryR (1BZL)

1.23

TryR

1.09

e

f

GR
a

Glutathione Reductase (34).

b

C-alpha deviation.

c

Drosophila melanogaster TR.

d

Mouse mitochondrial TR (35).

e

Rat cytosolic TR (36).

f

R.M.S.D. Å

mTR3 (1ZKQ)

DmTR
DmTR

b

Trypanothione reductase (37).

162

A.

B.
106

110

114

117

404

DmTR1 HKLVQSVQNHIKSVNWVTRVDLRDK
AmlTR EALRTAVQNHVKSVNWVTRVELRTK
AgTR ATLTESVQNHIKSVNWVTRVDLRDQ
MmTR3 KTMAEAVQNHVKSLNWGHRVQLQDR
HsTR2 RKMAEAVQNHVKSLNWGHRVQLQDR
RnTR1 EKMTESVQNHIGSLNWGYRVALREK

PTEFFIP
PTEFFIP
PTEFFIP
PLEFTVA
PLEFTVA
PLEWTVP

CeTR1 NHLRDSVQDHIASLNWGYRVQLREK

PLEYTIS

Figure 48. Tetrapeptide binding pocket ribbon overlay.
Panel A is a close-up view of the SCCS(ox) tetrapeptide (blue) in the C+ conformation
with Cys 489′ as the interchange residue positioned in the DmTR structure (green) with
an overlay of the mTR3 (PDB 1ZKQ) (35) colored in salmon. The residues for mTR3
are indicated in parentheses. Panel B is a multiple sequence alignment generated with
ClustalW (131) with either the PDB ID or accession number in parentheses. The
sequences are TR1 from D. melanogaster (AF301144_1), TR from A. mellifera
linguistica (AAP93583.1), TR from A. gambie (CAD30858.1), TR3 from M. musculus
(PDB 1ZKQ), TR2 from H. sapiens (Q9NNW7), TR1 from R. norvegicus (PDB 1H6V),
and TR1 from C. elegans (AF148217_1). The alignment shows helix 3 from Chain A
along with the loop from the dimerization domain of Chain B. The numbering is in
accordance with the TR from Drosophila.
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Figure 49. GR, TryR structural overlay.
Structural overlay of glutathione reductase in blue/light blue (1GRA) (34) and
trypanothine reductase (1BZL) (37) red/pink. The view is identical to the previous figure
demonstrating the equivalent helical shift to accommodate the larger trypanothine
substrate vs. GSSG.
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Figure 50. Electrostatic surface potentials.
Electrostatic surface potential showing a close-up of the reaction interface where thioldisulfide exchange occurs between the conserved N-terminal dithiol and the C-terminal
tetrapeptide of TR or the GSSG substrate for GR. A) GR (1GRA) (34); B) mTR3 (1ZKQ)
(35); C) DmTR; D) rat TR1 (1H6V) (36).
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Table 18. Tetrapeptide conformer distribution.
Conformer distributions (%) determined by NMR for oxidized tetrapeptides (Deker and
Hondal unpublished results).
a

Conformer

Ac-GCUG

Ac-GCCG

Ac-SCCS

C+ b

9

33

47

C-

0

6

5

T-

70

47

40

T-‘

21

14

8

a

The orientation of the peptide bond between the Cys-Cys or Cys-Sec
dyad can be cis (C) or trans (T).
b

The helicity (+ or -) of the disulfide bond.
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Figure 51. SCCS(ox) aligned with GSSG.
Alignment of the tetrapeptide SCCS(ox) in the structure of TR from Drosophila. The
tetrapeptide structures were determined by NMR spectroscopy and placed in the active
site of TR in accordance to the position of GSH I (the interchange position) in the GR
structure (PDB 1GRA). Shown is the FAD cofactor (dark red) and the helical loop of the
conserved active site sequence CVNVGC, which are components of chain A. Also
shown is Arg473′ from the B chain as well as His464′ and Glu469′, which are analogous
to His467′ and Glu472′ in GR. The oxidized C-terminal disulfide of the B chain is
reduced by the FAD-associated disulfide of the A chain during the enzymatic cycle. The
residues from TR are in gray, oxidized glutathione is in purple, the tetrapeptide is in
green, and omit electron density for the 2.4 Å structure is shown. Cys57 of DmTR is in
position for interchange with GSH I and the Cys489 of the SCCS(ox) tetrapeptide, which
is indicated by the orange dashed line. Glutathione II is in position from protonation
from His464′ as is Cys490′ of the SCCS(ox) tetrapeptide when in the C+ conformation
(Panel A), but not when in the T- conformation (Panel B) as indicated by the red dashed
line. Only the cysteines for the SCCS(ox) peptide and GSSG are shown for simplicity.
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Figure 52. DmTR and mTR3 surface potentials with peptide fits.
Electrostatic surface potential calculated using for TR showing a close-up of the reaction
interface where thiol-disulfide exchange occurs between the conserved N-terminal dithiol
and the C-terminal tetrapeptide of the adjacent subunit containing the 8-membered ring
that must be opened during redox cycling. (A) Interface for DmTR; (B) Interface for
mTR3 (PDB 1ZKQ) (35); C) The tetrapeptide SCCS(ox) in the C+ conformation with
Cys489′ in the interchange position for DmTR; D) The tetrapeptide GCUG(ox) in the Twith Cys522′ in the interchange position for mTR3.
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Figure 53. Stereo-view of mTR3 with GCUG(ox) C+.
Stereo diagram for mTR3 (PDB 1ZKQ) (35) showing residues from helix 3 along with
the tetrapeptide GCUG(ox) in the C+ conformation with Cys522′ (sulfur in yellow) in the
interchange position and Sec523′ (selenium in orange) in the leaving group position..
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Figure 54. Ribbon view of GCDCLG(ox) and GCLCDG(ox) fits.
Alignment of the testrapeptides GCDCLG(ox) (A) and GCLCDG(ox) (B) in the active site
of mTR3 (Salmon) (35) and DmTR (green).
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Figure 55. Co-crystallization trial of mTR3 and Trx.
A) Crystals (length 1.5 mm) with the oily background the thioredoxin. B) 12% SDSPAGE of the crystal drop. Lane 1, Markers; lane 2, purified mTR3; lane 3, purified Trx,
lane 4, blank, lane 5; mTR3 crystal from condition without Trx; lane 6 and 8, mTR3
crystal from co-crystallization trials; lanes 7 and 9, droplet solution from cocrystallization trials after crystal formation.
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CHAPTER 6.
CONCLUSION AND MODEL

Figure 56. Model for the requirement of Sec in mammalian TR.
Prior to the formation of the interchange mixed disulfide, the Cys-containing TR from
Drosophila melanogaster undergoes conformational change to the cis (+) conformation
for protonation of the first leaving group (left). The structure of DmTR accommodates the
flanking Ser residues as well as the peptide in the cis (+) conformation. The structure of
the mammalian enzyme restricts the peptide to the trans (-) conformation (right)
preventing protonation of the first leaving group. The low pKa of the selenol (Se-) of Sec
obviates the need for protonation during the ring opening step.
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The dissertation presented here has completed three specific aims: 1) development
of a semisynthetic technique (Chapter 2) to produce mTR3 for structure-function studies
(Chapter 3), 2) development of a new technique, peptide complementation (Chapter 4), to
investigate the mechanism of TR, and 3) determination of the crystal structure of DmTR
(Chapter 5) for comparison with mammalian TR. The results from these aims represent a
significant contribution to our field. The structural comparison of mammalian and
Drosophila melanogaster TRs, in combination with biochemical evidence from full
length and truncated enzymes has generated the first hypothesis (Figure 56) for the
requirement of Sec in mammalian TR in the 10 years since Sec was first identified in the
enzyme.
We have shown that maintaining Sec in the C-terminal position of the dyad is
essential to mTR3 function but that the vicinal motif is not. The data from the peptide
complementation assays show that the loss in activity by mutation of Sec in mTR3 is
attributed to a loss in activity in the ring opening step. The structural positioning of the
oxidized tetrapeptides in accordance with the interchange step of GR with GSSG explains
why the low pKa of Sec is required for the mammalian enzyme but not DmTR even
though the catalytic acid base, the His-Glu dyad, is conserved throughout the protein
family. Our hypothesis that protonation of the first leaving group is partially rate limiting
in the catalytic cycle of TR is complete agreement with the current understanding of the
mechanism of GR (88, 94, 95).
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KEEPING MECHANISMS IN PERSPECTIVE

The GR protein family is an ideal module for the merger of a structural biology
and biochemical analysis to understand how evolution selects for a common approach to
an essential process. That process is thiol-disulfide exchange. Each enzyme then adapts to
a specific need on the basis of a target or a cognate substrate. For example GR, TR and
TryR function to reduce their cognate disulfides by consumption of NADPH whereas
LipDH functions to generate NADH by consumption of the cognate dithiol. So, not only
does a common architecture evolve for compensation of a different cognate substrate, but
also allows for shifting of equilibrium to reverse the direction of the reaction.
Understanding the common elements of a general mechanism is as important as
understanding the unique elements of a specific mechanism within a protein family.
Taking both sets of elements into consideration is essential for structure-based design of
therapeutics to be effective (6, 14). TR is unique within the protein family in that its own
C-terminus is the cognate disulfide substrate for the conserved active site. This adds an
additional thiol-disulfide exchange reaction prior to reduction of its true cognate substrate
Trx. We expect that the common element is the interchange step resulting in the mixed
disulfide with the conserved FAD-associated active site. We hypothesize that this step is
structurally and biochemically conserved between GR and TR.
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MODEL FOR THE REQUIREMENT OF SEC IN MAMMALIAN TR

Selenocysteine has been shown to account for the broad substrate range unique to
mammalian TRs, including its ability to reduce peroxides (114) and ascorbate (115, 172).
It has been assumed that the incorporation of the selenium atom in mammalian TR for the
lower pKa expected for Sec compared to Cys (109), however, one must distinguish a
selective advantage (broad substrate range) from a necessary function (reduction of Trx).
The low pKa of Sec does not account for the requirement of Sec demonstrated by the
dramatic loss in Trx activity upon mutation of the Sec to Cys if the base-catalyzed
mechanism of the GR family is conserved. The structural analysis here could account for
the necessity for the selenium atom in the mammalian TR.
Both the Ac-GCUG(ox) and Ac-GCCG(ox) peptides show an equilibrium shift
towards the trans peptide conformation while Ac-SCCS(ox) shows an equilibrium
favoring the cis conformation.. Alignment of these peptides in the active site of mTR3
according to the interchange step of GR also shows a preference for the peptides in the
trans conformation. In our model, the more restricted tetrapeptide binding pocket of
mammalian TR resulting from incorporation of bulkier residues and a shift of helix 3
restricts the peptide to the trans conformation and does not accommodate the flanking
serines of the Drosophila motif. In the trans conformation, the low pKa of the Sec would
become essential due its inability to be protonated by His 497΄ (PDB 1ZKQ). The trans
conformation also shows an intramolecular hydrogen bond between the C-terminal
carboxylate and the amide hydrogen of the penultimate cysteine in the NMR structures of
the peptides containing a terminal Gly. This would contribute to the stability of the trans
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conformer and result in the shift in equilibrium to trans and decreasing the rate of
switching to the cis conformation. This could contribute to the decrease in activity
reported for the mutation of the terminal Ser to Gly (Ser491΄) for the Drosophila TR that
is not observed for the equivalent mutation for Ser488΄ (65).
The TR from Drosophila has evolved a different tetrapeptide binding pocket than
that of the mammalian form of the enzyme. The residues from helix 3 proximal to the
FAD-associated active site are less bulky to accommodate the hydroxyls of the flanking
serines of the SCCS motif and allow the peptide to adopt the cis conformation. The
increase in the available space is likely to make the enzyme more amenable for the
conformational switching of the GCCG peptide from trans to cis necessary to protonate
the leaving group cysteine during interchange.
Our hypothesis is that the catalytic cycle for TR is a dominated by a leaving group
effect. The first leaving group (Sec in mTR3) must either be in position for protonation
from the catalytic His during the ring opening step or have a significantly lower pKa. An
alterative brought to light in the Introduction and in Chapter 3 is the question of
nucleophilicity. While there is no disagreement in the likely nucelophilic difference
between Sec and Cys or that the flanking serines in DmTR may increase nucleophilicity,
the question is the fold contribution. Whitesides (173) and Hupe (156) have characterized
the rates of thiol-disulfide exchange as a function of pKa, as reviewed in (174, 175).
Using a series of alkyl and aromatic nucleophiles of determined pKa, Hupe and coworkers determined an ~3.2 fold change in rate per pKa unit (156). While these systems
are simplistic in that they do not account for protein conformations, it is rather striking
that it requires a >3 pKa unit shift for a given nucleophile to produce a 10-fold change in
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rate. This is important in that a thee pKa unit difference is that which has been estimated
for Cys compared to Sec (125).
It has been postulated that the Sec residue is the attacking nucleophile in the
reduction of Trx (109). This is due to the selenolate of a Sec residue being more
nucleophilic than the thiolate of a Cys residue.

Indirect evidence supporting this

hypothesis is the hydrogen peroxidase activity of the enzyme (63, 68), which is abolished
upon mutation of Sec to Cys (109). However another role for Sec is as the leaving group
position of the dyad during the ring opening step as we have argued in our model.
Placing the Cys residue in the leaving group position by switching positions of the Sec
and Cys residues should significantly decrease the activity towards all three substrates is
this study, as the C-terminal selenysulfide would be more difficult to reduce. This is what
we observed in our results in Chapter 3.
The kinetic profile of the hydrogen peroxidase activity of the WT enzyme is more
like that of a chemical reaction (2nd order kinetics) rather than an enzymatic reaction.
Therefore one would expect the position of Sec to have little impact on the peroxidase
activity. However, switching positions of the two atoms (S and Se) results in a 30 fold
decrease in peroxidase activity when selenium content is normalized. A probable
explanation for this is that the selenylsulfide in this mutant is poorly reduced in the assay.
This interpretation is further supported by the near WT activity of the Ala insertion
mutants for all three substrates. These mutants would maintain Cys in the interchange
position and Sec in the leaving group position of the ring opening step according to our
model.
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BINDING OR CHEMISTRY (kcat/Km).

The structural interpretation here raises the question of what is actually being
observed in the peptide complementation assays in Chapter 4. Since the assay conditions
do not reach saturation, the representation of the plot is in the form of kcat/Km. Can we
distinguish between binding or conformation and chemistry in our data? In terms of our
interpretation, we have developed a model that results in the chemistry being dependent
on binding the correct conformation of the peptide in the ring opening step. In this
interpretation, the only assumption is that the selenium is not a binding determinant for
the peptide, which is quite reasonable. The support for this comes from the agreement in
the fold difference in the kcat/Km of the peptide pairs in the peptide complementation
assays when compared to the fold difference in the Trx assays for the equivalent mutants
(Chapter 4, Table 14).
In the Trx assay, there is very little difference in the apparent Km for Trx between
the GCUG, GCCG and SCCS mutants of mTR3 (Chapter 3). Similar results are observed
for the Trx activity with mutants of DmTR published by Gromer et al. (65), which
included the C-terminal mutants GCUG, GCCG and SCUS in comparison with the wild
type SCCS. Therefore, the >200 fold difference in kcat/Km for the mutants of mTR3 is
attributed to the >200 fold difference in kcat. This is the same order of magnitude
difference in the kcat/Km determined in the peptide complementation assays (308 fold for
the GCUG/GCCG and 88 fold for the GCUG/SCCS). The agreement of these numbers
supports our model that the ring opening step is where Sec is required for mammalian TR
and that it is likely a function of the chemistry.
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Our model can be understood by relating the results for the truncated TR assays in
a more simplified form (Table 19) to that which has been observed in the literature for
GR (Table 20). The truncated forms of mTR3 and DmTR have good activity towards
DTNB (thiol pKa = 4.75 (159)) and GCUG (Sec pKa = 5.2 (125)). The peptide GCCG is a
substrate for DmTR as the tetrapeptide binding pocket for DmTR allows for the C+
conformation whereas mTR3 does not. Neither enzyme has activity for cystine, since
there is no ring structure to place the leaving group in the correct orientation for
protonation by the catalytic His. This is the same interpretation that can be made for GR.
The thiol pKa for glutathione is 8.6 (175), however GR binds GSSG in the correct
disulfide orientation for the catalytic cycle to occur. This is not the case for the mixed
disulfides GS-SCy (160) and GS-STNB (95) with each only having a single glutathione
moiety and not likely to have the disulfide in the correct orientation for protonation of the
first leaving group. Only the latter (GS-STNB) is a substrate for GR since it has the low
pKa TNB- leaving group, just like the tetrapeptide GCUG has the low pKa leaving group
of Sec.

OUR MODEL AND A MECHANISTIC EVOLUTIONARY ADVANTAGE

Incorporation of Sec into mammalian TR may be an evolutionary advantage
beyond a broader substrate range. In the proposed mechanism of GR, His 464΄ would
protonate both the leaving group GSHII and then GSHI upon resolution of the
interchange mixed disulfide. Incorporation of selenocysteine would eliminate the need
for the first leaving group protonation step and only require protonation upon resolution
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of the interchange. Upon re-oxidation of the vicinal disulfide with transfer of electrons to
Trx, the peptide bond would likely be in the trans conformation. Incorporation of Sec as
the first leaving group would remove the necessity for cis/trans conformational
switching. The differences in the two ring opening steps we hypothesize here are shown
in Figure 57 (mTR3) and Figure 58 (DmTR).

SUPPORT FROM THE STOPPED-FLOW TR LITERATURE

Minimal characterization has been done for the WT mammalian enzyme with the
stopped-flow technique described in Chapter 1 (79). The initial characterization of DmTR
(78) and analysis of mutants of PfTR (93) provide significant support to the model we
have presented here. In the DmTR study (78), a kcat was determined for Trx as ~ 5 s-1. For
the reductive half-reaction, three rate constants were determined; k1 ~ 100 s-1, k2 ~ 49 s-1,
and k3 ~ 21 s-1. The first two rate constants are essentially the reductive half-reaction of
GR with formation of the FADH- - NADP+ charge-transfer complex then the formation
of the thiolate-FAD charge-transfer complex EH2(B) (Please refer to Figure 10 in
Chapter 1 for the remainder of this discussion). Therefore, the third rate constant must be
the reduction of the C-terminal disulfide terminating at EH4(B). This indicates that
reduction of the C-terminal disulfide is rate limiting in the reductive half-reaction. This is
not surprising as with GR the protonation of the first leaving group in the oxidative halfreaction is rate limiting (88, 95). A single rate constant was determined for the oxidative
half-reaction for DmTR of ~ 11 s-1 (65). This led the authors to conclude that a step in the
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oxidative half-reaction was rate limiting overall. This, however, does not necessarily
mean the nucleophilic attack on Trx, as was clarified in the analysis PfTR.
The PfTR work is most interesting as it includes the mutants of the His-Glu dyad
(93). The results for the reductive half-reaction are similar to that of DmTR. Again k1 is
the largest at 425 – 815 s-1 depending on the mutant or the pH. This is the formation of
the FADH- - NADP+ charge-transfer complex and is only weakly affected by the
mutations. As with DmTR, k2 is ~ 50 % of k1 for the WT PfTR and significantly affected
by the mutations, between ~ 30 to 150 fold. The k3 for PfTR, the reduction of the Cterminus by the N-terminus, is ~ 5 % of k2 and again is dramatically reduced by either
mutation. With PfTR the reduction of the C-terminus is rate limiting in the reductive halfreaction, to an even greater extent than in DmTR.
For PfTR, three rate constants were estimated for the oxidative half-reaction. The
k1 was the fastest of the three and similar to k3 of the reductive half-reaction with the His
and Glu mutants ~ 50 % of wild type. The other two rate constants were very slow with
k2 ~ 10 % of k1, and k3 rate limiting (wild type). Each of these constants was significantly
lower for the mutants. In this analysis of PfTR it was proposed that k1 is the reduction of
Trx (EH4(B) to EH2(B)) and that the other two rate constants are EH2(B) back to Eox.
Therefore, in both half-reactions, the reduction of the C-terminus would be rate limiting
and thereby rate limiting overall. This interpretation can then be extrapolated to the
DmTR results where the step in the oxidative half-reaction that is rate limiting likely
involves the EH2(B) to Eox steps. The k1 for PfTR being unaffected by the His or Glu
mutations indicates that the dyad is not involved in the transfer of electrons to Trx as
suggested by Brandt (100), but is essential to the reduction of the C-terminus.
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CONTRADICTIONS TO THE TR LITERATURE

While there is a contribution of the flanking Ser residues to the activity of DmTR,
it is only a 7 fold increase over the activity of flanking Gly residues (65). Therefore, the
Ser can hardly be seen as critical when compared to the >100 fold loss in activity upon
mutation of the Sec in mTR3 (157) or mutation of the catalytic base in PfTR (93). The
other point of contention with our model is that the proposal for the Ser residues
facilitating thiolate formation is that it is based on the tetrapeptide modeled in all trans
configurations (65). Comparing the NMR structures of the SCCS(ox) tetrapeptide, the
hydroxyls of the Ser residues face the eight-membered ring only in the trans
configuration and not in the cis configuration (Figure 59). Based on our analysis, the Ser
hydroxyls would not be correctly oriented in the cis configuration during the ring opening
step.
It is still feasible that the hydroxyls could impact the oxidative half-reaction by
increasing the nucleophilicity of the attacking thiolate. The seven fold loss in activity for
DmTR could be accounted for by a decrease in pKa of the attacking thiolate. However, it
cannot account for the loss in activity for the SCCS mutant of mTR3, which is even
below that of the GCCG mutant. The same results were also demonstrated for human TR
where the SCCS mutant shows less activity than the GCCG mutant (154). The results
from the human TR SCCS mutant (hTR-SCCS) were interpreted by the authors to be a
function of the oxidative half-reaction. Both half-reactions were slow in comparison to
WT with the oxidative half-reaction determined to be 200 fold slower in the SCCS
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mutant. A closer inspection of the data presented does raise a question of the reaction
conditions (Figure 60). Comparing the reductive half-reaction (A) spectra 6 to the
oxidative half-reaction (B) spectra 2, it would appear that the latter has not reached
EH4(B). One of the primary characteristics of EH4(B) is an enhanced thiolate-flavin
charge-transfer complex at 540 nm (93) which is much lower in Figure 60B spectra 2
than Figure 60A spectra 6. The 460 nm peak also does not appear shifted to shorter
wavelengths as would be expected. Figure 60C is the oxidative half-reaction of PfTR for
spectral reference (93).

SEC AS LEAVING GROUP OR INTERCHANGE

The TR field is split as to the function of Sec in the catalytic cycle. While its role
as the nucleophile for Trx reduction is universally accepted, there are those who suggest
that Sec (36, 109) is the leaving group upon ring opening and those who suggest that it is
the interchange (35). However, prior to the data we present here, no biochemical
evidence was provided for either hypothesis. The high activity of the mTR3-GCAUG and
mTR3-GCAAUG mutants would support our model that Sec is the leaving group position
and not the interchange position. If Sec were the interchange, the insertion of residues
would be expected to prevent the interchange step from occurring during ring opening.
The Sec-relative position in DmTR (Cys490΄) has been suggested as the
interchange (78) and is in partial disagreement with our model. This suggestion was
generated from the difference in spectral properties of Cys489΄Ser and Cys490΄Ser
mutants. The Cys489΄Ser mutant showed a persistent FAD-thiolate charge-transfer
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complex. It was suggested that this was due to a stable mixed-disulfide between the
interchange thiol Cys57 and Cys490΄. In our modeling, there is no chemical distinction in
the SCCS or GCCG peptides as both residues in the dyad are Cys. Therefore, it is quite
possible that Cys490΄ forms the interchange with Cys57. This would suggest that the two
enzymes have different mechanisms, which we suspect is unlikely.

SUPPORTING EXPERIMENTS

The data produced in these studies and proposal for Sec as the leaving group in
the ring opening step for mammalian TRs is a testable model generating an extended list
of experiments of which the most direct will be discussed here. The first suggestion is the
production of DmTR-SCAUS by semisynthesis. Recovering activity compared to the
DmTR-SCACS mutant would support our model. In both mutants, there are still the
flanking serines except that there is not the vicinal disulfide. We suggested, based on the
high activity of mTR3-GCAUG and mTR3-GCAAUG, that the Sec position is the
leaving group and that we have not moved the interchange position or dramatically
affected the attack on Trx. Similar results for DmTR-SCAUS would make for a
convincing argument that both enzymes have a similar mechanism. Standard molecular
biology techniques can be used to test the effect of the residues from helix 3 proposed as
the conformational and peptide determinants for the two enzymes. The Thr114 DmTR
substitution for His or Tyr in mammalian TR would be the position of choice. A
collection of full length and truncated mutants was generated for DmTR that were not
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evaluated enzymatically but whose likely functions have been discussed. These mutations
provide opportunities for future crystallographic studies.
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Figure 57. Model for mTR3 ring opening steps.
The steps of ring opening within the reductive half-reaction for mTR3 with the Cterminal tetrapeptide GCUG in the tans (-) conformation. Binding of NADPH and
formation of the FADH-NADP+ charge -transfer complex (Boxed k1), thiolate-FAD
charge-transfer complex (k2), formation of the interchange mixed disulfide with Sec
(orange) not requiring protonation (k3), resolution of the mixed disulfide (k4) and
protonation of the Cys (k5).
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Figure 58. Model for DmTR ring opening steps.
The steps of ring opening within the reductive half-reaction for DmTR with the
tetrapeptide SCCS in the cis (+) conformation. Binding of NADPH and formation of the
FADH-NADP+ charge -transfer complex (Boxed k1). The peptide in the trans (-)
conformation must undergo conformational change the cis (-) (k2) then cis (+) (k3). The
thiolate-FAD charge-transfer complex (k4), formation of the interchange mixed disulfide
(k5) with Cys489’ requiring protonation (k6), resolution of the mixed disulfide (k7) and
protonation of the Cys49’ (k8).

188

Table 19. Substrates for truncated TR.
Enzyme

DTNB

GCUG

GCCG

+
+

+
+

+
-

c

CyS-SCy

-

a

DmTR-S

b

mTR-G

a

Drosophila melanogaster TR missing the C-terminal tripeptide Cys-Cys-Ser.

b

Mouse mitochondrial TR missing the C-terminal tripeptide Cys-Sec-Gly.

c

Cystine.

Table 20. Substrates for glutathione reductase.
Enzyme
GR

a

GS-SG

+

b

GS-STNB

+

c

GS-SCy

-

d

CyS-SCy

-

a

The natural substrate diglutathione (GSSG).

b

Glutathione-TNB mixed disulfide taken from (95).

c

Glutathione-cysteine mixed disulfide taken from (160).

d

Cystine taken from (160).
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Figure 59. Orientation of flanking serine hydroxyls.
Orientation of the flanking Ser hydroxyls in the SCCS(ox) tetrapeptide in trans
configuration (left) and the cis configuration (right). The Ser hydroxyls would not be
correctly oriented to impact thiolate formation during the ring opening step when in the
cis configuration.
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Figure 60. Interpretation of human TR-SCCS.
Interpretation of the human Ser-Cys-Cys-Ser TR mutant (hTR-SCCS) from (154)
reprinted with permission (176). A is the reductive half-reaction of hTR-SCCS. Spectra
1 is oxidized hTR-SCCS, spectra 4 is the addition of 1.7 equivalents of NADPH, spectra
5 is 3.3 equivalents of NADPH, spectra 6 is 7.7 equivalents of NADPH. B is the
Oxidative half-reaction of hTR-SCCS. Spectra 1 is the oxidized hTR-SCCS, spectra 2 is
reduction with 2.1 equivalents of NADPH, spectra 3 is reoxidation after addition of Trx.
C is the oxidative half-reaction of wild type TR from Plasmodium falciparum (PfTR) as a
reference (93). Spectra 1 is the oxidized PfTR, spectra 2 is reduction with 2.2 equivalents
of NADPH, spectra 3 and 4 are time points following addition of Trx. It is possible that
the slow oxidative half-reaction in the experiment is the incomplete reduction of hTRSCCS, based on the lack of shift in the 460 nm peak to shorter wavelength and the
weaker thiolate FAD charge-transfer complex at 540 nm.
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APPENDIXES
A. ABBREVIATIONS

AMP, adenosine monophosphate; β-Me, 2-mercaptoethanol; CATC, the sequence CysAla-Thr-Cys; CCG, the tripeptide Cys-Cys-Gly; CeTR; Caenorhabditis elegans TR;
CID, collision induced dissociation; CISS; the sequence Cys-Ile-Ser-Ser; CNS,
Crystallography and NMR system; CUG, the tripeptide Cys-Sec-Gly; DEAE,
diethylaminoethyl; DmTR, Drosophila melanogaster TR; dNTP, deoxyribonucleotide
triphosphate; DTNB, 5,5’-Dithio-bis(2-nitrobenzoic acid); DTT, dithiothreitol; EDTA,
ethylenediamintetraacetic acid; EH2, 2-electron reduced (1 NAPDH equivalent)
flavoprotein; EH4, 4-electron reduced (2 NAPDH equivalent) flavoprotein; Eox, oxidized
flavoprotein; EPL, expressed protein ligation; ESI-MS, electrospray ionization mass
spectrometry; FAD, flavin adenine dinucleotide; Fmoc, 9-fluoroenylmethoxycarbonyl;
GCCG, the tetrapeptide Gly-Cys-Cys-Gly; GCUG, the tetrapeptide Gly-Cys-Sec-Gly;
GITS, the sequence Gly-Ile-The-Ser; GR, glutathione reductase; GSH, reduced
glutathione (γ-glutamylcysteinylglycine); GSH I, interchange glutathione; GSH II, first
leaving group glutathione; GSSG, oxidized diglutathione; HPLC, high pressure liquid
chromatography; H2O2, hydrogen peroxide; ICP-MS, inductively coupled plasma mass
spectrometry; IPTG, isopropyl-β-D-thiogalactopyranoside; LB, Luria-Betami Media;
LipDH, dihydrolipoamide dehydrogenase; MALDI-TOF, matrix-assisted laser desorption
ionization time of flight mass spectrometry; MES, 2-(4-Morpholio)-Ethane Sulfonic
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Acid; Mr, molecular weight; MOPS; 3-(N-Morpholino) Propane-Sulfonic Acid; mTR3,
mouse mitochondrial TR; NADH, reduced nicotinamide adenine dinucleotide; NADP+,
oxidized nicotinamide adenine dinucleotide phosphate; NADPH, reduced nicotinamide
adenine dinucleotide phosphate; NF-ΚB, nuclear factor kappa B; NMA, Nmethylmeraptoacetamide; NMR, nuclear magnetic resonance; PDB, Protein Data Bank;
PEG, polyethylene glycol; PfTR, TR from Plasmodium falciparum; RMSD, root mean
squared deviation; RNR, ribonucleotide reductase; SCCS, the tetrapeptide Ser-Cys-CysSer; Sec, selenocysteine; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel
electrophoresis; SECIS, selenocysteine insertion sequence; TB, terrific broth; TNB-,
thiobis(2-nitrobenzoic acid) anion; TR, thioredoxin reductase; Trx, thioredoxin; TryR,
trypanothine reductase; U, the one-letter abbreviation for selenocysteine; WT, wild type;
Xa, protease Xa.
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B. COMPREHENSIVE LIST OF MATERIALS
Solvents for peptide synthesis were purchased from EMD Biosciences (San Diego, CA).
Fmoc amino acids were purchased from Synpep Corp. (Dublin, CA). Resins for solidphase synthesis were purchased from Novabiochem (San Diego, CA). All PCR primers
were purchased from Integrated DNA Technologies Inc., and PAGE purified (Coralville,
IA). Restriction endonucleases Nco I, Sap I, Hind III, Eco RI, Nde I, Sal I, Kpn I, Vent
DNA polymerase, plasmids pTYB1 and pTYB3, chitin agarose beads, T4 DNA ligase,
and reaction buffers were supplied by New England Biolabs (Ipswich, MA). All
restriction enonucleases, Vent DNA Polymerase, and T4 DNA ligase were used with the
supplied buffers according to manufacturers guidelines. Recombinant E. coli thioredoxin
was purchased from American Diagnostica (Greenwich, CT). DTNB, NADPH, NADP+,
Bovine Pancreatic Insulin and N-Methylmercaptoacetamide (NMA) were purchased from
Sigma-Aldrich (St. Louis, MO). Hydrogen peroxide 30% solution was purchased from
J.T Baker (Phillipsburg, NJ). The PEG 6000 used for crystallization was purchased from
Fluka (Sigma-Aldrich). All other chemicals were purchased from either Sigma-Aldrich or
Fisher Scientific and were of reagent grade or better.
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C. LIST OF PCR PRIMERS
CLONING OF MOUSE TR3 WITH pTYB3

Upstream mTR3 (labeled TRup2).
Downstream mTR3-GCCG 5’ACAGCCGCTCTTCAGCAGCCACAGCAACCAGTCACA-3’ (labeled TRCYS).
Downstream mTR3-SCCS 5′ACAGCCGCTCTTCAGCAGGAACAGCAAGAAGTCACAGTAGGCTCC-3′ (labeled
TRser).
Downstream mTR3-GSCG 5’ACAGCCGCTCTTCAGCAGCCACAGGAACCAGTCACA-3’ (labeled mTR-C488S).
QuickChange Stratagene Mutagenesis Forward mTR3-Cys52Ser/Cys57Ser 5’GGTGGCACCTCTGTCAACGTGGGTTCCATACCCAAGAAGC-3’ (labeled
mTRC52-57A-fwd).
QuickChange Stratagene Mutagenesis Reverse mTR3-Cys52Ser/Cys57Ser 5’GCTTCTTGGGTATGGAACCCACGTTGACAGAGGTGCCACC-3’ (labeled
mTRC52-57A-Rev).

CLONING OF DROSOPHILA TR WITH pTYB1

Upstream primer 5′ – AACAGACATATGGCGCCCGTGCAAGG – 3′ (labaled dmup2).
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Downstream DmTR-SCCS 5′ACAGCCGGTACCCTTGGCAAAGCAGCTGCAGCAGCTGGCCGG -3′ (labeled
dmdown2L).
Downstream truncated DmTR-S488 5′ACAGCCGGTACCCTTGGCAAAGCAGCTGGCCGGCGTGGGG-3′ (labeled
dmdown2s).
Downstream DmTR-SCACS 5′ACAGCCGGTACCCTTGGCAAAGCAGCTGCAGGCGCAGCTGGCCGGCGTGGG3′ (labeled DmTR-CAC).
Downstream DmTR-SCAACS 5′ACAGCCGGTACCCTTGGCAAAGCAGCTGCAGGCGGCGCAGCTGGCCGGCGTG
GG-3′ (labeled DmTR-CAAC).
QuickChange Stratagene Mutagenesis Forward DmTR His464Ala 5’CAACACCGTGGGCATCGCCCCCACTACCGCCGAAGAG-3’ (labeled
HIS464forward).
QuickChange Stratagene Mutagenesis Reverse DmTR His464Ala 5’CTCTTCGGCGGTAGTGGGGGCGATGCCCACGGTGTTG-3’ (labeled
HIS464reverse).
QuickChange Stratagene Mutagenesis Forward DmTR His106Ala 5’CTGGTGCAGTCCGTACAGAACGCCATTAAGTCCGTCAACTGG-3’ (labeled
His106f2).
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QuickChange Stratagene Mutagenesis Reverse DmTR His106Ala 5’CCAGTTGACGGACTTAATGGCGTTCTGTACGGACTGCACCAG-3’ (labeled
His106rev2).
QuickChange Stratagene Mutagenesis Forward DmTR Glu469Ala 5’CACTACCGCCGCAGAATTCACCCGGCTG-3’ (labeled E469Aforward).
QuickChange Stratagene Mutagenesis Reverse DmTR Glu469Ala 5’CAGCCGGGTGAATTCTGCGGCGGTAGTG-3’ (labeled E469Areverse).

CLONING OF THIOREDOXIN

QuickChange Stratagene Mutagenesis Forward Trx Cys36Ser 5’GGTGCGGTCGGTCCAAAATGATCGC-3’ (*labeled TrxC35Sfw).
QuickChange Stratagene Mutagenesis Reverse Trx Cys36Ser 5’GCGATCATTTTGGACGGACCGCACC-3’ (labeled TrxC35Srev).
*Cys36 is correct, the C35 was a typo in ordering.
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